[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmr1xvAM6Onwus-HbPDAeB3ipltXSskBl5f_d74xv594":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":84,"rows":91},"St. Jude Children's Research Hospital",[4],428,false,146,19,297595,224,[13,16,19,22,24,27,29,31],{"name":14,"count":15},"Acute Lymphoblastic Leukemia",38,{"name":17,"count":18},"Sickle Cell Disease",35,{"name":20,"count":21},"Cancer",22,{"name":23,"count":9},"Neuroblastoma",{"name":25,"count":26},"Acute Myeloid Leukemia",16,{"name":28,"count":26},"Hodgkin Lymphoma",{"name":30,"count":26},"Childhood Cancer",{"name":32,"count":33},"Rhabdomyosarcoma",13,[35,40,45,50,55,60,65,69,74,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT00539591","Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","2015-06","Peginterferon alfa-2b",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT01946529","Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","2015-08","vincristine",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT00602667","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","2017-09-27","Induction Chemotherapy",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT00846742","Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma","2019-01-11","Stanford V Chemotherapy",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT01920932","Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma","2020-11-16","brentuximab vedotin",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT02553460","Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","2022-05-10","ITMHA",{"nctId":66,"briefTitle":67,"date":68,"intervention":44},"NCT01783535","Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","2023-03-17",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT02125786","A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma","2023-05","^1^8F-Fluorodeoxyglucose",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT03573700","Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed\u002FRefractory CD19+ Acute Lymphoblastic Leukemia","2023-07-01","Cyclophosphamide",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT04898894","Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","2023-07-12","Venetoclax",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,411,585,782,888,931,961,1440,1563,1644,1682,1729,1775,1813,1843,1873,1899,1937,1967,1993,2019,2045,2103,2130,2148,2166,2184,2202,2338,2428,2584,2643,2705,2795,2853,2908,2956,2994,3032,3078,3123,3157,3187,3220,3260,3328,3370,3412,3446,3480,3510,3536,3558,3580,3602,3624,3646,3668,3690,3761,3791,3817,3843,3869,3895,3921,3947,3973,3999,4021,4043,4065,4097,4119,4141,4163,4187,4212,4230,4248,4266,4290,4314,4332,4362,4380,4398,4416,4434,4452,4470,4496,4514,4541,4559,4577,4595,4613,4631,4655,4673,4699,4717,4738,4756,4774,4792,4810,4828,4846,4864,4882,4906,4924,4942,4960,4978,4996,5014,5039,5057,5075,5093,5111,5129,5147,5165,5192,5234,5262,5295,5321,5347,5365,5383,5409,5427,5445,5463,5490,5508,5526,5544,5562,5585,5607,5631,5656,5694,5724,5742,5760,5778,5796,5822,5840,5863,5887,5905,5931,5959,5977,5995,6013,6038,6063,6081,6110,6128,6146,6164,6190,6208,6234,6252,6270,6288,6306,6324,6358,6392,6418,6444,6466,6488,6510,6544,6566,6588,6610,6632,6657,6675,6693,6711,6729,6757,6775,6793,6811,6834,6857,6875,6893,6911,6929,6953,6971,6989,7007,7029,7052,7077,7095,7113,7131,7156,7180,7201,7219,7237,7255,7273,7291,7309,7327,7353,7375,7403,7421,7439,7457,7481,7499,7517,7535,7553,7571,7589,7607,7625,7643,7667,7685,7708,7726,7744,7762,7780,7803,7821,7839,7857,7875,7893,7911,7929,7947,7975,7993,8011,8039,8067,8103,8127,8151,8173,8198,8220,8238,8256,8280,8298,8316,8339,8363,8381,8405,8428,8451,8469,8492,8517,8535,8553,8571,8595,8617,8641,8659,8677,8701,8722,8745,8763,8788,8806,8830,8848,8866,8884,8902,8925,8948,8970,8988,9006,9027,9052,9070,9105,9127,9151,9174,9196,9218,9242,9260,9278,9302,9325,9353,9371,9389],{"intervention":93,"totalTrials":94,"cells":95},"Vincristine",20,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":115,"PHASE3":358,"PHASE4":387,"NA":398},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":112},"NCT00718757","Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And\u002FOr Refractory Hematologic Malignancies","COMPLETED",[86],"2009-01","2005-01",4,[110,111,14],"Non-Hodgkins Lymphoma","Hodgkin's Disease",[113,114,93],"Dexamethasone","Irinotecan",{"trials":116,"activeCount":357,"soonestReadout":43},[117,140,166,183,202,218,230,245,262,276,288,303,318,331,345],{"nctId":118,"briefTitle":119,"status":104,"phases":120,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},"NCT01451515","NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma",[87],"2021-05-08","2022-05-31","2012-05-25",23,[126],"Lymphoblastic Lymphoma",[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],"Prednisone","Daunorubicin","PEG-asparaginase","Erwinia asparaginase","Doxorubicin","Cytarabine","Thioguanine","Clofarabine","Methotrexate","Mercaptopurine","Hydrocortisone","Etoposide",{"nctId":141,"briefTitle":142,"status":104,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":149},"NCT01857934","Therapy for Children With Advanced Stage Neuroblastoma",[87],"2021-10-21","2025-12-31","2013-07-05",153,[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],"cyclophosphamide","topotecan","hu14.18K322A","cisplatin","etoposide","doxorubicin","busulfan","melphalan","peripheral blood stem cell transplantation","natural killer cell","GM-CSF","G-CSF","mesna","levetiracetam","interleukin-2","Isotretinoin",{"nctId":41,"briefTitle":42,"status":167,"phases":168,"primaryCompletion":43,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":177},"ACTIVE_NOT_RECRUITING",[87],"2026-07","2013-12-27",24,[173,174,175,176],"Desmoplastic Small Round Cell Tumor","Ewing Sarcoma of Bone or Soft Tissue","Localized Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor","Metastatic Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor",[44,155,150,178,154,179,180,181,182],"ifosfamide","temozolomide","temsirolimus","bevacizumab","sorafenib",{"nctId":184,"briefTitle":185,"status":186,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":196},"NCT06390319","Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","RECRUITING",[87],"2027-12","2033-12","2024-12-27",100,[193,194,195],"T-cell Acute Lymphoblastic Leukemia","T-cell Lymphoma","Mixed Phenotype Acute Leukemia",[113,93,129,197,198,83,199,200,78,133,137,201,136,134],"Calaspargase pegol","Dasatinib","Bortezomib","Intrathecal triple therapy","Nelarabine",{"nctId":203,"briefTitle":204,"status":167,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":211},"NCT03755804","Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17",[87],"2027-01-01","2028-07-01","2018-12-12",232,[28],[212,139,132,213,93,214,128,215,216,78,217],"bendamustine","Bleomycin","Vinblastine","Filgrastim","Brentuximab Vedotin","DTIC",{"nctId":61,"briefTitle":62,"status":167,"phases":219,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":224},[86,87],"2031-10","2016-01-29",50,[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],"Mitoxantrone","Pegaspargase","Asparaginase Erwinia Chrysanthemi","Vorinostat","Leucovorin Calcium",{"nctId":231,"briefTitle":232,"status":186,"phases":233,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":239},"NCT06023641","Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease",[87],"2034-10","2037-10","2024-03-13",135,[32],[93,240,78,241,242,243,244],"Dactinomycin","Liposomal irinotecan","Vinorelbine","Temozolomide","Filgrastim, peg-filgrastim",{"nctId":246,"briefTitle":247,"status":167,"phases":248,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":253,"interventions":254},"NCT01871766","Risk-Adapted Focal Proton Beam Radiation and\u002For Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy",[87],"2026-12","2030-06","2013-12-04",115,[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],"Bevacizumab","Sorafenib","Myeloid Growth Factor","Ifosfamide","Etoposide Phosphate","Dexrazoxane","^1^1C-methionine",{"nctId":263,"briefTitle":264,"status":186,"phases":265,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":271},"NCT06533748","Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma",[87],"2028-05","2034-05","2025-01-23",128,[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],"Inotuzumab","Blinatumomab","6-Mercaptopurine","Calaspargase",{"nctId":66,"briefTitle":67,"status":167,"phases":277,"primaryCompletion":68,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":283},[87],"2028-01","2013-06-19",174,[282],"Retinoblastoma",[44,151,284,285,286,154,150,287,155],"filgrastim","PEG-filgrastim","carboplatin","MESNA",{"nctId":289,"briefTitle":290,"status":167,"phases":291,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":296,"interventions":298},"NCT01878617","A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma",[87],"2028-10-13","2031-10-13","2013-06-23",660,[297],"Medulloblastoma",[78,299,93,300,301,302],"Cisplatin","Vismodegib","Pemetrexed","Gemcitabine",{"nctId":304,"briefTitle":305,"status":167,"phases":306,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":310,"interventions":313},"NCT05192889","Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax",[86,87],"2024-06-13","2027-02","2022-08-25",[311,312],"Refractory Acute Lymphoblastic Leukemia","Relapsed Acute Lymphoblastic Leukemia",[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],"Navitoclax","Calaspargase Pegol","Leucovorin","Intrathecal Triples",{"nctId":319,"briefTitle":320,"status":104,"phases":321,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":328},"NCT00352027","Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma",[87],"2015-05","2022-11-15","2006-07-20",81,[327],"Hodgkin's Lymphoma",[329,214,330,78,93,213,139,128,161],"Adriamycin®","Nitrogen Mustard",{"nctId":332,"briefTitle":333,"status":167,"phases":334,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":342},"NCT02114229","Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors",[87],"2025-09-01","2027-09","2014-05-14",125,[340,341],"Malignant Rhabdoid Tumor","Atypical Teratoid Rhabdoid Tumor",[343,344,153,286,150,154,151,44],"alisertib","methotrexate",{"nctId":346,"briefTitle":347,"status":186,"phases":348,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":353},"NCT05535166","Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma",[87],"2035-07","2022-12-20",130,[297],[136,299,93,78,354,355,139,356,215,136],"Carboplatin","Topotecan","Pegfilgrastim",12,{"trials":359,"activeCount":386,"soonestReadout":375},[360,371],{"nctId":361,"briefTitle":362,"status":104,"phases":363,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":370},"NCT00085202","Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor",[88],"2016-12","2023-12-31","2003-08",416,[369],"Brain and Central Nervous System Tumors",[284,153,150,44],{"nctId":372,"briefTitle":373,"status":167,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":381},"NCT03117751","Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma",[87,88],"2026-09-30","2028-09-30","2017-03-29",790,[14,380],"Acute Lymphoblastic Lymphoma",[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],"Erwinase®","Ruxolitinib","Idarubicin","Asparaginase Erwinia chrysanthemi (recombinant)-rywn",1,{"trials":388,"activeCount":386,"soonestReadout":267},[389],{"nctId":390,"briefTitle":391,"status":186,"phases":392,"primaryCompletion":267,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":397},"NCT06289673","Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia\u002FLymphoma",[89],"2039-05","2024-12-26",850,[14,126,195],[113,93,129,200,136,133],{"trials":399,"activeCount":98},[400],{"nctId":401,"briefTitle":402,"status":104,"phases":403,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":408},"NCT00187122","Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma",[90],"2004-06","1993-03",42,[126],[93,409,410,133,136,137,139,78,128,113],"Daunomycin","L-Asparaginase",{"intervention":136,"totalTrials":412,"cells":413},18,{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":446,"PHASE3":555,"PHASE4":573,"NA":579},{"trials":415,"activeCount":98},[],{"trials":417,"activeCount":445,"soonestReadout":82},[418,431],{"nctId":80,"briefTitle":81,"status":167,"phases":419,"primaryCompletion":82,"completion":336,"start":420,"enrollment":421,"conditions":422,"interventions":427},[86],"2021-11-15",37,[423,424,425,426],"Acute Leukemia of Ambiguous Lineage in Relapse","Acute Myeloid Leukemia, in Relapse","Refractory Acute Leukemia of Ambiguous Lineage","Refractory Acute Myeloid Leukemia",[83,428,133,429,215,136,430],"Selinexor","Fludarabine","methotrexate\u002Fhydrocortisone\u002Fcytarabine",{"nctId":432,"briefTitle":433,"status":186,"phases":434,"primaryCompletion":435,"completion":436,"start":437,"enrollment":171,"conditions":438,"interventions":441},"NCT06177067","Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia",[86],"2026-10","2027-04","2024-04-19",[426,439,440],"Relapsed Acute Myeloid Leukemia","Acute Leukemia of Ambiguous Lineage",[442,83,443,444,133,136],"Revumenib","Azacitidine","intrathecal (IT) chemotherapy",2,{"trials":447,"activeCount":554,"soonestReadout":63},[448,452,456,479,483,487,501,505,517,529,533,550],{"nctId":118,"briefTitle":119,"status":104,"phases":449,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":450,"interventions":451},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":184,"briefTitle":185,"status":186,"phases":453,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":454,"interventions":455},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":457,"briefTitle":458,"status":104,"phases":459,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":466},"NCT01700946","Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma",[87],"2021-07-24","2013-04-15",80,[464,465],"Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood B-Lymphoblastic Lymphoma",[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],"dexamethasone","vincristine sulfate","rituximab","clofarabine","aldesleukin","pegaspargase","mercaptopurine","cytarabine","mitoxantrone","teniposide","vinblastine","therapeutic hydrocortisone",{"nctId":61,"briefTitle":62,"status":167,"phases":480,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":481,"interventions":482},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":263,"briefTitle":264,"status":186,"phases":484,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":485,"interventions":486},[87],[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],{"nctId":488,"briefTitle":489,"status":490,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":496},"NCT03913559","Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","TERMINATED",[87],"2025-09-15","2019-05-14",5,[14],[497,136,138,133,498,499,500],"Inotuzumab ozogamicin","Diphenhydramine","Acetaminophen","Methylprednisolone",{"nctId":304,"briefTitle":305,"status":167,"phases":502,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":503,"interventions":504},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"nctId":506,"briefTitle":507,"status":490,"phases":508,"primaryCompletion":509,"completion":509,"start":510,"enrollment":357,"conditions":511,"interventions":514},"NCT02419755","Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies",[87],"2016-12-31","2015-04-14",[512,25,513],"Mixed Lineage Acute Leukemia","Acute Lymphoid Leukemia",[199,228,225,133,136,138,515,516,113,137,132],"Peg-L-Asparaginase","Erwinia L-Asparaginase",{"nctId":518,"briefTitle":519,"status":104,"phases":520,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":528},"NCT00667342","A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma",[87],"2014-08","2017-08","2008-06-03",43,[526,527],"Osteosarcoma","Malignant Fibrous Histiocytoma (MFH) of Bone",[255,299,132,136,258,154],{"nctId":332,"briefTitle":333,"status":167,"phases":530,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":531,"interventions":532},[87],[340,341],[343,344,153,286,150,154,151,44],{"nctId":534,"briefTitle":535,"status":490,"phases":536,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":543},"NCT05579769","Pediatric Study of GVHD Ppx w\u002Fo Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.",[87],"2024-05-08","2023-03-14",3,[541,542],"Hematologic Malignancy","Myeloid Malignancy",[383,544,545,546,78,429,136,547,548,549],"Mesna","Anti-thymocyte globulin","Cyclosporine","Bone marrow","Busulfan","Thiotepa",{"nctId":346,"briefTitle":347,"status":186,"phases":551,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":552,"interventions":553},[87],[297],[136,299,93,78,354,355,139,356,215,136],6,{"trials":556,"activeCount":386,"soonestReadout":375},[557,569],{"nctId":558,"briefTitle":559,"status":104,"phases":560,"primaryCompletion":561,"completion":561,"start":562,"enrollment":554,"conditions":563,"interventions":567},"NCT01188798","Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies",[88],"2012-02","2010-09",[14,564,565,111,566],"Acute Myelocytic Leukemia","Chronic Myelocytic Leukemia","Myelodysplastic Syndrome",[136,568],"Pentostatin",{"nctId":372,"briefTitle":373,"status":167,"phases":570,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":571,"interventions":572},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":574,"activeCount":386,"soonestReadout":267},[575],{"nctId":390,"briefTitle":391,"status":186,"phases":576,"primaryCompletion":267,"completion":393,"start":394,"enrollment":395,"conditions":577,"interventions":578},[89],[14,126,195],[113,93,129,200,136,133],{"trials":580,"activeCount":98},[581],{"nctId":401,"briefTitle":402,"status":104,"phases":582,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":583,"interventions":584},[90],[126],[93,409,410,133,136,137,139,78,128,113],{"intervention":133,"totalTrials":171,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":657,"PHASE3":754,"PHASE4":770,"NA":776},{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":445,"soonestReadout":82},[591,595,604,615,626,642,653],{"nctId":80,"briefTitle":81,"status":167,"phases":592,"primaryCompletion":82,"completion":336,"start":420,"enrollment":421,"conditions":593,"interventions":594},[86],[423,424,425,426],[83,428,133,429,215,136,430],{"nctId":596,"briefTitle":597,"status":490,"phases":598,"primaryCompletion":599,"completion":599,"start":600,"enrollment":9,"conditions":601,"interventions":602},"NCT02676323","Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome",[86],"2018-04-09","2016-05-03",[25,566],[603,429,133,317,316],"Panobinostat",{"nctId":605,"briefTitle":606,"status":104,"phases":607,"primaryCompletion":608,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":613},"NCT03194932","Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage",[86],"2020-10-27","2022-06-22","2017-07-11",62,[25],[83,133,384,614,443],"Intrathecal Triple Therapy",{"nctId":616,"briefTitle":617,"status":104,"phases":618,"primaryCompletion":619,"completion":619,"start":521,"enrollment":9,"conditions":620,"interventions":625},"NCT02212561","Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome",[86],"2015-12",[621,622,623,624],"Acute Myeloid Leukemia (AML)","Acute Lymphoblastic Leukemia (ALL)","Myelodysplastic Syndrome (MDS)","Mixed Phenotype Acute Leukemia (MPAL)",[428,429,133,430],{"nctId":627,"briefTitle":628,"status":104,"phases":629,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":636},"NCT02130869","A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas",[86],"2017-12-20","2014-10-10",8,[23,634,635],"Lymphoma","High-risk Tumor",[637,638,152,548,639,160,640,139,133,354,161,641],"CD133+ selected autologous stem cell","IL-2","Melphalan","Bendamustine","Etoposide phosphate",{"nctId":643,"briefTitle":644,"status":104,"phases":645,"primaryCompletion":38,"completion":38,"start":646,"enrollment":647,"conditions":648,"interventions":652},"NCT00908167","Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies",[86],"2009-09",44,[25,649,566,650,651],"Infantile Leukemia (Both AML and ALL)","Myelodysplastic\u002FMyeloproliferative Neoplasms","Biphenotypic Leukemia",[256,133,135],{"nctId":432,"briefTitle":433,"status":186,"phases":654,"primaryCompletion":435,"completion":436,"start":437,"enrollment":171,"conditions":655,"interventions":656},[86],[426,439,440],[442,83,443,444,133,136],{"trials":658,"activeCount":494,"soonestReadout":63},[659,663,667,676,680,684,698,702,710,714,718,734,738],{"nctId":118,"briefTitle":119,"status":104,"phases":660,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":661,"interventions":662},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":184,"briefTitle":185,"status":186,"phases":664,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":665,"interventions":666},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":668,"briefTitle":669,"status":490,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":108,"conditions":673,"interventions":674},"NCT02433483","Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients",[87],"2017-05-08","2015-05-22",[621,623],[133,317,675],"HPC-A",{"nctId":457,"briefTitle":458,"status":104,"phases":677,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":678,"interventions":679},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"nctId":61,"briefTitle":62,"status":167,"phases":681,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":682,"interventions":683},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":685,"briefTitle":686,"status":167,"phases":687,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":694},"NCT03164057","A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia",[87],"2025-09-20","2027-06","2017-06-15",206,[25,693],"Myelodysplastic Syndromes",[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],"Decitabine","Stem Cell Transplant","Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn",{"nctId":263,"briefTitle":264,"status":186,"phases":699,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":700,"interventions":701},[87],[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],{"nctId":703,"briefTitle":704,"status":490,"phases":705,"primaryCompletion":706,"completion":706,"start":707,"enrollment":421,"conditions":708,"interventions":709},"NCT03071276","Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia",[87],"2019-04-30","2016-01-14",[621],[428,429,133,430],{"nctId":488,"briefTitle":489,"status":490,"phases":711,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":712,"interventions":713},[87],[14],[497,136,138,133,498,499,500],{"nctId":304,"briefTitle":305,"status":167,"phases":715,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":716,"interventions":717},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"nctId":719,"briefTitle":720,"status":721,"phases":722,"primaryCompletion":249,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":727},"NCT05955261","A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia","SUSPENDED",[87],"2034-03","2023-07-25",70,[25],[83,443,133,728,729,730,731,732,139,733],"Gemtuzumab Ozogamicin","Daunorubicin Hydrochloride","Fludarabine Phosphate","Idarubicin Hydrochloride","Mitoxantrone Hydrochloride","Gilteritinib",{"nctId":506,"briefTitle":507,"status":490,"phases":735,"primaryCompletion":509,"completion":509,"start":510,"enrollment":357,"conditions":736,"interventions":737},[87],[512,25,513],[199,228,225,133,136,138,515,516,113,137,132],{"nctId":739,"briefTitle":740,"status":490,"phases":741,"primaryCompletion":619,"completion":619,"start":742,"enrollment":743,"conditions":744,"interventions":748},"NCT01621477","T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant",[87],"2012-08",34,[14,564,565,745,566,746,747],"Juvenile Myelomonocytic Leukemia","Hodgkin or Non-Hodgkin Lymphoma","Sarcoma, Myeloid",[470,474,156,749,150,750,751,752,753],"Plerixafor","antithymocyte globulin","stem cells","Tacrolimus","mycophenolate mofetil",{"trials":755,"activeCount":386,"soonestReadout":375},[756,766],{"nctId":757,"briefTitle":758,"status":104,"phases":759,"primaryCompletion":760,"completion":761,"start":762,"enrollment":763,"conditions":764,"interventions":765},"NCT00703820","Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia",[88],"2017-03-30","2020-08-14","2008-08-04",324,[25],[133,129,139,135],{"nctId":372,"briefTitle":373,"status":167,"phases":767,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":768,"interventions":769},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":771,"activeCount":386,"soonestReadout":267},[772],{"nctId":390,"briefTitle":391,"status":186,"phases":773,"primaryCompletion":267,"completion":393,"start":394,"enrollment":395,"conditions":774,"interventions":775},[89],[14,126,195],[113,93,129,200,136,133],{"trials":777,"activeCount":98},[778],{"nctId":401,"briefTitle":402,"status":104,"phases":779,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":780,"interventions":781},[90],[126],[93,409,410,133,136,137,139,78,128,113],{"intervention":113,"totalTrials":783,"cells":784},15,{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":814,"PHASE3":870,"PHASE4":876,"NA":882},{"trials":786,"activeCount":98},[],{"trials":788,"activeCount":98},[789,800,810],{"nctId":790,"briefTitle":791,"status":490,"phases":792,"primaryCompletion":793,"completion":793,"start":794,"enrollment":357,"conditions":795,"interventions":798},"NCT03515200","Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia",[86],"2020-07-29","2018-04-20",[796,797],"Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission",[799,614,113,199,198,132,383],"Palbociclib Oral",{"nctId":801,"briefTitle":802,"status":104,"phases":803,"primaryCompletion":804,"completion":804,"start":805,"enrollment":26,"conditions":806,"interventions":809},"NCT01900509","Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies",[86],"2016-05","2013-08",[28,807,808],"Non-Hodgkin Lymphoma","Acute Leukemia",[640,135,139,641,113],{"nctId":102,"briefTitle":103,"status":104,"phases":811,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":812,"interventions":813},[86],[110,111,14],[113,114,93],{"trials":815,"activeCount":494,"soonestReadout":63},[816,820,824,835,839,843,847,851,855],{"nctId":118,"briefTitle":119,"status":104,"phases":817,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":818,"interventions":819},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":184,"briefTitle":185,"status":186,"phases":821,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":822,"interventions":823},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":825,"briefTitle":826,"status":167,"phases":827,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":832,"interventions":834},"NCT04551131","Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis",[86,87],"2025-11-07","2026-08","2021-07-13",10,[833],"Hemophagocytic Lymphohistiocytosis",[383,113,139],{"nctId":457,"briefTitle":458,"status":104,"phases":836,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":837,"interventions":838},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"nctId":61,"briefTitle":62,"status":167,"phases":840,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":841,"interventions":842},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":263,"briefTitle":264,"status":186,"phases":844,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":845,"interventions":846},[87],[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],{"nctId":304,"briefTitle":305,"status":167,"phases":848,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":849,"interventions":850},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"nctId":506,"briefTitle":507,"status":490,"phases":852,"primaryCompletion":509,"completion":509,"start":510,"enrollment":357,"conditions":853,"interventions":854},[87],[512,25,513],[199,228,225,133,136,138,515,516,113,137,132],{"nctId":856,"briefTitle":857,"status":490,"phases":858,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":861,"interventions":865},"NCT02518750","Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma",[87],"2018-03-11","2016-11-23",[14,862,863,864],"Lymphoma, Non-Hodgkin's","Leukemia, T-Cell","Leukemia, B-Cell",[113,603,866,225,867,199,317,868,274,869,201,78,139,135],"Liposomal vincristine","Peg-asparaginase","High-dose methotrexate","High-dose cytarabine",{"trials":871,"activeCount":386,"soonestReadout":375},[872],{"nctId":372,"briefTitle":373,"status":167,"phases":873,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":874,"interventions":875},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":877,"activeCount":386,"soonestReadout":267},[878],{"nctId":390,"briefTitle":391,"status":186,"phases":879,"primaryCompletion":267,"completion":393,"start":394,"enrollment":395,"conditions":880,"interventions":881},[89],[14,126,195],[113,93,129,200,136,133],{"trials":883,"activeCount":98},[884],{"nctId":401,"briefTitle":402,"status":104,"phases":885,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":886,"interventions":887},[90],[126],[93,409,410,133,136,137,139,78,128,113],{"intervention":129,"totalTrials":889,"cells":890},7,{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":913,"PHASE4":923,"NA":929},{"trials":892,"activeCount":98},[],{"trials":894,"activeCount":98},[],{"trials":896,"activeCount":539,"soonestReadout":688},[897,901,905,909],{"nctId":118,"briefTitle":119,"status":104,"phases":898,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":899,"interventions":900},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":184,"briefTitle":185,"status":186,"phases":902,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":903,"interventions":904},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":685,"briefTitle":686,"status":167,"phases":906,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":907,"interventions":908},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"nctId":263,"briefTitle":264,"status":186,"phases":910,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":911,"interventions":912},[87],[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],{"trials":914,"activeCount":386,"soonestReadout":375},[915,919],{"nctId":757,"briefTitle":758,"status":104,"phases":916,"primaryCompletion":760,"completion":761,"start":762,"enrollment":763,"conditions":917,"interventions":918},[88],[25],[133,129,139,135],{"nctId":372,"briefTitle":373,"status":167,"phases":920,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":921,"interventions":922},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":924,"activeCount":386,"soonestReadout":267},[925],{"nctId":390,"briefTitle":391,"status":186,"phases":926,"primaryCompletion":267,"completion":393,"start":394,"enrollment":395,"conditions":927,"interventions":928},[89],[14,126,195],[113,93,129,200,136,133],{"trials":930,"activeCount":98},[],{"intervention":614,"totalTrials":108,"cells":932},{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":945,"PHASE3":951,"PHASE4":953,"NA":959},{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":98},[937,941],{"nctId":790,"briefTitle":791,"status":490,"phases":938,"primaryCompletion":793,"completion":793,"start":794,"enrollment":357,"conditions":939,"interventions":940},[86],[796,797],[799,614,113,199,198,132,383],{"nctId":605,"briefTitle":606,"status":104,"phases":942,"primaryCompletion":608,"completion":609,"start":610,"enrollment":611,"conditions":943,"interventions":944},[86],[25],[83,133,384,614,443],{"trials":946,"activeCount":386,"soonestReadout":188},[947],{"nctId":184,"briefTitle":185,"status":186,"phases":948,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":949,"interventions":950},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":386,"soonestReadout":267},[955],{"nctId":390,"briefTitle":391,"status":186,"phases":956,"primaryCompletion":267,"completion":393,"start":394,"enrollment":395,"conditions":957,"interventions":958},[89],[14,126,195],[113,93,129,200,136,133],{"trials":960,"activeCount":98},[],{"intervention":78,"totalTrials":962,"cells":963},51,{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":1148,"PHASE3":1422,"PHASE4":1432,"NA":1434},{"trials":965,"activeCount":98},[],{"trials":967,"activeCount":632,"soonestReadout":1108},[968,978,990,1001,1014,1038,1050,1065,1079,1089,1104,1125,1137],{"nctId":969,"briefTitle":970,"status":104,"phases":971,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":977},"NCT00667927","Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission",[86],"1995-01","2008-01","1991-03",17,[25],[548,78,544],{"nctId":979,"briefTitle":980,"status":186,"phases":981,"primaryCompletion":982,"completion":207,"start":983,"enrollment":984,"conditions":985,"interventions":988},"NCT04881240","Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed\u002FRefractory CD19+ Leukemia",[86],"2027-07-01","2024-02-14",60,[796,986,987],"Acute Lymphoblastic Leukemia, Refractory","Pediatric ALL",[989,78,429,544],"CD19-CAR(Mem) T-cells",{"nctId":991,"briefTitle":992,"status":186,"phases":993,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":998,"interventions":999},"NCT07052370","TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies",[86],"2028-12","2030-12","2025-09-25",30,[541],[1000,78,429,549,639,544,215,273],"Thymoglobulin",{"nctId":1002,"briefTitle":1003,"status":186,"phases":1004,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":412,"conditions":1008,"interventions":1012},"NCT06326463","CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies",[86],"2030-07-01","2031-07-01","2024-10-16",[541,1009,1010,634,1011],"ALL, Childhood","AML, Childhood","MDS",[429,78,1013,544],"CD70-CAR T cell",{"nctId":1015,"briefTitle":1016,"status":104,"phases":1017,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":1022,"interventions":1035},"NCT04023669","Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3\u002FGroup 4 or SHH Medulloblastoma Brain Tumors",[86],"2023-05-01","2025-01-13","2019-08-08",21,[1023,1024,1025,1026,297,1027,1028,1029,1030,1031,1032,1033,1034],"Brain Tumor","Brain Tumor, Recurrent","Brain Tumor, Refractory","Brain Tumor, Pediatric","Medulloblastoma Recurrent","Medulloblastoma, Non-WNT\u002FNon-SHH","Medulloblastoma, Non-WNT\u002FNon-SHH, Group 3","Medulloblastoma, Non-WNT\u002FNon-SHH, Group 4","Brain Cancer","CNS Cancer","CNS Tumor","CNS Neoplasm",[1036,78,302,284,1037],"Prexasertib","peg-filgrastim",{"nctId":1039,"briefTitle":1040,"status":104,"phases":1041,"primaryCompletion":1042,"completion":1043,"start":1044,"enrollment":1045,"conditions":1046,"interventions":1048},"NCT00705120","Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation",[86],"2000-07","2007-10","1995-11",9,[1047],"Osteogenesis Imperfecta",[78,1049,548],"Cyclosporin",{"nctId":1051,"briefTitle":1052,"status":186,"phases":1053,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":406,"conditions":1057,"interventions":1063},"NCT07222735","Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed\u002FRefractory Sarcomas",[86],"2030-11-05","2031-11-05","2026-01-21",[1058,1059,1060,1061,1062],"Sarcoma","Childhood Osteosarcoma","Childhood Rhabdomyosarcoma","Childhood Soft Tissue Sarcoma","Ewing Sarcoma",[429,78,1064],"B7-H3-CAR T Cells",{"nctId":1066,"briefTitle":1067,"status":104,"phases":1068,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1076},"NCT00697671","Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies",[86],"2013-02","2013-05","2007-03",48,[14,1074,745,566,1075],"Chronic Myelogenous Leukemia","Non-Hodgkin's Lymphoma",[1077,1078,135,78,139],"Immunotherapy","Interleukin-2",{"nctId":1080,"briefTitle":1081,"status":104,"phases":1082,"primaryCompletion":805,"completion":805,"start":1083,"enrollment":1084,"conditions":1085,"interventions":1088},"NCT00665990","Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia",[86],"2007-11",49,[1086,1087],"Refractory Solid Tumors","Leukemia",[255,256,78],{"nctId":1090,"briefTitle":1091,"status":186,"phases":1092,"primaryCompletion":1093,"completion":1094,"start":793,"enrollment":1095,"conditions":1096,"interventions":1101},"NCT04318678","CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)",[86],"2029-07-29","2030-07-29",108,[1097,1098,1099,1100],"AML\u002FMDS","B-ALL","T-ALL","BPDCN",[1102,78,429,544,1103],"CD123-CAR T","Rituximab",{"nctId":1105,"briefTitle":1106,"status":186,"phases":1107,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1072,"conditions":1111,"interventions":1123},"NCT04897321","B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",[86],"2027-03-01","2028-03-01","2022-07-06",[1112,526,32,23,1062,1113,1114,173,1115,1116,1117,1118,1119,1120,1121,1122],"Pediatric Solid Tumor","Wilms Tumor","Adrenocortical Cancer","Germ Cell Cancer","Rhabdoid Tumor","Clear Cell Sarcoma","Hepatoblastoma","Melanoma","Carcinoma","Malignant Peripheral Nerve Sheath Tumors","Soft Tissue Sarcoma",[429,78,287,1124],"B7-H3 CAR T cells",{"nctId":1126,"briefTitle":1127,"status":186,"phases":1128,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":725,"conditions":1132,"interventions":1135},"NCT07257419","CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+\u002FCD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed\u002FRefractory CD19+ ALL and Lymphoma",[86],"2031-12","2035-12","2026-06-03",[1133,1134,541],"Relapsed Pediatric ALL","Hematopoietic Cell Transplantation",[1136,78,429,549,544,639,215],"Anti-Thymocyte Globulin",{"nctId":1138,"briefTitle":1139,"status":186,"phases":1140,"primaryCompletion":1141,"completion":1142,"start":1143,"enrollment":997,"conditions":1144,"interventions":1147},"NCT06777979","CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia",[86],"2030-01","2031-01","2025-04-28",[14,1145,1146],"Recurrent Acute Lymphoblastic Leukemia","Recurrent B Acute Lymphoblastic Leukemia",[429,78,544],{"trials":1149,"activeCount":1021,"soonestReadout":43},[1150,1154,1158,1174,1178,1182,1186,1199,1203,1207,1218,1222,1232,1236,1240,1244,1255,1265,1277,1289,1293,1304,1308,1314,1324,1328,1344,1354,1358,1375,1379,1399,1403,1407,1418],{"nctId":118,"briefTitle":119,"status":104,"phases":1151,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":1152,"interventions":1153},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":141,"briefTitle":142,"status":104,"phases":1155,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":1156,"interventions":1157},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":1159,"briefTitle":1160,"status":167,"phases":1161,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":1166,"interventions":1171},"NCT02790515","Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation",[87],"2025-07-01","2026-07-01","2016-07-14",170,[622,621,1167,1168,1169,623,1170],"Myeloid Sarcoma","Chronic Myeloid Leukemia (CML)","Juvenile Myelomonocytic Leukemia (JMML)","Non-Hodgkin Lymphoma (NHL)",[545,273,78,429,161,639,544,1103,752,549,1172,1173],"HPC,A","Sirolimus",{"nctId":41,"briefTitle":42,"status":167,"phases":1175,"primaryCompletion":43,"completion":169,"start":170,"enrollment":171,"conditions":1176,"interventions":1177},[87],[173,174,175,176],[44,155,150,178,154,179,180,181,182],{"nctId":184,"briefTitle":185,"status":186,"phases":1179,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":1180,"interventions":1181},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":203,"briefTitle":204,"status":167,"phases":1183,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":1184,"interventions":1185},[87],[28],[212,139,132,213,93,214,128,215,216,78,217],{"nctId":1187,"briefTitle":1188,"status":490,"phases":1189,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":357,"conditions":1193,"interventions":1195},"NCT02259348","Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation",[87],"2015-04","2016-03","2014-10",[622,621,1167,1194,1169,623,1170],"Chronic Myelogenous Leukemia (CML)",[78,429,161,1078,639,549,1103,1196,1197,1198],"Natural killer cell therapy","T-cell depleted HPC transplant","CD45RA-depleted HPC transplant",{"nctId":457,"briefTitle":458,"status":104,"phases":1200,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":1201,"interventions":1202},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"nctId":61,"briefTitle":62,"status":167,"phases":1204,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":1205,"interventions":1206},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":1208,"briefTitle":1209,"status":186,"phases":1210,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1216},"NCT06847269","CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia",[87],"2030-03","2031-04","2025-05-21",25,[14,311],[429,78,544,1217],"CD19-CAR T cell",{"nctId":231,"briefTitle":232,"status":186,"phases":1219,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":1220,"interventions":1221},[87],[32],[93,240,78,241,242,243,244],{"nctId":1223,"briefTitle":1224,"status":490,"phases":1225,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":108,"conditions":1228,"interventions":1229},"NCT00808899","Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma",[87],"2009-07","2008-12",[23],[1230,114,78,132,139,299,355,1231],"Temsirolimus","13-cis-retinoic acid",{"nctId":246,"briefTitle":247,"status":167,"phases":1233,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":1234,"interventions":1235},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"nctId":263,"briefTitle":264,"status":186,"phases":1237,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":1238,"interventions":1239},[87],[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],{"nctId":66,"briefTitle":67,"status":167,"phases":1241,"primaryCompletion":68,"completion":278,"start":279,"enrollment":280,"conditions":1242,"interventions":1243},[87],[282],[44,151,284,285,286,154,150,287,155],{"nctId":1245,"briefTitle":1246,"status":490,"phases":1247,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":171,"conditions":1250,"interventions":1252},"NCT02199041","Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen",[87],"2017-05-23","2014-07-11",[1251],"Hematological Malignancies",[78,549,429,639,544,161,1253,752,500,1254],"Mycophenolate mofetil","Lymphocyte infusions",{"nctId":1256,"briefTitle":1257,"status":104,"phases":1258,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":108,"conditions":1261,"interventions":1262},"NCT00004006","Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma",[87],"2005-09","1997-11",[282],[284,286,150,1263,154,1264],"doxorubicin hydrochloride","topotecan hydrochloride",{"nctId":1266,"briefTitle":1267,"status":186,"phases":1268,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1275},"NCT06528691","Entrectinib as a Single Agent in Upfront Therapy for Children \u003C3 Years of Age With NTRK1\u002F2\u002F3 or ROS1-FUSED CNS Tumors",[87],"2027-11","2032-11","2026-05-01",52,[1274,1033],"High Grade Glioma",[1276,78,139,354,161,356],"Entrectinib",{"nctId":1278,"briefTitle":1279,"status":186,"phases":1280,"primaryCompletion":1281,"completion":1005,"start":1282,"enrollment":1021,"conditions":1283,"interventions":1286},"NCT04558736","Haploidentical HCT for Severe Aplastic Anemia",[87],"2029-07-01","2021-01-21",[1284,1285],"Aplastic Anemia","Bone Marrow Failure Syndrome",[1136,429,78,544,161,1287,1288],"HPC, A","CD45RA-depleted DLI",{"nctId":289,"briefTitle":290,"status":167,"phases":1290,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":1291,"interventions":1292},[87],[297],[78,299,93,300,301,302],{"nctId":56,"briefTitle":57,"status":167,"phases":1294,"primaryCompletion":58,"completion":266,"start":1295,"enrollment":1296,"conditions":1297,"interventions":1301},[87],"2013-08-12",77,[1298,1299,1300],"Stage II Childhood Hodgkin Lymphoma","Stage III Childhood Hodgkin Lymphoma","Stage IV Childhood Hodgkin Lymphoma",[59,154,1302,155,150,1303,284],"prednisone","Dacarbazine",{"nctId":304,"briefTitle":305,"status":167,"phases":1305,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":1306,"interventions":1307},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"nctId":75,"briefTitle":76,"status":167,"phases":1309,"primaryCompletion":77,"completion":1163,"start":1310,"enrollment":171,"conditions":1311,"interventions":1312},[86,87],"2018-07-24",[796,986],[78,429,544,1313],"CD19- specific CAR engineered autologous T-cells",{"nctId":1315,"briefTitle":1316,"status":186,"phases":1317,"primaryCompletion":1318,"completion":1130,"start":1319,"enrollment":1320,"conditions":1321,"interventions":1323},"NCT07428993","Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma",[87],"2034-12","2026-06",41,[1322],"Pediatric Osteosarcoma",[78,429,544],{"nctId":739,"briefTitle":740,"status":490,"phases":1325,"primaryCompletion":619,"completion":619,"start":742,"enrollment":743,"conditions":1326,"interventions":1327},[87],[14,564,565,745,566,746,747],[470,474,156,749,150,750,751,752,753],{"nctId":1329,"briefTitle":1330,"status":186,"phases":1331,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":1336,"interventions":1342},"NCT05468359","Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients",[86,87],"2032-06","2037-06","2022-11-07",64,[1337,1338,1339,1340,1112,1341],"Refractory Solid Tumor","Hepatocellular Carcinoma","Malignant Solid Tumor","Pediatric Cancer","Fibrolamellar Carcinoma",[1343,256,255,78],"Atezolizumab",{"nctId":1345,"briefTitle":1346,"status":104,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1352},"NCT00003211","Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor",[87],"2007-06","1996-10",94,[369],[284,1353,153,150,468],"amifostine trihydrate",{"nctId":856,"briefTitle":857,"status":490,"phases":1355,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":1356,"interventions":1357},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"nctId":1359,"briefTitle":1360,"status":167,"phases":1361,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":1366,"interventions":1370},"NCT03849651","TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies",[87],"2024-08-07","2026-06-07","2019-01-31",69,[622,621,1367,1368,28,1369,1169,1168],"Myelodysplastic Syndromes (MDS)","NK-Cell Leukemia","Non Hodgkin Lymphoma (NHL)",[78,429,549,639,1371,544,1372,273,1373,1374,1288],"G-csf","ATG","TCRα\u002Fβ+","CD19+",{"nctId":319,"briefTitle":320,"status":104,"phases":1376,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":1377,"interventions":1378},[87],[327],[329,214,330,78,93,213,139,128,161],{"nctId":1380,"briefTitle":1381,"status":104,"phases":1382,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":1387,"interventions":1393},"NCT00566696","Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies",[87],"2016-01-27","2020-02-06","2007-12-14",73,[1388,1389,1390,1169,1391,28,1392,623],"Leukemia, Acute Lymphocytic (ALL)","Leukemia, Myeloid, Acute(AML)","Leukemia, Myeloid, Chronic(CML)","Hemoglobinuria, Paroxysmal Nocturnal (PNH)","Lymphoma, Non-Hodgkin (NHL)",[429,1394,1395,1253,1396,1397,78,545,161,1398],"Thioplex®","L-phenylalanine mustard","Rituxan™","Alemtuzumab","Muromonab",{"nctId":332,"briefTitle":333,"status":167,"phases":1400,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":1401,"interventions":1402},[87],[340,341],[343,344,153,286,150,154,151,44],{"nctId":534,"briefTitle":535,"status":490,"phases":1404,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":1405,"interventions":1406},[87],[541,542],[383,544,545,546,78,429,136,547,548,549],{"nctId":1408,"briefTitle":1409,"status":104,"phases":1410,"primaryCompletion":1411,"completion":1412,"start":1413,"enrollment":1414,"conditions":1415,"interventions":1416},"NCT01807611","Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy",[87],"2021-08-27","2021-09-27","2013-05-16",82,[1087,634],[429,78,549,639,1172,1417,161,544,1253],"TC-NK",{"nctId":346,"briefTitle":347,"status":186,"phases":1419,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":1420,"interventions":1421},[87],[297],[136,299,93,78,354,355,139,356,215,136],{"trials":1423,"activeCount":386,"soonestReadout":375},[1424,1428],{"nctId":361,"briefTitle":362,"status":104,"phases":1425,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":1426,"interventions":1427},[88],[369],[284,153,150,44],{"nctId":372,"briefTitle":373,"status":167,"phases":1429,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1430,"interventions":1431},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1433,"activeCount":98},[],{"trials":1435,"activeCount":98},[1436],{"nctId":401,"briefTitle":402,"status":104,"phases":1437,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":1438,"interventions":1439},[90],[126],[93,409,410,133,136,137,139,78,128,113],{"intervention":139,"totalTrials":1441,"cells":1442},27,{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1459,"PHASE3":1545,"PHASE4":1555,"NA":1557},{"trials":1444,"activeCount":98},[],{"trials":1446,"activeCount":98},[1447,1451,1455],{"nctId":1066,"briefTitle":1067,"status":104,"phases":1448,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":1449,"interventions":1450},[86],[14,1074,745,566,1075],[1077,1078,135,78,139],{"nctId":627,"briefTitle":628,"status":104,"phases":1452,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":1453,"interventions":1454},[86],[23,634,635],[637,638,152,548,639,160,640,139,133,354,161,641],{"nctId":801,"briefTitle":802,"status":104,"phases":1456,"primaryCompletion":804,"completion":804,"start":805,"enrollment":26,"conditions":1457,"interventions":1458},[86],[28,807,808],[640,135,139,641,113],{"trials":1460,"activeCount":357,"soonestReadout":43},[1461,1465,1469,1473,1477,1481,1485,1489,1493,1497,1501,1505,1509,1513,1517,1521,1525,1529,1533,1537,1541],{"nctId":118,"briefTitle":119,"status":104,"phases":1462,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":1463,"interventions":1464},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":141,"briefTitle":142,"status":104,"phases":1466,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":1467,"interventions":1468},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":41,"briefTitle":42,"status":167,"phases":1470,"primaryCompletion":43,"completion":169,"start":170,"enrollment":171,"conditions":1471,"interventions":1472},[87],[173,174,175,176],[44,155,150,178,154,179,180,181,182],{"nctId":825,"briefTitle":826,"status":167,"phases":1474,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":1475,"interventions":1476},[86,87],[833],[383,113,139],{"nctId":203,"briefTitle":204,"status":167,"phases":1478,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":1479,"interventions":1480},[87],[28],[212,139,132,213,93,214,128,215,216,78,217],{"nctId":457,"briefTitle":458,"status":104,"phases":1482,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":1483,"interventions":1484},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"nctId":61,"briefTitle":62,"status":167,"phases":1486,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":1487,"interventions":1488},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":1223,"briefTitle":1224,"status":490,"phases":1490,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":108,"conditions":1491,"interventions":1492},[87],[23],[1230,114,78,132,139,299,355,1231],{"nctId":246,"briefTitle":247,"status":167,"phases":1494,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":1495,"interventions":1496},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"nctId":685,"briefTitle":686,"status":167,"phases":1498,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":1499,"interventions":1500},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"nctId":66,"briefTitle":67,"status":167,"phases":1502,"primaryCompletion":68,"completion":278,"start":279,"enrollment":280,"conditions":1503,"interventions":1504},[87],[282],[44,151,284,285,286,154,150,287,155],{"nctId":1256,"briefTitle":1257,"status":104,"phases":1506,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":108,"conditions":1507,"interventions":1508},[87],[282],[284,286,150,1263,154,1264],{"nctId":1266,"briefTitle":1267,"status":186,"phases":1510,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":1511,"interventions":1512},[87],[1274,1033],[1276,78,139,354,161,356],{"nctId":56,"briefTitle":57,"status":167,"phases":1514,"primaryCompletion":58,"completion":266,"start":1295,"enrollment":1296,"conditions":1515,"interventions":1516},[87],[1298,1299,1300],[59,154,1302,155,150,1303,284],{"nctId":304,"briefTitle":305,"status":167,"phases":1518,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":1519,"interventions":1520},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"nctId":719,"briefTitle":720,"status":721,"phases":1522,"primaryCompletion":249,"completion":723,"start":724,"enrollment":725,"conditions":1523,"interventions":1524},[87],[25],[83,443,133,728,729,730,731,732,139,733],{"nctId":856,"briefTitle":857,"status":490,"phases":1526,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":1527,"interventions":1528},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"nctId":518,"briefTitle":519,"status":104,"phases":1530,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":1531,"interventions":1532},[87],[526,527],[255,299,132,136,258,154],{"nctId":319,"briefTitle":320,"status":104,"phases":1534,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":1535,"interventions":1536},[87],[327],[329,214,330,78,93,213,139,128,161],{"nctId":332,"briefTitle":333,"status":167,"phases":1538,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":1539,"interventions":1540},[87],[340,341],[343,344,153,286,150,154,151,44],{"nctId":346,"briefTitle":347,"status":186,"phases":1542,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":1543,"interventions":1544},[87],[297],[136,299,93,78,354,355,139,356,215,136],{"trials":1546,"activeCount":386,"soonestReadout":375},[1547,1551],{"nctId":757,"briefTitle":758,"status":104,"phases":1548,"primaryCompletion":760,"completion":761,"start":762,"enrollment":763,"conditions":1549,"interventions":1550},[88],[25],[133,129,139,135],{"nctId":372,"briefTitle":373,"status":167,"phases":1552,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1553,"interventions":1554},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1556,"activeCount":98},[],{"trials":1558,"activeCount":98},[1559],{"nctId":401,"briefTitle":402,"status":104,"phases":1560,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":1561,"interventions":1562},[90],[126],[93,409,410,133,136,137,139,78,128,113],{"intervention":132,"totalTrials":33,"cells":1564},{"EARLY_PHASE1":1565,"PHASE1":1567,"PHASE2":1573,"PHASE3":1634,"PHASE4":1640,"NA":1642},{"trials":1566,"activeCount":98},[],{"trials":1568,"activeCount":98},[1569],{"nctId":790,"briefTitle":791,"status":490,"phases":1570,"primaryCompletion":793,"completion":793,"start":794,"enrollment":357,"conditions":1571,"interventions":1572},[86],[796,797],[799,614,113,199,198,132,383],{"trials":1574,"activeCount":554,"soonestReadout":43},[1575,1579,1583,1587,1591,1595,1599,1603,1607,1611,1630],{"nctId":118,"briefTitle":119,"status":104,"phases":1576,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":1577,"interventions":1578},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":141,"briefTitle":142,"status":104,"phases":1580,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":1581,"interventions":1582},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":41,"briefTitle":42,"status":167,"phases":1584,"primaryCompletion":43,"completion":169,"start":170,"enrollment":171,"conditions":1585,"interventions":1586},[87],[173,174,175,176],[44,155,150,178,154,179,180,181,182],{"nctId":203,"briefTitle":204,"status":167,"phases":1588,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":1589,"interventions":1590},[87],[28],[212,139,132,213,93,214,128,215,216,78,217],{"nctId":1223,"briefTitle":1224,"status":490,"phases":1592,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":108,"conditions":1593,"interventions":1594},[87],[23],[1230,114,78,132,139,299,355,1231],{"nctId":246,"briefTitle":247,"status":167,"phases":1596,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":1597,"interventions":1598},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"nctId":66,"briefTitle":67,"status":167,"phases":1600,"primaryCompletion":68,"completion":278,"start":279,"enrollment":280,"conditions":1601,"interventions":1602},[87],[282],[44,151,284,285,286,154,150,287,155],{"nctId":56,"briefTitle":57,"status":167,"phases":1604,"primaryCompletion":58,"completion":266,"start":1295,"enrollment":1296,"conditions":1605,"interventions":1606},[87],[1298,1299,1300],[59,154,1302,155,150,1303,284],{"nctId":506,"briefTitle":507,"status":490,"phases":1608,"primaryCompletion":509,"completion":509,"start":510,"enrollment":357,"conditions":1609,"interventions":1610},[87],[512,25,513],[199,228,225,133,136,138,515,516,113,137,132],{"nctId":1612,"briefTitle":1613,"status":186,"phases":1614,"primaryCompletion":1615,"completion":1333,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1628},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[86,87],"2034-06","2024-03-27",139,[1619,1620,1621,1622,1623,1624,1625,1626,1627],"Adipocytic Neoplasm","Liposarcoma","Atypical Fibroxanthoma","Angiomatoid Fibrous Histiocytoma","Myoepithelioma","Fibrosarcoma NOS","Myxofibrosarcoma","Angiosarcoma","Osteosarcoma, Extraskeletal",[1629,258,132,428],"Pazopanib",{"nctId":518,"briefTitle":519,"status":104,"phases":1631,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":1632,"interventions":1633},[87],[526,527],[255,299,132,136,258,154],{"trials":1635,"activeCount":386,"soonestReadout":375},[1636],{"nctId":372,"briefTitle":373,"status":167,"phases":1637,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1638,"interventions":1639},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1641,"activeCount":98},[],{"trials":1643,"activeCount":98},[],{"intervention":273,"totalTrials":554,"cells":1645},{"EARLY_PHASE1":1646,"PHASE1":1648,"PHASE2":1654,"PHASE3":1672,"PHASE4":1678,"NA":1680},{"trials":1647,"activeCount":98},[],{"trials":1649,"activeCount":386,"soonestReadout":994},[1650],{"nctId":991,"briefTitle":992,"status":186,"phases":1651,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":1652,"interventions":1653},[86],[541],[1000,78,429,549,639,544,215,273],{"trials":1655,"activeCount":108,"soonestReadout":307},[1656,1660,1664,1668],{"nctId":1159,"briefTitle":1160,"status":167,"phases":1657,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":1658,"interventions":1659},[87],[622,621,1167,1168,1169,623,1170],[545,273,78,429,161,639,544,1103,752,549,1172,1173],{"nctId":263,"briefTitle":264,"status":186,"phases":1661,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":1662,"interventions":1663},[87],[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],{"nctId":304,"briefTitle":305,"status":167,"phases":1665,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":1666,"interventions":1667},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"nctId":1359,"briefTitle":1360,"status":167,"phases":1669,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":1670,"interventions":1671},[87],[622,621,1367,1368,28,1369,1169,1168],[78,429,549,639,1371,544,1372,273,1373,1374,1288],{"trials":1673,"activeCount":386,"soonestReadout":375},[1674],{"nctId":372,"briefTitle":373,"status":167,"phases":1675,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1676,"interventions":1677},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1679,"activeCount":98},[],{"trials":1681,"activeCount":98},[],{"intervention":198,"totalTrials":554,"cells":1683},{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1705,"PHASE3":1719,"PHASE4":1725,"NA":1727},{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[1688,1692],{"nctId":790,"briefTitle":791,"status":490,"phases":1689,"primaryCompletion":793,"completion":793,"start":794,"enrollment":357,"conditions":1690,"interventions":1691},[86],[796,797],[799,614,113,199,198,132,383],{"nctId":1693,"briefTitle":1694,"status":104,"phases":1695,"primaryCompletion":1696,"completion":1697,"start":1698,"enrollment":1699,"conditions":1700,"interventions":1703},"NCT01644773","Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)",[86],"2018-03-07","2018-09-28","2012-11-27",36,[1701,1702],"Diffuse Intrinsic Pontine Glioma","High-grade Glioma",[1704,198],"Crizotinib",{"trials":1706,"activeCount":539,"soonestReadout":307},[1707,1711,1715],{"nctId":184,"briefTitle":185,"status":186,"phases":1708,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":1709,"interventions":1710},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":263,"briefTitle":264,"status":186,"phases":1712,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":1713,"interventions":1714},[87],[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],{"nctId":304,"briefTitle":305,"status":167,"phases":1716,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":1717,"interventions":1718},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"trials":1720,"activeCount":386,"soonestReadout":375},[1721],{"nctId":372,"briefTitle":373,"status":167,"phases":1722,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1723,"interventions":1724},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1726,"activeCount":98},[],{"trials":1728,"activeCount":98},[],{"intervention":137,"totalTrials":632,"cells":1730},{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1761,"PHASE4":1767,"NA":1769},{"trials":1732,"activeCount":98},[],{"trials":1734,"activeCount":98},[],{"trials":1736,"activeCount":539,"soonestReadout":63},[1737,1741,1745,1749,1753,1757],{"nctId":118,"briefTitle":119,"status":104,"phases":1738,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":1739,"interventions":1740},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":184,"briefTitle":185,"status":186,"phases":1742,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":1743,"interventions":1744},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":457,"briefTitle":458,"status":104,"phases":1746,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":1747,"interventions":1748},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"nctId":61,"briefTitle":62,"status":167,"phases":1750,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":1751,"interventions":1752},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":304,"briefTitle":305,"status":167,"phases":1754,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":1755,"interventions":1756},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"nctId":506,"briefTitle":507,"status":490,"phases":1758,"primaryCompletion":509,"completion":509,"start":510,"enrollment":357,"conditions":1759,"interventions":1760},[87],[512,25,513],[199,228,225,133,136,138,515,516,113,137,132],{"trials":1762,"activeCount":386,"soonestReadout":375},[1763],{"nctId":372,"briefTitle":373,"status":167,"phases":1764,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1765,"interventions":1766},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1768,"activeCount":98},[],{"trials":1770,"activeCount":98},[1771],{"nctId":401,"briefTitle":402,"status":104,"phases":1772,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":1773,"interventions":1774},[90],[126],[93,409,410,133,136,137,139,78,128,113],{"intervention":199,"totalTrials":554,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1785,"PHASE3":1803,"PHASE4":1809,"NA":1811},{"trials":1778,"activeCount":98},[],{"trials":1780,"activeCount":98},[1781],{"nctId":790,"briefTitle":791,"status":490,"phases":1782,"primaryCompletion":793,"completion":793,"start":794,"enrollment":357,"conditions":1783,"interventions":1784},[86],[796,797],[799,614,113,199,198,132,383],{"trials":1786,"activeCount":445,"soonestReadout":63},[1787,1791,1795,1799],{"nctId":184,"briefTitle":185,"status":186,"phases":1788,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":1789,"interventions":1790},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":61,"briefTitle":62,"status":167,"phases":1792,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":1793,"interventions":1794},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":506,"briefTitle":507,"status":490,"phases":1796,"primaryCompletion":509,"completion":509,"start":510,"enrollment":357,"conditions":1797,"interventions":1798},[87],[512,25,513],[199,228,225,133,136,138,515,516,113,137,132],{"nctId":856,"briefTitle":857,"status":490,"phases":1800,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":1801,"interventions":1802},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"trials":1804,"activeCount":386,"soonestReadout":375},[1805],{"nctId":372,"briefTitle":373,"status":167,"phases":1806,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1807,"interventions":1808},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1810,"activeCount":98},[],{"trials":1812,"activeCount":98},[],{"intervention":134,"totalTrials":108,"cells":1814},{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1819,"PHASE3":1833,"PHASE4":1839,"NA":1841},{"trials":1816,"activeCount":98},[],{"trials":1818,"activeCount":98},[],{"trials":1820,"activeCount":445,"soonestReadout":188},[1821,1825,1829],{"nctId":118,"briefTitle":119,"status":104,"phases":1822,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":1823,"interventions":1824},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":184,"briefTitle":185,"status":186,"phases":1826,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":1827,"interventions":1828},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":263,"briefTitle":264,"status":186,"phases":1830,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":1831,"interventions":1832},[87],[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],{"trials":1834,"activeCount":386,"soonestReadout":375},[1835],{"nctId":372,"briefTitle":373,"status":167,"phases":1836,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1837,"interventions":1838},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1840,"activeCount":98},[],{"trials":1842,"activeCount":98},[],{"intervention":226,"totalTrials":108,"cells":1844},{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1849,"PHASE3":1863,"PHASE4":1869,"NA":1871},{"trials":1846,"activeCount":98},[],{"trials":1848,"activeCount":98},[],{"trials":1850,"activeCount":445,"soonestReadout":63},[1851,1855,1859],{"nctId":457,"briefTitle":458,"status":104,"phases":1852,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":1853,"interventions":1854},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"nctId":61,"briefTitle":62,"status":167,"phases":1856,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":1857,"interventions":1858},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":304,"briefTitle":305,"status":167,"phases":1860,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":1861,"interventions":1862},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"trials":1864,"activeCount":386,"soonestReadout":375},[1865],{"nctId":372,"briefTitle":373,"status":167,"phases":1866,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1867,"interventions":1868},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1870,"activeCount":98},[],{"trials":1872,"activeCount":98},[],{"intervention":315,"totalTrials":539,"cells":1874},{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1879,"PHASE3":1889,"PHASE4":1895,"NA":1897},{"trials":1876,"activeCount":98},[],{"trials":1878,"activeCount":98},[],{"trials":1880,"activeCount":445,"soonestReadout":307},[1881,1885],{"nctId":184,"briefTitle":185,"status":186,"phases":1882,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":1883,"interventions":1884},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":304,"briefTitle":305,"status":167,"phases":1886,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":1887,"interventions":1888},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"trials":1890,"activeCount":386,"soonestReadout":375},[1891],{"nctId":372,"briefTitle":373,"status":167,"phases":1892,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1893,"interventions":1894},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1896,"activeCount":98},[],{"trials":1898,"activeCount":98},[],{"intervention":128,"totalTrials":554,"cells":1900},{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1905,"PHASE3":1923,"PHASE4":1929,"NA":1931},{"trials":1902,"activeCount":98},[],{"trials":1904,"activeCount":98},[],{"trials":1906,"activeCount":445,"soonestReadout":58},[1907,1911,1915,1919],{"nctId":118,"briefTitle":119,"status":104,"phases":1908,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":1909,"interventions":1910},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":203,"briefTitle":204,"status":167,"phases":1912,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":1913,"interventions":1914},[87],[28],[212,139,132,213,93,214,128,215,216,78,217],{"nctId":56,"briefTitle":57,"status":167,"phases":1916,"primaryCompletion":58,"completion":266,"start":1295,"enrollment":1296,"conditions":1917,"interventions":1918},[87],[1298,1299,1300],[59,154,1302,155,150,1303,284],{"nctId":319,"briefTitle":320,"status":104,"phases":1920,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":1921,"interventions":1922},[87],[327],[329,214,330,78,93,213,139,128,161],{"trials":1924,"activeCount":386,"soonestReadout":375},[1925],{"nctId":372,"briefTitle":373,"status":167,"phases":1926,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1927,"interventions":1928},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1930,"activeCount":98},[],{"trials":1932,"activeCount":98},[1933],{"nctId":401,"briefTitle":402,"status":104,"phases":1934,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":1935,"interventions":1936},[90],[126],[93,409,410,133,136,137,139,78,128,113],{"intervention":383,"totalTrials":108,"cells":1938},{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1947,"PHASE3":1957,"PHASE4":1963,"NA":1965},{"trials":1940,"activeCount":98},[],{"trials":1942,"activeCount":98},[1943],{"nctId":790,"briefTitle":791,"status":490,"phases":1944,"primaryCompletion":793,"completion":793,"start":794,"enrollment":357,"conditions":1945,"interventions":1946},[86],[796,797],[799,614,113,199,198,132,383],{"trials":1948,"activeCount":386,"soonestReadout":828},[1949,1953],{"nctId":825,"briefTitle":826,"status":167,"phases":1950,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":1951,"interventions":1952},[86,87],[833],[383,113,139],{"nctId":534,"briefTitle":535,"status":490,"phases":1954,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":1955,"interventions":1956},[87],[541,542],[383,544,545,546,78,429,136,547,548,549],{"trials":1958,"activeCount":386,"soonestReadout":375},[1959],{"nctId":372,"briefTitle":373,"status":167,"phases":1960,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1961,"interventions":1962},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1964,"activeCount":98},[],{"trials":1966,"activeCount":98},[],{"intervention":201,"totalTrials":539,"cells":1968},{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1983,"PHASE4":1989,"NA":1991},{"trials":1970,"activeCount":98},[],{"trials":1972,"activeCount":98},[],{"trials":1974,"activeCount":386,"soonestReadout":188},[1975,1979],{"nctId":184,"briefTitle":185,"status":186,"phases":1976,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":1977,"interventions":1978},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":856,"briefTitle":857,"status":490,"phases":1980,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":1981,"interventions":1982},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"trials":1984,"activeCount":386,"soonestReadout":375},[1985],{"nctId":372,"briefTitle":373,"status":167,"phases":1986,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":1987,"interventions":1988},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":1990,"activeCount":98},[],{"trials":1992,"activeCount":98},[],{"intervention":228,"totalTrials":539,"cells":1994},{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2009,"PHASE4":2015,"NA":2017},{"trials":1996,"activeCount":98},[],{"trials":1998,"activeCount":98},[],{"trials":2000,"activeCount":386,"soonestReadout":63},[2001,2005],{"nctId":61,"briefTitle":62,"status":167,"phases":2002,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":2003,"interventions":2004},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":506,"briefTitle":507,"status":490,"phases":2006,"primaryCompletion":509,"completion":509,"start":510,"enrollment":357,"conditions":2007,"interventions":2008},[87],[512,25,513],[199,228,225,133,136,138,515,516,113,137,132],{"trials":2010,"activeCount":386,"soonestReadout":375},[2011],{"nctId":372,"briefTitle":373,"status":167,"phases":2012,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":2013,"interventions":2014},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":2016,"activeCount":98},[],{"trials":2018,"activeCount":98},[],{"intervention":384,"totalTrials":539,"cells":2020},{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2029,"PHASE3":2035,"PHASE4":2041,"NA":2043},{"trials":2022,"activeCount":98},[],{"trials":2024,"activeCount":98},[2025],{"nctId":605,"briefTitle":606,"status":104,"phases":2026,"primaryCompletion":608,"completion":609,"start":610,"enrollment":611,"conditions":2027,"interventions":2028},[86],[25],[83,133,384,614,443],{"trials":2030,"activeCount":386,"soonestReadout":688},[2031],{"nctId":685,"briefTitle":686,"status":167,"phases":2032,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":2033,"interventions":2034},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"trials":2036,"activeCount":386,"soonestReadout":375},[2037],{"nctId":372,"briefTitle":373,"status":167,"phases":2038,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":2039,"interventions":2040},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":2042,"activeCount":98},[],{"trials":2044,"activeCount":98},[],{"intervention":135,"totalTrials":831,"cells":2046},{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2071,"PHASE3":2089,"PHASE4":2099,"NA":2101},{"trials":2048,"activeCount":98},[],{"trials":2050,"activeCount":98},[2051,2059,2063,2067],{"nctId":2052,"briefTitle":2053,"status":104,"phases":2054,"primaryCompletion":2055,"completion":364,"start":106,"enrollment":743,"conditions":2056,"interventions":2058},"NCT00824135","Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies",[86],"2012-10",[2057],"Hematologic Malignancies",[135,549,639,1253,1103],{"nctId":1066,"briefTitle":1067,"status":104,"phases":2060,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":2061,"interventions":2062},[86],[14,1074,745,566,1075],[1077,1078,135,78,139],{"nctId":643,"briefTitle":644,"status":104,"phases":2064,"primaryCompletion":38,"completion":38,"start":646,"enrollment":647,"conditions":2065,"interventions":2066},[86],[25,649,566,650,651],[256,133,135],{"nctId":801,"briefTitle":802,"status":104,"phases":2068,"primaryCompletion":804,"completion":804,"start":805,"enrollment":26,"conditions":2069,"interventions":2070},[86],[28,807,808],[640,135,139,641,113],{"trials":2072,"activeCount":98},[2073,2077,2081,2085],{"nctId":118,"briefTitle":119,"status":104,"phases":2074,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":2075,"interventions":2076},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":457,"briefTitle":458,"status":104,"phases":2078,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":2079,"interventions":2080},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"nctId":739,"briefTitle":740,"status":490,"phases":2082,"primaryCompletion":619,"completion":619,"start":742,"enrollment":743,"conditions":2083,"interventions":2084},[87],[14,564,565,745,566,746,747],[470,474,156,749,150,750,751,752,753],{"nctId":856,"briefTitle":857,"status":490,"phases":2086,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":2087,"interventions":2088},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"trials":2090,"activeCount":386,"soonestReadout":375},[2091,2095],{"nctId":757,"briefTitle":758,"status":104,"phases":2092,"primaryCompletion":760,"completion":761,"start":762,"enrollment":763,"conditions":2093,"interventions":2094},[88],[25],[133,129,139,135],{"nctId":372,"briefTitle":373,"status":167,"phases":2096,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":2097,"interventions":2098},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[],{"intervention":2104,"totalTrials":386,"cells":2105},"COPAD",{"EARLY_PHASE1":2106,"PHASE1":2108,"PHASE2":2110,"PHASE3":2112,"PHASE4":2126,"NA":2128},{"trials":2107,"activeCount":98},[],{"trials":2109,"activeCount":98},[],{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":386,"soonestReadout":2118},[2114],{"nctId":2115,"briefTitle":2116,"status":167,"phases":2117,"primaryCompletion":2118,"completion":2119,"start":2120,"enrollment":269,"conditions":2121,"interventions":2123},"NCT01046825","Mature B-Cell Lymphoma And Leukemia Study III",[87,88],"2023-08-31","2027-08","2010-09-09",[2122],"Mature B-Cell Lymphoma",[2104,2124,2125],"COP, COPD M3, CYM","COP, COPADM8, CYVE",{"trials":2127,"activeCount":98},[],{"trials":2129,"activeCount":98},[],{"intervention":2124,"totalTrials":386,"cells":2131},{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2138,"PHASE4":2144,"NA":2146},{"trials":2133,"activeCount":98},[],{"trials":2135,"activeCount":98},[],{"trials":2137,"activeCount":98},[],{"trials":2139,"activeCount":386,"soonestReadout":2118},[2140],{"nctId":2115,"briefTitle":2116,"status":167,"phases":2141,"primaryCompletion":2118,"completion":2119,"start":2120,"enrollment":269,"conditions":2142,"interventions":2143},[87,88],[2122],[2104,2124,2125],{"trials":2145,"activeCount":98},[],{"trials":2147,"activeCount":98},[],{"intervention":2125,"totalTrials":386,"cells":2149},{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2154,"PHASE3":2156,"PHASE4":2162,"NA":2164},{"trials":2151,"activeCount":98},[],{"trials":2153,"activeCount":98},[],{"trials":2155,"activeCount":98},[],{"trials":2157,"activeCount":386,"soonestReadout":2118},[2158],{"nctId":2115,"briefTitle":2116,"status":167,"phases":2159,"primaryCompletion":2118,"completion":2119,"start":2120,"enrollment":269,"conditions":2160,"interventions":2161},[87,88],[2122],[2104,2124,2125],{"trials":2163,"activeCount":98},[],{"trials":2165,"activeCount":98},[],{"intervention":382,"totalTrials":386,"cells":2167},{"EARLY_PHASE1":2168,"PHASE1":2170,"PHASE2":2172,"PHASE3":2174,"PHASE4":2180,"NA":2182},{"trials":2169,"activeCount":98},[],{"trials":2171,"activeCount":98},[],{"trials":2173,"activeCount":98},[],{"trials":2175,"activeCount":386,"soonestReadout":375},[2176],{"nctId":372,"briefTitle":373,"status":167,"phases":2177,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":2178,"interventions":2179},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":98},[],{"intervention":385,"totalTrials":386,"cells":2185},{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2190,"PHASE3":2192,"PHASE4":2198,"NA":2200},{"trials":2187,"activeCount":98},[],{"trials":2189,"activeCount":98},[],{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":386,"soonestReadout":375},[2194],{"nctId":372,"briefTitle":373,"status":167,"phases":2195,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":2196,"interventions":2197},[87,88],[14,380],[128,93,129,226,382,78,133,137,198,136,273,383,199,113,132,139,135,228,384,201,134,385,315],{"trials":2199,"activeCount":98},[],{"trials":2201,"activeCount":98},[],{"intervention":429,"totalTrials":2203,"cells":2204},26,{"EARLY_PHASE1":2205,"PHASE1":2207,"PHASE2":2270,"PHASE3":2332,"PHASE4":2334,"NA":2336},{"trials":2206,"activeCount":98},[],{"trials":2208,"activeCount":1045,"soonestReadout":82},[2209,2213,2217,2221,2225,2229,2233,2237,2241,2245,2249,2253],{"nctId":80,"briefTitle":81,"status":167,"phases":2210,"primaryCompletion":82,"completion":336,"start":420,"enrollment":421,"conditions":2211,"interventions":2212},[86],[423,424,425,426],[83,428,133,429,215,136,430],{"nctId":979,"briefTitle":980,"status":186,"phases":2214,"primaryCompletion":982,"completion":207,"start":983,"enrollment":984,"conditions":2215,"interventions":2216},[86],[796,986,987],[989,78,429,544],{"nctId":991,"briefTitle":992,"status":186,"phases":2218,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":2219,"interventions":2220},[86],[541],[1000,78,429,549,639,544,215,273],{"nctId":1002,"briefTitle":1003,"status":186,"phases":2222,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":412,"conditions":2223,"interventions":2224},[86],[541,1009,1010,634,1011],[429,78,1013,544],{"nctId":1051,"briefTitle":1052,"status":186,"phases":2226,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":406,"conditions":2227,"interventions":2228},[86],[1058,1059,1060,1061,1062],[429,78,1064],{"nctId":596,"briefTitle":597,"status":490,"phases":2230,"primaryCompletion":599,"completion":599,"start":600,"enrollment":9,"conditions":2231,"interventions":2232},[86],[25,566],[603,429,133,317,316],{"nctId":616,"briefTitle":617,"status":104,"phases":2234,"primaryCompletion":619,"completion":619,"start":521,"enrollment":9,"conditions":2235,"interventions":2236},[86],[621,622,623,624],[428,429,133,430],{"nctId":1090,"briefTitle":1091,"status":186,"phases":2238,"primaryCompletion":1093,"completion":1094,"start":793,"enrollment":1095,"conditions":2239,"interventions":2240},[86],[1097,1098,1099,1100],[1102,78,429,544,1103],{"nctId":1105,"briefTitle":1106,"status":186,"phases":2242,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1072,"conditions":2243,"interventions":2244},[86],[1112,526,32,23,1062,1113,1114,173,1115,1116,1117,1118,1119,1120,1121,1122],[429,78,287,1124],{"nctId":1126,"briefTitle":1127,"status":186,"phases":2246,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":725,"conditions":2247,"interventions":2248},[86],[1133,1134,541],[1136,78,429,549,544,639,215],{"nctId":1138,"briefTitle":1139,"status":186,"phases":2250,"primaryCompletion":1141,"completion":1142,"start":1143,"enrollment":997,"conditions":2251,"interventions":2252},[86],[14,1145,1146],[429,78,544],{"nctId":2254,"briefTitle":2255,"status":104,"phases":2256,"primaryCompletion":2257,"completion":2257,"start":2258,"enrollment":124,"conditions":2259,"interventions":2266},"NCT01625351","A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas",[86],"2020-02-10","2012-08-20",[1062,2260,2261,2262,634,1113,1116,2263,2264,1119,23,32,2265],"Gastrointestinal Tumor","Germ Cell Tumor","Hepatic Tumor","Clear Cell Carcinoma","Renal Cell Carcinoma","Non-rhabdomyosarcoma",[2267,2268,2269,548,157,751],"alemtuzumab","fludarabine","sirolimus",{"trials":2271,"activeCount":632,"soonestReadout":77},[2272,2276,2280,2288,2292,2296,2300,2304,2308,2312,2316,2320,2324,2328],{"nctId":1159,"briefTitle":1160,"status":167,"phases":2273,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":2274,"interventions":2275},[87],[622,621,1167,1168,1169,623,1170],[545,273,78,429,161,639,544,1103,752,549,1172,1173],{"nctId":1187,"briefTitle":1188,"status":490,"phases":2277,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":357,"conditions":2278,"interventions":2279},[87],[622,621,1167,1194,1169,623,1170],[78,429,161,1078,639,549,1103,1196,1197,1198],{"nctId":2281,"briefTitle":2282,"status":167,"phases":2283,"primaryCompletion":982,"completion":207,"start":2284,"enrollment":108,"conditions":2285,"interventions":2287},"NCT03597594","Haplocompatible Transplant Using TCRα\u002Fβ Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)",[86,87],"2021-09-02",[2286],"Severe Combined Immunodeficiency",[545,548,429,549],{"nctId":1208,"briefTitle":1209,"status":186,"phases":2289,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":2290,"interventions":2291},[87],[14,311],[429,78,544,1217],{"nctId":685,"briefTitle":686,"status":167,"phases":2293,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":2294,"interventions":2295},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"nctId":1245,"briefTitle":1246,"status":490,"phases":2297,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":171,"conditions":2298,"interventions":2299},[87],[1251],[78,549,429,639,544,161,1253,752,500,1254],{"nctId":703,"briefTitle":704,"status":490,"phases":2301,"primaryCompletion":706,"completion":706,"start":707,"enrollment":421,"conditions":2302,"interventions":2303},[87],[621],[428,429,133,430],{"nctId":1278,"briefTitle":1279,"status":186,"phases":2305,"primaryCompletion":1281,"completion":1005,"start":1282,"enrollment":1021,"conditions":2306,"interventions":2307},[87],[1284,1285],[1136,429,78,544,161,1287,1288],{"nctId":75,"briefTitle":76,"status":167,"phases":2309,"primaryCompletion":77,"completion":1163,"start":1310,"enrollment":171,"conditions":2310,"interventions":2311},[86,87],[796,986],[78,429,544,1313],{"nctId":1315,"briefTitle":1316,"status":186,"phases":2313,"primaryCompletion":1318,"completion":1130,"start":1319,"enrollment":1320,"conditions":2314,"interventions":2315},[87],[1322],[78,429,544],{"nctId":1359,"briefTitle":1360,"status":167,"phases":2317,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":2318,"interventions":2319},[87],[622,621,1367,1368,28,1369,1169,1168],[78,429,549,639,1371,544,1372,273,1373,1374,1288],{"nctId":1380,"briefTitle":1381,"status":104,"phases":2321,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":2322,"interventions":2323},[87],[1388,1389,1390,1169,1391,28,1392,623],[429,1394,1395,1253,1396,1397,78,545,161,1398],{"nctId":534,"briefTitle":535,"status":490,"phases":2325,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":2326,"interventions":2327},[87],[541,542],[383,544,545,546,78,429,136,547,548,549],{"nctId":1408,"briefTitle":1409,"status":104,"phases":2329,"primaryCompletion":1411,"completion":1412,"start":1413,"enrollment":1414,"conditions":2330,"interventions":2331},[87],[1087,634],[429,78,549,639,1172,1417,161,544,1253],{"trials":2333,"activeCount":98},[],{"trials":2335,"activeCount":98},[],{"trials":2337,"activeCount":98},[],{"intervention":544,"totalTrials":9,"cells":2339},{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2376,"PHASE3":2422,"PHASE4":2424,"NA":2426},{"trials":2341,"activeCount":98},[],{"trials":2343,"activeCount":889,"soonestReadout":1108},[2344,2348,2352,2356,2360,2364,2368,2372],{"nctId":969,"briefTitle":970,"status":104,"phases":2345,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":2346,"interventions":2347},[86],[25],[548,78,544],{"nctId":979,"briefTitle":980,"status":186,"phases":2349,"primaryCompletion":982,"completion":207,"start":983,"enrollment":984,"conditions":2350,"interventions":2351},[86],[796,986,987],[989,78,429,544],{"nctId":991,"briefTitle":992,"status":186,"phases":2353,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":2354,"interventions":2355},[86],[541],[1000,78,429,549,639,544,215,273],{"nctId":1002,"briefTitle":1003,"status":186,"phases":2357,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":412,"conditions":2358,"interventions":2359},[86],[541,1009,1010,634,1011],[429,78,1013,544],{"nctId":1090,"briefTitle":1091,"status":186,"phases":2361,"primaryCompletion":1093,"completion":1094,"start":793,"enrollment":1095,"conditions":2362,"interventions":2363},[86],[1097,1098,1099,1100],[1102,78,429,544,1103],{"nctId":1105,"briefTitle":1106,"status":186,"phases":2365,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1072,"conditions":2366,"interventions":2367},[86],[1112,526,32,23,1062,1113,1114,173,1115,1116,1117,1118,1119,1120,1121,1122],[429,78,287,1124],{"nctId":1126,"briefTitle":1127,"status":186,"phases":2369,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":725,"conditions":2370,"interventions":2371},[86],[1133,1134,541],[1136,78,429,549,544,639,215],{"nctId":1138,"briefTitle":1139,"status":186,"phases":2373,"primaryCompletion":1141,"completion":1142,"start":1143,"enrollment":997,"conditions":2374,"interventions":2375},[86],[14,1145,1146],[429,78,544],{"trials":2377,"activeCount":889,"soonestReadout":68},[2378,2382,2386,2390,2394,2398,2402,2406,2410,2414,2418],{"nctId":141,"briefTitle":142,"status":104,"phases":2379,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":2380,"interventions":2381},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":1159,"briefTitle":1160,"status":167,"phases":2383,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":2384,"interventions":2385},[87],[622,621,1167,1168,1169,623,1170],[545,273,78,429,161,639,544,1103,752,549,1172,1173],{"nctId":1208,"briefTitle":1209,"status":186,"phases":2387,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":2388,"interventions":2389},[87],[14,311],[429,78,544,1217],{"nctId":66,"briefTitle":67,"status":167,"phases":2391,"primaryCompletion":68,"completion":278,"start":279,"enrollment":280,"conditions":2392,"interventions":2393},[87],[282],[44,151,284,285,286,154,150,287,155],{"nctId":1245,"briefTitle":1246,"status":490,"phases":2395,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":171,"conditions":2396,"interventions":2397},[87],[1251],[78,549,429,639,544,161,1253,752,500,1254],{"nctId":1278,"briefTitle":1279,"status":186,"phases":2399,"primaryCompletion":1281,"completion":1005,"start":1282,"enrollment":1021,"conditions":2400,"interventions":2401},[87],[1284,1285],[1136,429,78,544,161,1287,1288],{"nctId":75,"briefTitle":76,"status":167,"phases":2403,"primaryCompletion":77,"completion":1163,"start":1310,"enrollment":171,"conditions":2404,"interventions":2405},[86,87],[796,986],[78,429,544,1313],{"nctId":1315,"briefTitle":1316,"status":186,"phases":2407,"primaryCompletion":1318,"completion":1130,"start":1319,"enrollment":1320,"conditions":2408,"interventions":2409},[87],[1322],[78,429,544],{"nctId":1359,"briefTitle":1360,"status":167,"phases":2411,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":2412,"interventions":2413},[87],[622,621,1367,1368,28,1369,1169,1168],[78,429,549,639,1371,544,1372,273,1373,1374,1288],{"nctId":534,"briefTitle":535,"status":490,"phases":2415,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":2416,"interventions":2417},[87],[541,542],[383,544,545,546,78,429,136,547,548,549],{"nctId":1408,"briefTitle":1409,"status":104,"phases":2419,"primaryCompletion":1411,"completion":1412,"start":1413,"enrollment":1414,"conditions":2420,"interventions":2421},[87],[1087,634],[429,78,549,639,1172,1417,161,544,1253],{"trials":2423,"activeCount":98},[],{"trials":2425,"activeCount":98},[],{"trials":2427,"activeCount":98},[],{"intervention":215,"totalTrials":783,"cells":2429},{"EARLY_PHASE1":2430,"PHASE1":2432,"PHASE2":2534,"PHASE3":2574,"PHASE4":2580,"NA":2582},{"trials":2431,"activeCount":98},[],{"trials":2433,"activeCount":108,"soonestReadout":82},[2434,2438,2442,2446,2458,2522,2530],{"nctId":80,"briefTitle":81,"status":167,"phases":2435,"primaryCompletion":82,"completion":336,"start":420,"enrollment":421,"conditions":2436,"interventions":2437},[86],[423,424,425,426],[83,428,133,429,215,136,430],{"nctId":991,"briefTitle":992,"status":186,"phases":2439,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":2440,"interventions":2441},[86],[541],[1000,78,429,549,639,544,215,273],{"nctId":1015,"briefTitle":1016,"status":104,"phases":2443,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":2444,"interventions":2445},[86],[1023,1024,1025,1026,297,1027,1028,1029,1030,1031,1032,1033,1034],[1036,78,302,284,1037],{"nctId":2447,"briefTitle":2448,"status":104,"phases":2449,"primaryCompletion":2450,"completion":2451,"start":2452,"enrollment":524,"conditions":2453,"interventions":2455},"NCT02392793","Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies",[86],"2019-02-20","2019-08-30","2015-03-25",[2454],"Childhood Solid Tumors",[2456,114,243,215,2457],"Talazoparib","Peg-filgrastim",{"nctId":2459,"briefTitle":2460,"status":104,"phases":2461,"primaryCompletion":2462,"completion":2463,"start":2464,"enrollment":2465,"conditions":2466,"interventions":2518},"NCT03434262","SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors",[86],"2022-09-30","2024-05-24","2018-03-05",68,[2467,2468,2469,2470,2471,2472,2473,1031,1023,2474,2475,2476,2477,1033,2478,2479,2480,2481,2482,297,2483,2484,2485,2486,2487,2488,2489,2490,2491,2492,2493,2494,2495,2496,2497,2498,2499,2500,2501,2502,2503,2504,2505,1028,2506,2507,2508,2509,2510,2511,2512,2513,2514,2515,2516,2517],"Anaplastic Astrocytoma","Anaplastic Ependymoma","Anaplastic Ganglioglioma","Anaplastic Meningioma","Anaplastic Oligodendroglioma","Pleomorphic Xanthoastrocytoma, Anaplastic","Atypical Teratoid\u002FRhabdoid Tumor","Central Nervous System Neoplasms","Choroid Plexus Carcinoma","CNS Embryonal Tumor With Rhabdoid Features","Ganglioneuroblastoma of Central Nervous System","Embryonal Tumor of CNS","Ependymoma","Glioblastoma","Glioma","Glioma, Malignant","Medulloblastoma; Unspecified Site","Medulloepithelioma","Neuroepithelial Tumor","Neoplasms","Neoplasms, Neuroepithelial","Papillary Tumor of the Pineal Region (High-grade Only)","Pediatric Brain Tumor","Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)","Pineoblastoma","Primitive Neuroectodermal Tumor","Recurrent Medulloblastoma","Refractory Brain Tumor","Neuroblastoma. CNS","Glioblastoma, IDH-mutant","Glioblastoma, IDH-wildtype","Medulloblastoma, Group 3","Medulloblastoma, Group 4","Glioma, High Grade","Neuroepithelial Tumor, High Grade","Medulloblastoma, SHH-activated and TP53 Mutant","Medulloblastoma, SHH-activated and TP53 Wildtype","Medulloblastoma, Chromosome 9q Loss","Medulloblastoma, Non-WNT Non-SHH, NOS","Medulloblastoma, PTCH1 Mutation","Medulloblastoma, WNT-activated","Ependymoma, Recurrent","Glioma, Recurrent High Grade","Glioma, Recurrent Malignant","Embryonal Tumor, NOS","Glioma, Diffuse Midline, H3K27M-mutant","Embryonal Tumor With Multilayered Rosettes (ETMR)","Ependymoma, NOS, WHO Grade III","Ependymoma, NOS, WHO Grade II","Medulloblastoma, G3\u002FG4","Ependymoma, RELA Fusion Positive",[302,2519,2520,2521,284],"ribociclib","sonidegib","trametinib",{"nctId":2523,"briefTitle":2524,"status":2525,"phases":2526,"primaryCompletion":2527,"completion":1281,"start":1319,"enrollment":357,"conditions":2528,"interventions":2529},"NCT07585136","Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders","NOT_YET_RECRUITING",[86],"2028-12-01",[1285],[215,749],{"nctId":1126,"briefTitle":1127,"status":186,"phases":2531,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":725,"conditions":2532,"interventions":2533},[86],[1133,1134,541],[1136,78,429,549,544,639,215],{"trials":2535,"activeCount":494,"soonestReadout":58},[2536,2540,2544,2548,2552,2566,2570],{"nctId":203,"briefTitle":204,"status":167,"phases":2537,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":2538,"interventions":2539},[87],[28],[212,139,132,213,93,214,128,215,216,78,217],{"nctId":66,"briefTitle":67,"status":167,"phases":2541,"primaryCompletion":68,"completion":278,"start":279,"enrollment":280,"conditions":2542,"interventions":2543},[87],[282],[44,151,284,285,286,154,150,287,155],{"nctId":1256,"briefTitle":1257,"status":104,"phases":2545,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":108,"conditions":2546,"interventions":2547},[87],[282],[284,286,150,1263,154,1264],{"nctId":56,"briefTitle":57,"status":167,"phases":2549,"primaryCompletion":58,"completion":266,"start":1295,"enrollment":1296,"conditions":2550,"interventions":2551},[87],[1298,1299,1300],[59,154,1302,155,150,1303,284],{"nctId":2553,"briefTitle":2554,"status":2525,"phases":2555,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":2559,"conditions":2560,"interventions":2561},"NCT07616154","Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease",[87],"2034-09","2035-09","2026-09",45,[17],[2562,2563,1397,2564,549,215,1173,2565],"Cyclophosphamide 50mg","Abatacept","Hydroxyurea","Azathioprine",{"nctId":1345,"briefTitle":1346,"status":104,"phases":2567,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":2568,"interventions":2569},[87],[369],[284,1353,153,150,468],{"nctId":346,"briefTitle":347,"status":186,"phases":2571,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":2572,"interventions":2573},[87],[297],[136,299,93,78,354,355,139,356,215,136],{"trials":2575,"activeCount":98},[2576],{"nctId":361,"briefTitle":362,"status":104,"phases":2577,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":2578,"interventions":2579},[88],[369],[284,153,150,44],{"trials":2581,"activeCount":98},[],{"trials":2583,"activeCount":98},[],{"intervention":549,"totalTrials":2585,"cells":2586},11,{"EARLY_PHASE1":2587,"PHASE1":2589,"PHASE2":2603,"PHASE3":2637,"PHASE4":2639,"NA":2641},{"trials":2588,"activeCount":98},[],{"trials":2590,"activeCount":445,"soonestReadout":994},[2591,2595,2599],{"nctId":991,"briefTitle":992,"status":186,"phases":2592,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":2593,"interventions":2594},[86],[541],[1000,78,429,549,639,544,215,273],{"nctId":2052,"briefTitle":2053,"status":104,"phases":2596,"primaryCompletion":2055,"completion":364,"start":106,"enrollment":743,"conditions":2597,"interventions":2598},[86],[2057],[135,549,639,1253,1103],{"nctId":1126,"briefTitle":1127,"status":186,"phases":2600,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":725,"conditions":2601,"interventions":2602},[86],[1133,1134,541],[1136,78,429,549,544,639,215],{"trials":2604,"activeCount":108,"soonestReadout":1362},[2605,2609,2613,2617,2621,2625,2629,2633],{"nctId":1159,"briefTitle":1160,"status":167,"phases":2606,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":2607,"interventions":2608},[87],[622,621,1167,1168,1169,623,1170],[545,273,78,429,161,639,544,1103,752,549,1172,1173],{"nctId":1187,"briefTitle":1188,"status":490,"phases":2610,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":357,"conditions":2611,"interventions":2612},[87],[622,621,1167,1194,1169,623,1170],[78,429,161,1078,639,549,1103,1196,1197,1198],{"nctId":2281,"briefTitle":2282,"status":167,"phases":2614,"primaryCompletion":982,"completion":207,"start":2284,"enrollment":108,"conditions":2615,"interventions":2616},[86,87],[2286],[545,548,429,549],{"nctId":1245,"briefTitle":1246,"status":490,"phases":2618,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":171,"conditions":2619,"interventions":2620},[87],[1251],[78,549,429,639,544,161,1253,752,500,1254],{"nctId":2553,"briefTitle":2554,"status":2525,"phases":2622,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":2559,"conditions":2623,"interventions":2624},[87],[17],[2562,2563,1397,2564,549,215,1173,2565],{"nctId":1359,"briefTitle":1360,"status":167,"phases":2626,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":2627,"interventions":2628},[87],[622,621,1367,1368,28,1369,1169,1168],[78,429,549,639,1371,544,1372,273,1373,1374,1288],{"nctId":534,"briefTitle":535,"status":490,"phases":2630,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":2631,"interventions":2632},[87],[541,542],[383,544,545,546,78,429,136,547,548,549],{"nctId":1408,"briefTitle":1409,"status":104,"phases":2634,"primaryCompletion":1411,"completion":1412,"start":1413,"enrollment":1414,"conditions":2635,"interventions":2636},[87],[1087,634],[429,78,549,639,1172,1417,161,544,1253],{"trials":2638,"activeCount":98},[],{"trials":2640,"activeCount":98},[],{"trials":2642,"activeCount":98},[],{"intervention":161,"totalTrials":357,"cells":2644},{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2653,"PHASE3":2699,"PHASE4":2701,"NA":2703},{"trials":2646,"activeCount":98},[],{"trials":2648,"activeCount":98},[2649],{"nctId":627,"briefTitle":628,"status":104,"phases":2650,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":2651,"interventions":2652},[86],[23,634,635],[637,638,152,548,639,160,640,139,133,354,161,641],{"trials":2654,"activeCount":494,"soonestReadout":1362},[2655,2659,2663,2667,2671,2675,2679,2683,2687,2691,2695],{"nctId":141,"briefTitle":142,"status":104,"phases":2656,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":2657,"interventions":2658},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":1159,"briefTitle":1160,"status":167,"phases":2660,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":2661,"interventions":2662},[87],[622,621,1167,1168,1169,623,1170],[545,273,78,429,161,639,544,1103,752,549,1172,1173],{"nctId":1187,"briefTitle":1188,"status":490,"phases":2664,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":357,"conditions":2665,"interventions":2666},[87],[622,621,1167,1194,1169,623,1170],[78,429,161,1078,639,549,1103,1196,1197,1198],{"nctId":685,"briefTitle":686,"status":167,"phases":2668,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":2669,"interventions":2670},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"nctId":1245,"briefTitle":1246,"status":490,"phases":2672,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":171,"conditions":2673,"interventions":2674},[87],[1251],[78,549,429,639,544,161,1253,752,500,1254],{"nctId":1266,"briefTitle":1267,"status":186,"phases":2676,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":2677,"interventions":2678},[87],[1274,1033],[1276,78,139,354,161,356],{"nctId":1278,"briefTitle":1279,"status":186,"phases":2680,"primaryCompletion":1281,"completion":1005,"start":1282,"enrollment":1021,"conditions":2681,"interventions":2682},[87],[1284,1285],[1136,429,78,544,161,1287,1288],{"nctId":1359,"briefTitle":1360,"status":167,"phases":2684,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":2685,"interventions":2686},[87],[622,621,1367,1368,28,1369,1169,1168],[78,429,549,639,1371,544,1372,273,1373,1374,1288],{"nctId":319,"briefTitle":320,"status":104,"phases":2688,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":2689,"interventions":2690},[87],[327],[329,214,330,78,93,213,139,128,161],{"nctId":1380,"briefTitle":1381,"status":104,"phases":2692,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":2693,"interventions":2694},[87],[1388,1389,1390,1169,1391,28,1392,623],[429,1394,1395,1253,1396,1397,78,545,161,1398],{"nctId":1408,"briefTitle":1409,"status":104,"phases":2696,"primaryCompletion":1411,"completion":1412,"start":1413,"enrollment":1414,"conditions":2697,"interventions":2698},[87],[1087,634],[429,78,549,639,1172,1417,161,544,1253],{"trials":2700,"activeCount":98},[],{"trials":2702,"activeCount":98},[],{"trials":2704,"activeCount":98},[],{"intervention":243,"totalTrials":889,"cells":2706},{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2715,"PHASE3":2789,"PHASE4":2791,"NA":2793},{"trials":2708,"activeCount":98},[],{"trials":2710,"activeCount":98},[2711],{"nctId":2447,"briefTitle":2448,"status":104,"phases":2712,"primaryCompletion":2450,"completion":2451,"start":2452,"enrollment":524,"conditions":2713,"interventions":2714},[86],[2454],[2456,114,243,215,2457],{"trials":2716,"activeCount":494,"soonestReadout":38},[2717,2721,2730,2734,2744,2776],{"nctId":41,"briefTitle":42,"status":167,"phases":2718,"primaryCompletion":43,"completion":169,"start":170,"enrollment":171,"conditions":2719,"interventions":2720},[87],[173,174,175,176],[44,155,150,178,154,179,180,181,182],{"nctId":36,"briefTitle":37,"status":167,"phases":2722,"primaryCompletion":38,"completion":2723,"start":2724,"enrollment":2725,"conditions":2726,"interventions":2728},[87],"2026-05","2008-05-09",29,[2727],"Malignant Melanoma",[39,243,2729],"Recombinant interferon alfa-2b",{"nctId":231,"briefTitle":232,"status":186,"phases":2731,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":2732,"interventions":2733},[87],[32],[93,240,78,241,242,243,244],{"nctId":2735,"briefTitle":2736,"status":104,"phases":2737,"primaryCompletion":2738,"completion":2738,"start":2739,"enrollment":2740,"conditions":2741,"interventions":2742},"NCT00004068","Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor",[87],"2003-04","1999-03",53,[369],[2743,179],"irinotecan hydrochloride",{"nctId":2745,"briefTitle":2746,"status":186,"phases":2747,"primaryCompletion":2748,"completion":2748,"start":2749,"enrollment":2750,"conditions":2751,"interventions":2774},"NCT04901702","Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma",[86,87],"2026-12-31","2021-06-09",90,[2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763,2764,2765,2766,2767,2768,2769,2770,2771,2772,2773],"Recurrent Solid Tumor","Recurrent Ewing Sarcoma","Recurrent Hepatoblastoma","Recurrent Malignant Germ Cell Tumor","Recurrent Malignant Solid Neoplasm","Recurrent Neuroblastoma","Recurrent Osteosarcoma","Recurrent Peripheral Primitive Neuroectodermal Tumor","Recurrent Rhabdoid Tumor","Recurrent Rhabdomyosarcoma","Recurrent Soft Tissue Sarcoma","Recurrent Wilms Tumor","Refractory Ewing Sarcoma","Refractory Hepatoblastoma","Refractory Malignant Germ Cell Tumor","Refractory Malignant Solid Neoplasm","Refractory Neuroblastoma","Refractory Osteosarcoma","Refractory Peripheral Primitive Neuroectodermal Tumor","Refractory Rhabdoid Tumor","Refractory Rhabdomyosarcoma","Refractory Soft Tissue Sarcoma",[2775,2456,243],"Onivyde",{"nctId":2777,"briefTitle":2778,"status":186,"phases":2779,"primaryCompletion":2780,"completion":2781,"start":2782,"enrollment":2783,"conditions":2784,"interventions":2786},"NCT07085338","A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma",[87],"2028-02-01","2029-02-01","2025-11-10",54,[2785],"Neuroblastoma Recurrent",[243,114,152,2787,2788],"N803","Sargramostim",{"trials":2790,"activeCount":98},[],{"trials":2792,"activeCount":98},[],{"trials":2794,"activeCount":98},[],{"intervention":639,"totalTrials":2585,"cells":2796},{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2821,"PHASE3":2847,"PHASE4":2849,"NA":2851},{"trials":2798,"activeCount":98},[],{"trials":2800,"activeCount":445,"soonestReadout":994},[2801,2805,2809,2813,2817],{"nctId":991,"briefTitle":992,"status":186,"phases":2802,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":2803,"interventions":2804},[86],[541],[1000,78,429,549,639,544,215,273],{"nctId":2052,"briefTitle":2053,"status":104,"phases":2806,"primaryCompletion":2055,"completion":364,"start":106,"enrollment":743,"conditions":2807,"interventions":2808},[86],[2057],[135,549,639,1253,1103],{"nctId":627,"briefTitle":628,"status":104,"phases":2810,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":2811,"interventions":2812},[86],[23,634,635],[637,638,152,548,639,160,640,139,133,354,161,641],{"nctId":1126,"briefTitle":1127,"status":186,"phases":2814,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":725,"conditions":2815,"interventions":2816},[86],[1133,1134,541],[1136,78,429,549,544,639,215],{"nctId":2254,"briefTitle":2255,"status":104,"phases":2818,"primaryCompletion":2257,"completion":2257,"start":2258,"enrollment":124,"conditions":2819,"interventions":2820},[86],[1062,2260,2261,2262,634,1113,1116,2263,2264,1119,23,32,2265],[2267,2268,2269,548,157,751],{"trials":2822,"activeCount":445,"soonestReadout":1362},[2823,2827,2831,2835,2839,2843],{"nctId":141,"briefTitle":142,"status":104,"phases":2824,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":2825,"interventions":2826},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":1159,"briefTitle":1160,"status":167,"phases":2828,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":2829,"interventions":2830},[87],[622,621,1167,1168,1169,623,1170],[545,273,78,429,161,639,544,1103,752,549,1172,1173],{"nctId":1187,"briefTitle":1188,"status":490,"phases":2832,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":357,"conditions":2833,"interventions":2834},[87],[622,621,1167,1194,1169,623,1170],[78,429,161,1078,639,549,1103,1196,1197,1198],{"nctId":1245,"briefTitle":1246,"status":490,"phases":2836,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":171,"conditions":2837,"interventions":2838},[87],[1251],[78,549,429,639,544,161,1253,752,500,1254],{"nctId":1359,"briefTitle":1360,"status":167,"phases":2840,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":2841,"interventions":2842},[87],[622,621,1367,1368,28,1369,1169,1168],[78,429,549,639,1371,544,1372,273,1373,1374,1288],{"nctId":1408,"briefTitle":1409,"status":104,"phases":2844,"primaryCompletion":1411,"completion":1412,"start":1413,"enrollment":1414,"conditions":2845,"interventions":2846},[87],[1087,634],[429,78,549,639,1172,1417,161,544,1253],{"trials":2848,"activeCount":98},[],{"trials":2850,"activeCount":98},[],{"trials":2852,"activeCount":98},[],{"intervention":354,"totalTrials":632,"cells":2854},{"EARLY_PHASE1":2855,"PHASE1":2857,"PHASE2":2872,"PHASE3":2902,"PHASE4":2904,"NA":2906},{"trials":2856,"activeCount":98},[],{"trials":2858,"activeCount":98},[2859,2868],{"nctId":2860,"briefTitle":2861,"status":104,"phases":2862,"primaryCompletion":2863,"completion":2863,"start":2864,"enrollment":632,"conditions":2865,"interventions":2866},"NCT02792036","Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma",[86],"2019-10-04","2016-11-01",[282],[354,2867],"Maxitrol®",{"nctId":627,"briefTitle":628,"status":104,"phases":2869,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":2870,"interventions":2871},[86],[23,634,635],[637,638,152,548,639,160,640,139,133,354,161,641],{"trials":2873,"activeCount":108,"soonestReadout":68},[2874,2882,2886,2890,2894,2898],{"nctId":2875,"briefTitle":2876,"status":104,"phases":2877,"primaryCompletion":2878,"completion":2878,"start":2879,"enrollment":1214,"conditions":2880,"interventions":2881},"NCT00002794","Carboplatin Plus Vincristine in Treating Children With Retinoblastoma",[87],"2001-06","1996-02",[282],[286,468],{"nctId":66,"briefTitle":67,"status":167,"phases":2883,"primaryCompletion":68,"completion":278,"start":279,"enrollment":280,"conditions":2884,"interventions":2885},[87],[282],[44,151,284,285,286,154,150,287,155],{"nctId":1256,"briefTitle":1257,"status":104,"phases":2887,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":108,"conditions":2888,"interventions":2889},[87],[282],[284,286,150,1263,154,1264],{"nctId":1266,"briefTitle":1267,"status":186,"phases":2891,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":2892,"interventions":2893},[87],[1274,1033],[1276,78,139,354,161,356],{"nctId":332,"briefTitle":333,"status":167,"phases":2895,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":2896,"interventions":2897},[87],[340,341],[343,344,153,286,150,154,151,44],{"nctId":346,"briefTitle":347,"status":186,"phases":2899,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":2900,"interventions":2901},[87],[297],[136,299,93,78,354,355,139,356,215,136],{"trials":2903,"activeCount":98},[],{"trials":2905,"activeCount":98},[],{"trials":2907,"activeCount":98},[],{"intervention":256,"totalTrials":889,"cells":2909},{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2932,"PHASE3":2950,"PHASE4":2952,"NA":2954},{"trials":2911,"activeCount":98},[],{"trials":2913,"activeCount":98},[2914,2924,2928],{"nctId":2915,"briefTitle":2916,"status":104,"phases":2917,"primaryCompletion":2918,"completion":2918,"start":2919,"enrollment":831,"conditions":2920,"interventions":2921},"NCT02270788","Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies",[86],"2016-10-17","2015-04-02",[25],[2922,256,2923],"Crenolanib","methotrexate, hydrocortisone and cytarabine with leucovorin",{"nctId":1080,"briefTitle":1081,"status":104,"phases":2925,"primaryCompletion":805,"completion":805,"start":1083,"enrollment":1084,"conditions":2926,"interventions":2927},[86],[1086,1087],[255,256,78],{"nctId":643,"briefTitle":644,"status":104,"phases":2929,"primaryCompletion":38,"completion":38,"start":646,"enrollment":647,"conditions":2930,"interventions":2931},[86],[25,649,566,650,651],[256,133,135],{"trials":2933,"activeCount":108,"soonestReadout":43},[2934,2938,2942,2946],{"nctId":41,"briefTitle":42,"status":167,"phases":2935,"primaryCompletion":43,"completion":169,"start":170,"enrollment":171,"conditions":2936,"interventions":2937},[87],[173,174,175,176],[44,155,150,178,154,179,180,181,182],{"nctId":246,"briefTitle":247,"status":167,"phases":2939,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":2940,"interventions":2941},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"nctId":685,"briefTitle":686,"status":167,"phases":2943,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":2944,"interventions":2945},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"nctId":1329,"briefTitle":1330,"status":186,"phases":2947,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":2948,"interventions":2949},[86,87],[1337,1338,1339,1340,1112,1341],[1343,256,255,78],{"trials":2951,"activeCount":98},[],{"trials":2953,"activeCount":98},[],{"trials":2955,"activeCount":98},[],{"intervention":83,"totalTrials":554,"cells":2957},{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2974,"PHASE3":2988,"PHASE4":2990,"NA":2992},{"trials":2959,"activeCount":98},[],{"trials":2961,"activeCount":445,"soonestReadout":82},[2962,2966,2970],{"nctId":80,"briefTitle":81,"status":167,"phases":2963,"primaryCompletion":82,"completion":336,"start":420,"enrollment":421,"conditions":2964,"interventions":2965},[86],[423,424,425,426],[83,428,133,429,215,136,430],{"nctId":605,"briefTitle":606,"status":104,"phases":2967,"primaryCompletion":608,"completion":609,"start":610,"enrollment":611,"conditions":2968,"interventions":2969},[86],[25],[83,133,384,614,443],{"nctId":432,"briefTitle":433,"status":186,"phases":2971,"primaryCompletion":435,"completion":436,"start":437,"enrollment":171,"conditions":2972,"interventions":2973},[86],[426,439,440],[442,83,443,444,133,136],{"trials":2975,"activeCount":445,"soonestReadout":307},[2976,2980,2984],{"nctId":184,"briefTitle":185,"status":186,"phases":2977,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":2978,"interventions":2979},[87],[193,194,195],[113,93,129,197,198,83,199,200,78,133,137,201,136,134],{"nctId":304,"briefTitle":305,"status":167,"phases":2981,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":2982,"interventions":2983},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"nctId":719,"briefTitle":720,"status":721,"phases":2985,"primaryCompletion":249,"completion":723,"start":724,"enrollment":725,"conditions":2986,"interventions":2987},[87],[25],[83,443,133,728,729,730,731,732,139,733],{"trials":2989,"activeCount":98},[],{"trials":2991,"activeCount":98},[],{"trials":2993,"activeCount":98},[],{"intervention":545,"totalTrials":554,"cells":2995},{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3004,"PHASE3":3026,"PHASE4":3028,"NA":3030},{"trials":2997,"activeCount":98},[],{"trials":2999,"activeCount":386,"soonestReadout":1129},[3000],{"nctId":1126,"briefTitle":1127,"status":186,"phases":3001,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":725,"conditions":3002,"interventions":3003},[86],[1133,1134,541],[1136,78,429,549,544,639,215],{"trials":3005,"activeCount":539,"soonestReadout":1162},[3006,3010,3014,3018,3022],{"nctId":1159,"briefTitle":1160,"status":167,"phases":3007,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":3008,"interventions":3009},[87],[622,621,1167,1168,1169,623,1170],[545,273,78,429,161,639,544,1103,752,549,1172,1173],{"nctId":2281,"briefTitle":2282,"status":167,"phases":3011,"primaryCompletion":982,"completion":207,"start":2284,"enrollment":108,"conditions":3012,"interventions":3013},[86,87],[2286],[545,548,429,549],{"nctId":1278,"briefTitle":1279,"status":186,"phases":3015,"primaryCompletion":1281,"completion":1005,"start":1282,"enrollment":1021,"conditions":3016,"interventions":3017},[87],[1284,1285],[1136,429,78,544,161,1287,1288],{"nctId":1380,"briefTitle":1381,"status":104,"phases":3019,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":3020,"interventions":3021},[87],[1388,1389,1390,1169,1391,28,1392,623],[429,1394,1395,1253,1396,1397,78,545,161,1398],{"nctId":534,"briefTitle":535,"status":490,"phases":3023,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":3024,"interventions":3025},[87],[541,542],[383,544,545,546,78,429,136,547,548,549],{"trials":3027,"activeCount":98},[],{"trials":3029,"activeCount":98},[],{"trials":3031,"activeCount":98},[],{"intervention":153,"totalTrials":632,"cells":3033},{"EARLY_PHASE1":3034,"PHASE1":3036,"PHASE2":3038,"PHASE3":3068,"PHASE4":3074,"NA":3076},{"trials":3035,"activeCount":98},[],{"trials":3037,"activeCount":98},[],{"trials":3039,"activeCount":539,"soonestReadout":335},[3040,3044,3048,3052,3056,3060,3064],{"nctId":141,"briefTitle":142,"status":104,"phases":3041,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":3042,"interventions":3043},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":1223,"briefTitle":1224,"status":490,"phases":3045,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":108,"conditions":3046,"interventions":3047},[87],[23],[1230,114,78,132,139,299,355,1231],{"nctId":289,"briefTitle":290,"status":167,"phases":3049,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":3050,"interventions":3051},[87],[297],[78,299,93,300,301,302],{"nctId":1345,"briefTitle":1346,"status":104,"phases":3053,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":3054,"interventions":3055},[87],[369],[284,1353,153,150,468],{"nctId":518,"briefTitle":519,"status":104,"phases":3057,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":3058,"interventions":3059},[87],[526,527],[255,299,132,136,258,154],{"nctId":332,"briefTitle":333,"status":167,"phases":3061,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":3062,"interventions":3063},[87],[340,341],[343,344,153,286,150,154,151,44],{"nctId":346,"briefTitle":347,"status":186,"phases":3065,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":3066,"interventions":3067},[87],[297],[136,299,93,78,354,355,139,356,215,136],{"trials":3069,"activeCount":98},[3070],{"nctId":361,"briefTitle":362,"status":104,"phases":3071,"primaryCompletion":364,"completion":365,"start":366,"enrollment":367,"conditions":3072,"interventions":3073},[88],[369],[284,153,150,44],{"trials":3075,"activeCount":98},[],{"trials":3077,"activeCount":98},[],{"intervention":255,"totalTrials":554,"cells":3079},{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3099,"PHASE3":3117,"PHASE4":3119,"NA":3121},{"trials":3081,"activeCount":98},[],{"trials":3083,"activeCount":98},[3084,3095],{"nctId":3085,"briefTitle":3086,"status":104,"phases":3087,"primaryCompletion":3088,"completion":3088,"start":3089,"enrollment":26,"conditions":3090,"interventions":3093},"NCT00756340","A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors",[86],"2015-09","2008-07",[3091,3092],"Recurrent or Refractory Solid Tumors","CNS Malignancies",[255,3094],"Everolimus",{"nctId":1080,"briefTitle":1081,"status":104,"phases":3096,"primaryCompletion":805,"completion":805,"start":1083,"enrollment":1084,"conditions":3097,"interventions":3098},[86],[1086,1087],[255,256,78],{"trials":3100,"activeCount":539,"soonestReadout":43},[3101,3105,3109,3113],{"nctId":41,"briefTitle":42,"status":167,"phases":3102,"primaryCompletion":43,"completion":169,"start":170,"enrollment":171,"conditions":3103,"interventions":3104},[87],[173,174,175,176],[44,155,150,178,154,179,180,181,182],{"nctId":246,"briefTitle":247,"status":167,"phases":3106,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":3107,"interventions":3108},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"nctId":1329,"briefTitle":1330,"status":186,"phases":3110,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":3111,"interventions":3112},[86,87],[1337,1338,1339,1340,1112,1341],[1343,256,255,78],{"nctId":518,"briefTitle":519,"status":104,"phases":3114,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":3115,"interventions":3116},[87],[526,527],[255,299,132,136,258,154],{"trials":3118,"activeCount":98},[],{"trials":3120,"activeCount":98},[],{"trials":3122,"activeCount":98},[],{"intervention":151,"totalTrials":494,"cells":3124},{"EARLY_PHASE1":3125,"PHASE1":3127,"PHASE2":3129,"PHASE3":3151,"PHASE4":3153,"NA":3155},{"trials":3126,"activeCount":98},[],{"trials":3128,"activeCount":98},[],{"trials":3130,"activeCount":539,"soonestReadout":68},[3131,3135,3139,3143,3147],{"nctId":141,"briefTitle":142,"status":104,"phases":3132,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":3133,"interventions":3134},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":1223,"briefTitle":1224,"status":490,"phases":3136,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":108,"conditions":3137,"interventions":3138},[87],[23],[1230,114,78,132,139,299,355,1231],{"nctId":66,"briefTitle":67,"status":167,"phases":3140,"primaryCompletion":68,"completion":278,"start":279,"enrollment":280,"conditions":3141,"interventions":3142},[87],[282],[44,151,284,285,286,154,150,287,155],{"nctId":332,"briefTitle":333,"status":167,"phases":3144,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":3145,"interventions":3146},[87],[340,341],[343,344,153,286,150,154,151,44],{"nctId":346,"briefTitle":347,"status":186,"phases":3148,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":3149,"interventions":3150},[87],[297],[136,299,93,78,354,355,139,356,215,136],{"trials":3152,"activeCount":98},[],{"trials":3154,"activeCount":98},[],{"trials":3156,"activeCount":98},[],{"intervention":258,"totalTrials":108,"cells":3158},{"EARLY_PHASE1":3159,"PHASE1":3161,"PHASE2":3163,"PHASE3":3181,"PHASE4":3183,"NA":3185},{"trials":3160,"activeCount":98},[],{"trials":3162,"activeCount":98},[],{"trials":3164,"activeCount":539,"soonestReadout":43},[3165,3169,3173,3177],{"nctId":41,"briefTitle":42,"status":167,"phases":3166,"primaryCompletion":43,"completion":169,"start":170,"enrollment":171,"conditions":3167,"interventions":3168},[87],[173,174,175,176],[44,155,150,178,154,179,180,181,182],{"nctId":246,"briefTitle":247,"status":167,"phases":3170,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":3171,"interventions":3172},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"nctId":1612,"briefTitle":1613,"status":186,"phases":3174,"primaryCompletion":1615,"completion":1333,"start":1616,"enrollment":1617,"conditions":3175,"interventions":3176},[86,87],[1619,1620,1621,1622,1623,1624,1625,1626,1627],[1629,258,132,428],{"nctId":518,"briefTitle":519,"status":104,"phases":3178,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":3179,"interventions":3180},[87],[526,527],[255,299,132,136,258,154],{"trials":3182,"activeCount":98},[],{"trials":3184,"activeCount":98},[],{"trials":3186,"activeCount":98},[],{"intervention":261,"totalTrials":539,"cells":3188},{"EARLY_PHASE1":3189,"PHASE1":3191,"PHASE2":3193,"PHASE3":3214,"PHASE4":3216,"NA":3218},{"trials":3190,"activeCount":98},[],{"trials":3192,"activeCount":98},[],{"trials":3194,"activeCount":539,"soonestReadout":72},[3195,3199,3209],{"nctId":246,"briefTitle":247,"status":167,"phases":3196,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":3197,"interventions":3198},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"nctId":3200,"briefTitle":3201,"status":167,"phases":3202,"primaryCompletion":169,"completion":169,"start":3203,"enrollment":3204,"conditions":3205,"interventions":3207},"NCT01419067","A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection",[87],"2011-08-22",112,[3206],"Craniopharyngioma",[3208,261],"^1^8F-fluorodeoxyglucose",{"nctId":70,"briefTitle":71,"status":167,"phases":3210,"primaryCompletion":72,"completion":266,"start":3211,"enrollment":2465,"conditions":3212,"interventions":3213},[87],"2014-05-07",[2479],[73,261],{"trials":3215,"activeCount":98},[],{"trials":3217,"activeCount":98},[],{"trials":3219,"activeCount":98},[],{"intervention":131,"totalTrials":108,"cells":3221},{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3226,"PHASE3":3240,"PHASE4":3256,"NA":3258},{"trials":3223,"activeCount":98},[],{"trials":3225,"activeCount":98},[],{"trials":3227,"activeCount":445,"soonestReadout":307},[3228,3232,3236],{"nctId":118,"briefTitle":119,"status":104,"phases":3229,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":3230,"interventions":3231},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":685,"briefTitle":686,"status":167,"phases":3233,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":3234,"interventions":3235},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"nctId":304,"briefTitle":305,"status":167,"phases":3237,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":3238,"interventions":3239},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"trials":3241,"activeCount":98},[3242],{"nctId":3243,"briefTitle":3244,"status":104,"phases":3245,"primaryCompletion":3246,"completion":3246,"start":3247,"enrollment":3248,"conditions":3249,"interventions":3250},"NCT00187083","A Study of Children With Refractory or Relapsed ALL",[88],"2003-12","1997-02",40,[14],[3251,3252,3253,3254,3255],"Topotecan, dexamethasone, vincristine","E. coli Asparaginase, PEG-L-asparaginase","erwinia asparaginase","fludarabine, methotrexate, mercaptopurine","idarubicin, etoposide, cytarbine, teniposide",{"trials":3257,"activeCount":98},[],{"trials":3259,"activeCount":98},[],{"intervention":548,"totalTrials":831,"cells":3261},{"EARLY_PHASE1":3262,"PHASE1":3264,"PHASE2":3293,"PHASE3":3322,"PHASE4":3324,"NA":3326},{"trials":3263,"activeCount":98},[],{"trials":3265,"activeCount":386,"soonestReadout":3278},[3266,3270,3274,3285,3289],{"nctId":969,"briefTitle":970,"status":104,"phases":3267,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":3268,"interventions":3269},[86],[25],[548,78,544],{"nctId":1039,"briefTitle":1040,"status":104,"phases":3271,"primaryCompletion":1042,"completion":1043,"start":1044,"enrollment":1045,"conditions":3272,"interventions":3273},[86],[1047],[78,1049,548],{"nctId":3275,"briefTitle":3276,"status":186,"phases":3277,"primaryCompletion":3278,"completion":3279,"start":3280,"enrollment":1214,"conditions":3281,"interventions":3282},"NCT06506461","Gene Editing For Sickle Cell Disease",[86],"2029-12","2032-12","2025-03-21",[17],[749,548,3283,3284],"Gene-modified CD34+ cells","Motixafortide",{"nctId":627,"briefTitle":628,"status":104,"phases":3286,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":3287,"interventions":3288},[86],[23,634,635],[637,638,152,548,639,160,640,139,133,354,161,641],{"nctId":2254,"briefTitle":2255,"status":104,"phases":3290,"primaryCompletion":2257,"completion":2257,"start":2258,"enrollment":124,"conditions":3291,"interventions":3292},[86],[1062,2260,2261,2262,634,1113,1116,2263,2264,1119,23,32,2265],[2267,2268,2269,548,157,751],{"trials":3294,"activeCount":386,"soonestReadout":982},[3295,3299,3310,3314,3318],{"nctId":141,"briefTitle":142,"status":104,"phases":3296,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":3297,"interventions":3298},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":3300,"briefTitle":3301,"status":721,"phases":3302,"primaryCompletion":829,"completion":3303,"start":3304,"enrollment":3305,"conditions":3306,"interventions":3308},"NCT01512888","Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants",[86,87],"2034-08","2016-08-17",28,[3307],"Severe Combined Immunodeficiency Disease, X-linked",[3309,548],"CL20-i4-EF1α-hγc-OPT",{"nctId":2281,"briefTitle":2282,"status":167,"phases":3311,"primaryCompletion":982,"completion":207,"start":2284,"enrollment":108,"conditions":3312,"interventions":3313},[86,87],[2286],[545,548,429,549],{"nctId":739,"briefTitle":740,"status":490,"phases":3315,"primaryCompletion":619,"completion":619,"start":742,"enrollment":743,"conditions":3316,"interventions":3317},[87],[14,564,565,745,566,746,747],[470,474,156,749,150,750,751,752,753],{"nctId":534,"briefTitle":535,"status":490,"phases":3319,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":3320,"interventions":3321},[87],[541,542],[383,544,545,546,78,429,136,547,548,549],{"trials":3323,"activeCount":98},[],{"trials":3325,"activeCount":98},[],{"trials":3327,"activeCount":98},[],{"intervention":114,"totalTrials":554,"cells":3329},{"EARLY_PHASE1":3330,"PHASE1":3332,"PHASE2":3350,"PHASE3":3364,"PHASE4":3366,"NA":3368},{"trials":3331,"activeCount":98},[],{"trials":3333,"activeCount":98},[3334,3342,3346],{"nctId":3335,"briefTitle":3336,"status":104,"phases":3337,"primaryCompletion":3338,"completion":3338,"start":1259,"enrollment":9,"conditions":3339,"interventions":3341},"NCT00132158","ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors",[86],"2011-10",[2480,3340,23,526],"Rhabdomyosarcomas",[114],{"nctId":2447,"briefTitle":2448,"status":104,"phases":3343,"primaryCompletion":2450,"completion":2451,"start":2452,"enrollment":524,"conditions":3344,"interventions":3345},[86],[2454],[2456,114,243,215,2457],{"nctId":102,"briefTitle":103,"status":104,"phases":3347,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":3348,"interventions":3349},[86],[110,111,14],[113,114,93],{"trials":3351,"activeCount":445,"soonestReadout":249},[3352,3356,3360],{"nctId":1223,"briefTitle":1224,"status":490,"phases":3353,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":108,"conditions":3354,"interventions":3355},[87],[23],[1230,114,78,132,139,299,355,1231],{"nctId":246,"briefTitle":247,"status":167,"phases":3357,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":3358,"interventions":3359},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"nctId":2777,"briefTitle":2778,"status":186,"phases":3361,"primaryCompletion":2780,"completion":2781,"start":2782,"enrollment":2783,"conditions":3362,"interventions":3363},[87],[2785],[243,114,152,2787,2788],{"trials":3365,"activeCount":98},[],{"trials":3367,"activeCount":98},[],{"trials":3369,"activeCount":98},[],{"intervention":428,"totalTrials":494,"cells":3371},{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3396,"PHASE3":3406,"PHASE4":3408,"NA":3410},{"trials":3373,"activeCount":98},[],{"trials":3375,"activeCount":386,"soonestReadout":82},[3376,3380,3384],{"nctId":80,"briefTitle":81,"status":167,"phases":3377,"primaryCompletion":82,"completion":336,"start":420,"enrollment":421,"conditions":3378,"interventions":3379},[86],[423,424,425,426],[83,428,133,429,215,136,430],{"nctId":616,"briefTitle":617,"status":104,"phases":3381,"primaryCompletion":619,"completion":619,"start":521,"enrollment":9,"conditions":3382,"interventions":3383},[86],[621,622,623,624],[428,429,133,430],{"nctId":3385,"briefTitle":3386,"status":3387,"phases":3388,"primaryCompletion":3389,"completion":3390,"start":3391,"enrollment":98,"conditions":3392,"interventions":3394},"NCT05952687","Trial of Idasanutlin and Selinexor Therapy for Children With Progressive\u002FRelapsed AT\u002FRT or Extra-CNS Malignant Rhabdoid Tumors","WITHDRAWN",[86],"2025-09","2032-08","2024-03",[1116,2473,3393,1033],"Atypical Teratoid\u002FRhabdoid Tumor of CNS",[3395,3395,428],"Idasanutlin",{"trials":3397,"activeCount":386,"soonestReadout":1615},[3398,3402],{"nctId":703,"briefTitle":704,"status":490,"phases":3399,"primaryCompletion":706,"completion":706,"start":707,"enrollment":421,"conditions":3400,"interventions":3401},[87],[621],[428,429,133,430],{"nctId":1612,"briefTitle":1613,"status":186,"phases":3403,"primaryCompletion":1615,"completion":1333,"start":1616,"enrollment":1617,"conditions":3404,"interventions":3405},[86,87],[1619,1620,1621,1622,1623,1624,1625,1626,1627],[1629,258,132,428],{"trials":3407,"activeCount":98},[],{"trials":3409,"activeCount":98},[],{"trials":3411,"activeCount":98},[],{"intervention":1103,"totalTrials":494,"cells":3413},{"EARLY_PHASE1":3414,"PHASE1":3416,"PHASE2":3426,"PHASE3":3440,"PHASE4":3442,"NA":3444},{"trials":3415,"activeCount":98},[],{"trials":3417,"activeCount":386,"soonestReadout":1093},[3418,3422],{"nctId":2052,"briefTitle":2053,"status":104,"phases":3419,"primaryCompletion":2055,"completion":364,"start":106,"enrollment":743,"conditions":3420,"interventions":3421},[86],[2057],[135,549,639,1253,1103],{"nctId":1090,"briefTitle":1091,"status":186,"phases":3423,"primaryCompletion":1093,"completion":1094,"start":793,"enrollment":1095,"conditions":3424,"interventions":3425},[86],[1097,1098,1099,1100],[1102,78,429,544,1103],{"trials":3427,"activeCount":386,"soonestReadout":1162},[3428,3432,3436],{"nctId":1159,"briefTitle":1160,"status":167,"phases":3429,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":3430,"interventions":3431},[87],[622,621,1167,1168,1169,623,1170],[545,273,78,429,161,639,544,1103,752,549,1172,1173],{"nctId":1187,"briefTitle":1188,"status":490,"phases":3433,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":357,"conditions":3434,"interventions":3435},[87],[622,621,1167,1194,1169,623,1170],[78,429,161,1078,639,549,1103,1196,1197,1198],{"nctId":457,"briefTitle":458,"status":104,"phases":3437,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":3438,"interventions":3439},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"trials":3441,"activeCount":98},[],{"trials":3443,"activeCount":98},[],{"trials":3445,"activeCount":98},[],{"intervention":225,"totalTrials":494,"cells":3447},{"EARLY_PHASE1":3448,"PHASE1":3450,"PHASE2":3452,"PHASE3":3474,"PHASE4":3476,"NA":3478},{"trials":3449,"activeCount":98},[],{"trials":3451,"activeCount":98},[],{"trials":3453,"activeCount":445,"soonestReadout":63},[3454,3458,3462,3466,3470],{"nctId":457,"briefTitle":458,"status":104,"phases":3455,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":3456,"interventions":3457},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"nctId":61,"briefTitle":62,"status":167,"phases":3459,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":3460,"interventions":3461},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":685,"briefTitle":686,"status":167,"phases":3463,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":3464,"interventions":3465},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"nctId":506,"briefTitle":507,"status":490,"phases":3467,"primaryCompletion":509,"completion":509,"start":510,"enrollment":357,"conditions":3468,"interventions":3469},[87],[512,25,513],[199,228,225,133,136,138,515,516,113,137,132],{"nctId":856,"briefTitle":857,"status":490,"phases":3471,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":3472,"interventions":3473},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"trials":3475,"activeCount":98},[],{"trials":3477,"activeCount":98},[],{"trials":3479,"activeCount":98},[],{"intervention":443,"totalTrials":108,"cells":3481},{"EARLY_PHASE1":3482,"PHASE1":3484,"PHASE2":3494,"PHASE3":3504,"PHASE4":3506,"NA":3508},{"trials":3483,"activeCount":98},[],{"trials":3485,"activeCount":386,"soonestReadout":435},[3486,3490],{"nctId":605,"briefTitle":606,"status":104,"phases":3487,"primaryCompletion":608,"completion":609,"start":610,"enrollment":611,"conditions":3488,"interventions":3489},[86],[25],[83,133,384,614,443],{"nctId":432,"briefTitle":433,"status":186,"phases":3491,"primaryCompletion":435,"completion":436,"start":437,"enrollment":171,"conditions":3492,"interventions":3493},[86],[426,439,440],[442,83,443,444,133,136],{"trials":3495,"activeCount":386,"soonestReadout":688},[3496,3500],{"nctId":685,"briefTitle":686,"status":167,"phases":3497,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":3498,"interventions":3499},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"nctId":719,"briefTitle":720,"status":721,"phases":3501,"primaryCompletion":249,"completion":723,"start":724,"enrollment":725,"conditions":3502,"interventions":3503},[87],[25],[83,443,133,728,729,730,731,732,139,733],{"trials":3505,"activeCount":98},[],{"trials":3507,"activeCount":98},[],{"trials":3509,"activeCount":98},[],{"intervention":1173,"totalTrials":539,"cells":3511},{"EARLY_PHASE1":3512,"PHASE1":3514,"PHASE2":3520,"PHASE3":3530,"PHASE4":3532,"NA":3534},{"trials":3513,"activeCount":98},[],{"trials":3515,"activeCount":98},[3516],{"nctId":2254,"briefTitle":2255,"status":104,"phases":3517,"primaryCompletion":2257,"completion":2257,"start":2258,"enrollment":124,"conditions":3518,"interventions":3519},[86],[1062,2260,2261,2262,634,1113,1116,2263,2264,1119,23,32,2265],[2267,2268,2269,548,157,751],{"trials":3521,"activeCount":445,"soonestReadout":1162},[3522,3526],{"nctId":1159,"briefTitle":1160,"status":167,"phases":3523,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":3524,"interventions":3525},[87],[622,621,1167,1168,1169,623,1170],[545,273,78,429,161,639,544,1103,752,549,1172,1173],{"nctId":2553,"briefTitle":2554,"status":2525,"phases":3527,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":2559,"conditions":3528,"interventions":3529},[87],[17],[2562,2563,1397,2564,549,215,1173,2565],{"trials":3531,"activeCount":98},[],{"trials":3533,"activeCount":98},[],{"trials":3535,"activeCount":98},[],{"intervention":216,"totalTrials":445,"cells":3537},{"EARLY_PHASE1":3538,"PHASE1":3540,"PHASE2":3542,"PHASE3":3552,"PHASE4":3554,"NA":3556},{"trials":3539,"activeCount":98},[],{"trials":3541,"activeCount":98},[],{"trials":3543,"activeCount":445,"soonestReadout":58},[3544,3548],{"nctId":203,"briefTitle":204,"status":167,"phases":3545,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":3546,"interventions":3547},[87],[28],[212,139,132,213,93,214,128,215,216,78,217],{"nctId":56,"briefTitle":57,"status":167,"phases":3549,"primaryCompletion":58,"completion":266,"start":1295,"enrollment":1296,"conditions":3550,"interventions":3551},[87],[1298,1299,1300],[59,154,1302,155,150,1303,284],{"trials":3553,"activeCount":98},[],{"trials":3555,"activeCount":98},[],{"trials":3557,"activeCount":98},[],{"intervention":64,"totalTrials":445,"cells":3559},{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3564,"PHASE3":3574,"PHASE4":3576,"NA":3578},{"trials":3561,"activeCount":98},[],{"trials":3563,"activeCount":98},[],{"trials":3565,"activeCount":445,"soonestReadout":63},[3566,3570],{"nctId":61,"briefTitle":62,"status":167,"phases":3567,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":3568,"interventions":3569},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":685,"briefTitle":686,"status":167,"phases":3571,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":3572,"interventions":3573},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"trials":3575,"activeCount":98},[],{"trials":3577,"activeCount":98},[],{"trials":3579,"activeCount":98},[],{"intervention":240,"totalTrials":445,"cells":3581},{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3586,"PHASE3":3596,"PHASE4":3598,"NA":3600},{"trials":3583,"activeCount":98},[],{"trials":3585,"activeCount":98},[],{"trials":3587,"activeCount":445,"soonestReadout":249},[3588,3592],{"nctId":231,"briefTitle":232,"status":186,"phases":3589,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":3590,"interventions":3591},[87],[32],[93,240,78,241,242,243,244],{"nctId":246,"briefTitle":247,"status":167,"phases":3593,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":3594,"interventions":3595},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"trials":3597,"activeCount":98},[],{"trials":3599,"activeCount":98},[],{"trials":3601,"activeCount":98},[],{"intervention":260,"totalTrials":445,"cells":3603},{"EARLY_PHASE1":3604,"PHASE1":3606,"PHASE2":3608,"PHASE3":3618,"PHASE4":3620,"NA":3622},{"trials":3605,"activeCount":98},[],{"trials":3607,"activeCount":98},[],{"trials":3609,"activeCount":445,"soonestReadout":688},[3610,3614],{"nctId":246,"briefTitle":247,"status":167,"phases":3611,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":3612,"interventions":3613},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"nctId":685,"briefTitle":686,"status":167,"phases":3615,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":3616,"interventions":3617},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"trials":3619,"activeCount":98},[],{"trials":3621,"activeCount":98},[],{"trials":3623,"activeCount":98},[],{"intervention":356,"totalTrials":445,"cells":3625},{"EARLY_PHASE1":3626,"PHASE1":3628,"PHASE2":3630,"PHASE3":3640,"PHASE4":3642,"NA":3644},{"trials":3627,"activeCount":98},[],{"trials":3629,"activeCount":98},[],{"trials":3631,"activeCount":445,"soonestReadout":1269},[3632,3636],{"nctId":1266,"briefTitle":1267,"status":186,"phases":3633,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":3634,"interventions":3635},[87],[1274,1033],[1276,78,139,354,161,356],{"nctId":346,"briefTitle":347,"status":186,"phases":3637,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":3638,"interventions":3639},[87],[297],[136,299,93,78,354,355,139,356,215,136],{"trials":3641,"activeCount":98},[],{"trials":3643,"activeCount":98},[],{"trials":3645,"activeCount":98},[],{"intervention":3208,"totalTrials":445,"cells":3647},{"EARLY_PHASE1":3648,"PHASE1":3650,"PHASE2":3652,"PHASE3":3662,"PHASE4":3664,"NA":3666},{"trials":3649,"activeCount":98},[],{"trials":3651,"activeCount":98},[],{"trials":3653,"activeCount":445,"soonestReadout":72},[3654,3658],{"nctId":3200,"briefTitle":3201,"status":167,"phases":3655,"primaryCompletion":169,"completion":169,"start":3203,"enrollment":3204,"conditions":3656,"interventions":3657},[87],[3206],[3208,261],{"nctId":70,"briefTitle":71,"status":167,"phases":3659,"primaryCompletion":72,"completion":266,"start":3211,"enrollment":2465,"conditions":3660,"interventions":3661},[87],[2479],[73,261],{"trials":3663,"activeCount":98},[],{"trials":3665,"activeCount":98},[],{"trials":3667,"activeCount":98},[],{"intervention":1288,"totalTrials":445,"cells":3669},{"EARLY_PHASE1":3670,"PHASE1":3672,"PHASE2":3674,"PHASE3":3684,"PHASE4":3686,"NA":3688},{"trials":3671,"activeCount":98},[],{"trials":3673,"activeCount":98},[],{"trials":3675,"activeCount":445,"soonestReadout":1362},[3676,3680],{"nctId":1278,"briefTitle":1279,"status":186,"phases":3677,"primaryCompletion":1281,"completion":1005,"start":1282,"enrollment":1021,"conditions":3678,"interventions":3679},[87],[1284,1285],[1136,429,78,544,161,1287,1288],{"nctId":1359,"briefTitle":1360,"status":167,"phases":3681,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":3682,"interventions":3683},[87],[622,621,1367,1368,28,1369,1169,1168],[78,429,549,639,1371,544,1372,273,1373,1374,1288],{"trials":3685,"activeCount":98},[],{"trials":3687,"activeCount":98},[],{"trials":3689,"activeCount":98},[],{"intervention":2564,"totalTrials":554,"cells":3691},{"EARLY_PHASE1":3692,"PHASE1":3694,"PHASE2":3696,"PHASE3":3741,"PHASE4":3757,"NA":3759},{"trials":3693,"activeCount":98},[],{"trials":3695,"activeCount":98},[],{"trials":3697,"activeCount":386,"soonestReadout":2556},[3698,3708,3718,3729,3737],{"nctId":3699,"briefTitle":3700,"status":490,"phases":3701,"primaryCompletion":3702,"completion":3702,"start":3703,"enrollment":386,"conditions":3704,"interventions":3706},"NCT03825341","Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere",[87],"2022-01-20","2019-06-10",[17,3705],"Thalassemia",[2564,3707],"Hydroxyurea Oral",{"nctId":3709,"briefTitle":3710,"status":104,"phases":3711,"primaryCompletion":3712,"completion":3712,"start":3713,"enrollment":3714,"conditions":3715,"interventions":3717},"NCT03020615","Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies",[87],"2020-06-08","2017-05-12",58,[3716],"Sickle Cell Anemia",[2564],{"nctId":3719,"briefTitle":3720,"status":490,"phases":3721,"primaryCompletion":3722,"completion":3723,"start":3724,"enrollment":647,"conditions":3725,"interventions":3727},"NCT00532883","Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease",[87],"2009-03","2009-08","2007-01",[3726],"Hemoglobin SC Disease",[2564,3728],"Magnesium Pidolate",{"nctId":3730,"briefTitle":3731,"status":104,"phases":3732,"primaryCompletion":3733,"completion":3733,"start":1349,"conditions":3734,"interventions":3735},"NCT00002940","Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS",[87],"2002-03",[634],[3736],"hydroxyurea",{"nctId":2553,"briefTitle":2554,"status":2525,"phases":3738,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":2559,"conditions":3739,"interventions":3740},[87],[17],[2562,2563,1397,2564,549,215,1173,2565],{"trials":3742,"activeCount":98},[3743],{"nctId":3744,"briefTitle":3745,"status":490,"phases":3746,"primaryCompletion":3747,"completion":3748,"start":3749,"enrollment":3750,"conditions":3751,"interventions":3756},"NCT00122980","Stroke With Transfusions Changing to Hydroxyurea",[88],"2010-06","2010-12","2006-10",134,[3752,3753,3754,3755],"Hemochromatosis","Cerebrovascular Accident","Anemia, Sickle Cell","Hematologic Diseases",[2564],{"trials":3758,"activeCount":98},[],{"trials":3760,"activeCount":98},[],{"intervention":317,"totalTrials":108,"cells":3762},{"EARLY_PHASE1":3763,"PHASE1":3765,"PHASE2":3771,"PHASE3":3785,"PHASE4":3787,"NA":3789},{"trials":3764,"activeCount":98},[],{"trials":3766,"activeCount":98},[3767],{"nctId":596,"briefTitle":597,"status":490,"phases":3768,"primaryCompletion":599,"completion":599,"start":600,"enrollment":9,"conditions":3769,"interventions":3770},[86],[25,566],[603,429,133,317,316],{"trials":3772,"activeCount":386,"soonestReadout":307},[3773,3777,3781],{"nctId":668,"briefTitle":669,"status":490,"phases":3774,"primaryCompletion":671,"completion":671,"start":672,"enrollment":108,"conditions":3775,"interventions":3776},[87],[621,623],[133,317,675],{"nctId":304,"briefTitle":305,"status":167,"phases":3778,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":3779,"interventions":3780},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"nctId":856,"briefTitle":857,"status":490,"phases":3782,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":3783,"interventions":3784},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"trials":3786,"activeCount":98},[],{"trials":3788,"activeCount":98},[],{"trials":3790,"activeCount":98},[],{"intervention":152,"totalTrials":539,"cells":3792},{"EARLY_PHASE1":3793,"PHASE1":3795,"PHASE2":3801,"PHASE3":3811,"PHASE4":3813,"NA":3815},{"trials":3794,"activeCount":98},[],{"trials":3796,"activeCount":98},[3797],{"nctId":627,"briefTitle":628,"status":104,"phases":3798,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":3799,"interventions":3800},[86],[23,634,635],[637,638,152,548,639,160,640,139,133,354,161,641],{"trials":3802,"activeCount":386,"soonestReadout":2780},[3803,3807],{"nctId":141,"briefTitle":142,"status":104,"phases":3804,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":3805,"interventions":3806},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":2777,"briefTitle":2778,"status":186,"phases":3808,"primaryCompletion":2780,"completion":2781,"start":2782,"enrollment":2783,"conditions":3809,"interventions":3810},[87],[2785],[243,114,152,2787,2788],{"trials":3812,"activeCount":98},[],{"trials":3814,"activeCount":98},[],{"trials":3816,"activeCount":98},[],{"intervention":752,"totalTrials":539,"cells":3818},{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3823,"PHASE3":3837,"PHASE4":3839,"NA":3841},{"trials":3820,"activeCount":98},[],{"trials":3822,"activeCount":98},[],{"trials":3824,"activeCount":386,"soonestReadout":1162},[3825,3829,3833],{"nctId":1159,"briefTitle":1160,"status":167,"phases":3826,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":3827,"interventions":3828},[87],[622,621,1167,1168,1169,623,1170],[545,273,78,429,161,639,544,1103,752,549,1172,1173],{"nctId":1245,"briefTitle":1246,"status":490,"phases":3830,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":171,"conditions":3831,"interventions":3832},[87],[1251],[78,549,429,639,544,161,1253,752,500,1254],{"nctId":739,"briefTitle":740,"status":490,"phases":3834,"primaryCompletion":619,"completion":619,"start":742,"enrollment":743,"conditions":3835,"interventions":3836},[87],[14,564,565,745,566,746,747],[470,474,156,749,150,750,751,752,753],{"trials":3838,"activeCount":98},[],{"trials":3840,"activeCount":98},[],{"trials":3842,"activeCount":98},[],{"intervention":302,"totalTrials":539,"cells":3844},{"EARLY_PHASE1":3845,"PHASE1":3847,"PHASE2":3857,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3846,"activeCount":98},[],{"trials":3848,"activeCount":98},[3849,3853],{"nctId":1015,"briefTitle":1016,"status":104,"phases":3850,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":3851,"interventions":3852},[86],[1023,1024,1025,1026,297,1027,1028,1029,1030,1031,1032,1033,1034],[1036,78,302,284,1037],{"nctId":2459,"briefTitle":2460,"status":104,"phases":3854,"primaryCompletion":2462,"completion":2463,"start":2464,"enrollment":2465,"conditions":3855,"interventions":3856},[86],[2467,2468,2469,2470,2471,2472,2473,1031,1023,2474,2475,2476,2477,1033,2478,2479,2480,2481,2482,297,2483,2484,2485,2486,2487,2488,2489,2490,2491,2492,2493,2494,2495,2496,2497,2498,2499,2500,2501,2502,2503,2504,2505,1028,2506,2507,2508,2509,2510,2511,2512,2513,2514,2515,2516,2517],[302,2519,2520,2521,284],{"trials":3858,"activeCount":386,"soonestReadout":292},[3859],{"nctId":289,"briefTitle":290,"status":167,"phases":3860,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":3861,"interventions":3862},[87],[297],[78,299,93,300,301,302],{"trials":3864,"activeCount":98},[],{"trials":3866,"activeCount":98},[],{"trials":3868,"activeCount":98},[],{"intervention":1037,"totalTrials":539,"cells":3870},{"EARLY_PHASE1":3871,"PHASE1":3873,"PHASE2":3883,"PHASE3":3889,"PHASE4":3891,"NA":3893},{"trials":3872,"activeCount":98},[],{"trials":3874,"activeCount":98},[3875,3879],{"nctId":1015,"briefTitle":1016,"status":104,"phases":3876,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":3877,"interventions":3878},[86],[1023,1024,1025,1026,297,1027,1028,1029,1030,1031,1032,1033,1034],[1036,78,302,284,1037],{"nctId":2447,"briefTitle":2448,"status":104,"phases":3880,"primaryCompletion":2450,"completion":2451,"start":2452,"enrollment":524,"conditions":3881,"interventions":3882},[86],[2454],[2456,114,243,215,2457],{"trials":3884,"activeCount":386,"soonestReadout":68},[3885],{"nctId":66,"briefTitle":67,"status":167,"phases":3886,"primaryCompletion":68,"completion":278,"start":279,"enrollment":280,"conditions":3887,"interventions":3888},[87],[282],[44,151,284,285,286,154,150,287,155],{"trials":3890,"activeCount":98},[],{"trials":3892,"activeCount":98},[],{"trials":3894,"activeCount":98},[],{"intervention":640,"totalTrials":539,"cells":3896},{"EARLY_PHASE1":3897,"PHASE1":3899,"PHASE2":3909,"PHASE3":3915,"PHASE4":3917,"NA":3919},{"trials":3898,"activeCount":98},[],{"trials":3900,"activeCount":98},[3901,3905],{"nctId":627,"briefTitle":628,"status":104,"phases":3902,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":3903,"interventions":3904},[86],[23,634,635],[637,638,152,548,639,160,640,139,133,354,161,641],{"nctId":801,"briefTitle":802,"status":104,"phases":3906,"primaryCompletion":804,"completion":804,"start":805,"enrollment":26,"conditions":3907,"interventions":3908},[86],[28,807,808],[640,135,139,641,113],{"trials":3910,"activeCount":386,"soonestReadout":206},[3911],{"nctId":203,"briefTitle":204,"status":167,"phases":3912,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":3913,"interventions":3914},[87],[28],[212,139,132,213,93,214,128,215,216,78,217],{"trials":3916,"activeCount":98},[],{"trials":3918,"activeCount":98},[],{"trials":3920,"activeCount":98},[],{"intervention":214,"totalTrials":539,"cells":3922},{"EARLY_PHASE1":3923,"PHASE1":3925,"PHASE2":3927,"PHASE3":3941,"PHASE4":3943,"NA":3945},{"trials":3924,"activeCount":98},[],{"trials":3926,"activeCount":98},[],{"trials":3928,"activeCount":386,"soonestReadout":206},[3929,3933,3937],{"nctId":203,"briefTitle":204,"status":167,"phases":3930,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":3931,"interventions":3932},[87],[28],[212,139,132,213,93,214,128,215,216,78,217],{"nctId":457,"briefTitle":458,"status":104,"phases":3934,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":3935,"interventions":3936},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"nctId":319,"briefTitle":320,"status":104,"phases":3938,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":3939,"interventions":3940},[87],[327],[329,214,330,78,93,213,139,128,161],{"trials":3942,"activeCount":98},[],{"trials":3944,"activeCount":98},[],{"trials":3946,"activeCount":98},[],{"intervention":641,"totalTrials":539,"cells":3948},{"EARLY_PHASE1":3949,"PHASE1":3951,"PHASE2":3961,"PHASE3":3967,"PHASE4":3969,"NA":3971},{"trials":3950,"activeCount":98},[],{"trials":3952,"activeCount":98},[3953,3957],{"nctId":627,"briefTitle":628,"status":104,"phases":3954,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":3955,"interventions":3956},[86],[23,634,635],[637,638,152,548,639,160,640,139,133,354,161,641],{"nctId":801,"briefTitle":802,"status":104,"phases":3958,"primaryCompletion":804,"completion":804,"start":805,"enrollment":26,"conditions":3959,"interventions":3960},[86],[28,807,808],[640,135,139,641,113],{"trials":3962,"activeCount":386,"soonestReadout":249},[3963],{"nctId":246,"briefTitle":247,"status":167,"phases":3964,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":3965,"interventions":3966},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"trials":3968,"activeCount":98},[],{"trials":3970,"activeCount":98},[],{"trials":3972,"activeCount":98},[],{"intervention":1397,"totalTrials":539,"cells":3974},{"EARLY_PHASE1":3975,"PHASE1":3977,"PHASE2":3983,"PHASE3":3993,"PHASE4":3995,"NA":3997},{"trials":3976,"activeCount":98},[],{"trials":3978,"activeCount":98},[3979],{"nctId":2254,"briefTitle":2255,"status":104,"phases":3980,"primaryCompletion":2257,"completion":2257,"start":2258,"enrollment":124,"conditions":3981,"interventions":3982},[86],[1062,2260,2261,2262,634,1113,1116,2263,2264,1119,23,32,2265],[2267,2268,2269,548,157,751],{"trials":3984,"activeCount":386,"soonestReadout":2556},[3985,3989],{"nctId":2553,"briefTitle":2554,"status":2525,"phases":3986,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":2559,"conditions":3987,"interventions":3988},[87],[17],[2562,2563,1397,2564,549,215,1173,2565],{"nctId":1380,"briefTitle":1381,"status":104,"phases":3990,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":3991,"interventions":3992},[87],[1388,1389,1390,1169,1391,28,1392,623],[429,1394,1395,1253,1396,1397,78,545,161,1398],{"trials":3994,"activeCount":98},[],{"trials":3996,"activeCount":98},[],{"trials":3998,"activeCount":98},[],{"intervention":1172,"totalTrials":445,"cells":4000},{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4005,"PHASE3":4015,"PHASE4":4017,"NA":4019},{"trials":4002,"activeCount":98},[],{"trials":4004,"activeCount":98},[],{"trials":4006,"activeCount":386,"soonestReadout":1162},[4007,4011],{"nctId":1159,"briefTitle":1160,"status":167,"phases":4008,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":4009,"interventions":4010},[87],[622,621,1167,1168,1169,623,1170],[545,273,78,429,161,639,544,1103,752,549,1172,1173],{"nctId":1408,"briefTitle":1409,"status":104,"phases":4012,"primaryCompletion":1411,"completion":1412,"start":1413,"enrollment":1414,"conditions":4013,"interventions":4014},[87],[1087,634],[429,78,549,639,1172,1417,161,544,1253],{"trials":4016,"activeCount":98},[],{"trials":4018,"activeCount":98},[],{"trials":4020,"activeCount":98},[],{"intervention":180,"totalTrials":445,"cells":4022},{"EARLY_PHASE1":4023,"PHASE1":4025,"PHASE2":4027,"PHASE3":4037,"PHASE4":4039,"NA":4041},{"trials":4024,"activeCount":98},[],{"trials":4026,"activeCount":98},[],{"trials":4028,"activeCount":386,"soonestReadout":43},[4029,4033],{"nctId":41,"briefTitle":42,"status":167,"phases":4030,"primaryCompletion":43,"completion":169,"start":170,"enrollment":171,"conditions":4031,"interventions":4032},[87],[173,174,175,176],[44,155,150,178,154,179,180,181,182],{"nctId":1223,"briefTitle":1224,"status":490,"phases":4034,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":108,"conditions":4035,"interventions":4036},[87],[23],[1230,114,78,132,139,299,355,1231],{"trials":4038,"activeCount":98},[],{"trials":4040,"activeCount":98},[],{"trials":4042,"activeCount":98},[],{"intervention":213,"totalTrials":445,"cells":4044},{"EARLY_PHASE1":4045,"PHASE1":4047,"PHASE2":4049,"PHASE3":4059,"PHASE4":4061,"NA":4063},{"trials":4046,"activeCount":98},[],{"trials":4048,"activeCount":98},[],{"trials":4050,"activeCount":386,"soonestReadout":206},[4051,4055],{"nctId":203,"briefTitle":204,"status":167,"phases":4052,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":4053,"interventions":4054},[87],[28],[212,139,132,213,93,214,128,215,216,78,217],{"nctId":319,"briefTitle":320,"status":104,"phases":4056,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":4057,"interventions":4058},[87],[327],[329,214,330,78,93,213,139,128,161],{"trials":4060,"activeCount":98},[],{"trials":4062,"activeCount":98},[],{"trials":4064,"activeCount":98},[],{"intervention":229,"totalTrials":445,"cells":4066},{"EARLY_PHASE1":4067,"PHASE1":4069,"PHASE2":4071,"PHASE3":4091,"PHASE4":4093,"NA":4095},{"trials":4068,"activeCount":98},[],{"trials":4070,"activeCount":98},[],{"trials":4072,"activeCount":386,"soonestReadout":63},[4073,4077],{"nctId":61,"briefTitle":62,"status":167,"phases":4074,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":4075,"interventions":4076},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"nctId":4078,"briefTitle":4079,"status":104,"phases":4080,"primaryCompletion":4081,"completion":4081,"start":4082,"enrollment":357,"conditions":4083,"interventions":4088},"NCT00004005","Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin",[87],"2005-10","1998-09",[4084,4085,4086,4087],"Carcinoma of Unknown Primary","Colorectal Cancer","Unspecified Adult Solid Tumor, Protocol Specific","Unspecified Childhood Solid Tumor, Protocol Specific",[4089,2743,4090],"fluorouracil","leucovorin calcium",{"trials":4092,"activeCount":98},[],{"trials":4094,"activeCount":98},[],{"trials":4096,"activeCount":98},[],{"intervention":316,"totalTrials":445,"cells":4098},{"EARLY_PHASE1":4099,"PHASE1":4101,"PHASE2":4107,"PHASE3":4113,"PHASE4":4115,"NA":4117},{"trials":4100,"activeCount":98},[],{"trials":4102,"activeCount":98},[4103],{"nctId":596,"briefTitle":597,"status":490,"phases":4104,"primaryCompletion":599,"completion":599,"start":600,"enrollment":9,"conditions":4105,"interventions":4106},[86],[25,566],[603,429,133,317,316],{"trials":4108,"activeCount":386,"soonestReadout":307},[4109],{"nctId":304,"briefTitle":305,"status":167,"phases":4110,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":4111,"interventions":4112},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"trials":4114,"activeCount":98},[],{"trials":4116,"activeCount":98},[],{"trials":4118,"activeCount":98},[],{"intervention":274,"totalTrials":445,"cells":4120},{"EARLY_PHASE1":4121,"PHASE1":4123,"PHASE2":4125,"PHASE3":4135,"PHASE4":4137,"NA":4139},{"trials":4122,"activeCount":98},[],{"trials":4124,"activeCount":98},[],{"trials":4126,"activeCount":386,"soonestReadout":266},[4127,4131],{"nctId":263,"briefTitle":264,"status":186,"phases":4128,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":4129,"interventions":4130},[87],[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],{"nctId":856,"briefTitle":857,"status":490,"phases":4132,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":4133,"interventions":4134},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"trials":4136,"activeCount":98},[],{"trials":4138,"activeCount":98},[],{"trials":4140,"activeCount":98},[],{"intervention":2456,"totalTrials":445,"cells":4142},{"EARLY_PHASE1":4143,"PHASE1":4145,"PHASE2":4151,"PHASE3":4157,"PHASE4":4159,"NA":4161},{"trials":4144,"activeCount":98},[],{"trials":4146,"activeCount":98},[4147],{"nctId":2447,"briefTitle":2448,"status":104,"phases":4148,"primaryCompletion":2450,"completion":2451,"start":2452,"enrollment":524,"conditions":4149,"interventions":4150},[86],[2454],[2456,114,243,215,2457],{"trials":4152,"activeCount":386,"soonestReadout":2748},[4153],{"nctId":2745,"briefTitle":2746,"status":186,"phases":4154,"primaryCompletion":2748,"completion":2748,"start":2749,"enrollment":2750,"conditions":4155,"interventions":4156},[86,87],[2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763,2764,2765,2766,2767,2768,2769,2770,2771,2772,2773],[2775,2456,243],{"trials":4158,"activeCount":98},[],{"trials":4160,"activeCount":98},[],{"trials":4162,"activeCount":98},[],{"intervention":4164,"totalTrials":386,"cells":4165},"[18F]DPA714",{"EARLY_PHASE1":4166,"PHASE1":4168,"PHASE2":4170,"PHASE3":4181,"PHASE4":4183,"NA":4185},{"trials":4167,"activeCount":98},[],{"trials":4169,"activeCount":98},[],{"trials":4171,"activeCount":386,"soonestReadout":4176},[4172],{"nctId":4173,"briefTitle":4174,"status":167,"phases":4175,"primaryCompletion":4176,"completion":4177,"start":4178,"enrollment":21,"conditions":4179,"interventions":4180},"NCT05128903","Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study",[87],"2035-10-26","2035-12-31","2022-07-05",[1023,297],[4164],{"trials":4182,"activeCount":98},[],{"trials":4184,"activeCount":98},[],{"trials":4186,"activeCount":98},[],{"intervention":4188,"totalTrials":386,"cells":4189},"CM4620",{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4194,"PHASE3":4206,"PHASE4":4208,"NA":4210},{"trials":4191,"activeCount":98},[],{"trials":4193,"activeCount":98},[],{"trials":4195,"activeCount":386,"soonestReadout":4200},[4196],{"nctId":4197,"briefTitle":4198,"status":186,"phases":4199,"primaryCompletion":4200,"completion":4201,"start":4202,"enrollment":406,"conditions":4203,"interventions":4205},"NCT04195347","Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase",[86,87],"2027-01","2029-01","2020-09-04",[4204],"Acute Pancreatitis",[4188],{"trials":4207,"activeCount":98},[],{"trials":4209,"activeCount":98},[],{"trials":4211,"activeCount":98},[],{"intervention":39,"totalTrials":386,"cells":4213},{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4218,"PHASE3":4224,"PHASE4":4226,"NA":4228},{"trials":4215,"activeCount":98},[],{"trials":4217,"activeCount":98},[],{"trials":4219,"activeCount":386,"soonestReadout":38},[4220],{"nctId":36,"briefTitle":37,"status":167,"phases":4221,"primaryCompletion":38,"completion":2723,"start":2724,"enrollment":2725,"conditions":4222,"interventions":4223},[87],[2727],[39,243,2729],{"trials":4225,"activeCount":98},[],{"trials":4227,"activeCount":98},[],{"trials":4229,"activeCount":98},[],{"intervention":2729,"totalTrials":386,"cells":4231},{"EARLY_PHASE1":4232,"PHASE1":4234,"PHASE2":4236,"PHASE3":4242,"PHASE4":4244,"NA":4246},{"trials":4233,"activeCount":98},[],{"trials":4235,"activeCount":98},[],{"trials":4237,"activeCount":386,"soonestReadout":38},[4238],{"nctId":36,"briefTitle":37,"status":167,"phases":4239,"primaryCompletion":38,"completion":2723,"start":2724,"enrollment":2725,"conditions":4240,"interventions":4241},[87],[2727],[39,243,2729],{"trials":4243,"activeCount":98},[],{"trials":4245,"activeCount":98},[],{"trials":4247,"activeCount":98},[],{"intervention":217,"totalTrials":386,"cells":4249},{"EARLY_PHASE1":4250,"PHASE1":4252,"PHASE2":4254,"PHASE3":4260,"PHASE4":4262,"NA":4264},{"trials":4251,"activeCount":98},[],{"trials":4253,"activeCount":98},[],{"trials":4255,"activeCount":386,"soonestReadout":206},[4256],{"nctId":203,"briefTitle":204,"status":167,"phases":4257,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":4258,"interventions":4259},[87],[28],[212,139,132,213,93,214,128,215,216,78,217],{"trials":4261,"activeCount":98},[],{"trials":4263,"activeCount":98},[],{"trials":4265,"activeCount":98},[],{"intervention":4267,"totalTrials":386,"cells":4268},"DD-4A Chemotherapy Regimen",{"EARLY_PHASE1":4269,"PHASE1":4271,"PHASE2":4273,"PHASE3":4284,"PHASE4":4286,"NA":4288},{"trials":4270,"activeCount":98},[],{"trials":4272,"activeCount":98},[],{"trials":4274,"activeCount":386,"soonestReadout":249},[4275],{"nctId":4276,"briefTitle":4277,"status":186,"phases":4278,"primaryCompletion":249,"completion":4279,"start":4280,"enrollment":4281,"conditions":4282,"interventions":4283},"NCT04968990","Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation",[87],"2036-12","2021-08-19",260,[1113],[4267],{"trials":4285,"activeCount":98},[],{"trials":4287,"activeCount":98},[],{"trials":4289,"activeCount":98},[],{"intervention":4291,"totalTrials":386,"cells":4292},"[13N]NH3",{"EARLY_PHASE1":4293,"PHASE1":4295,"PHASE2":4297,"PHASE3":4308,"PHASE4":4310,"NA":4312},{"trials":4294,"activeCount":98},[],{"trials":4296,"activeCount":98},[],{"trials":4298,"activeCount":386,"soonestReadout":336},[4299],{"nctId":4300,"briefTitle":4301,"status":186,"phases":4302,"primaryCompletion":336,"completion":4303,"start":4304,"enrollment":3248,"conditions":4305,"interventions":4306},"NCT05583721","Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET",[87],"2028-09","2023-10-10",[17],[4291,4307],"Lexiscan",{"trials":4309,"activeCount":98},[],{"trials":4311,"activeCount":98},[],{"trials":4313,"activeCount":98},[],{"intervention":4307,"totalTrials":386,"cells":4315},{"EARLY_PHASE1":4316,"PHASE1":4318,"PHASE2":4320,"PHASE3":4326,"PHASE4":4328,"NA":4330},{"trials":4317,"activeCount":98},[],{"trials":4319,"activeCount":98},[],{"trials":4321,"activeCount":386,"soonestReadout":336},[4322],{"nctId":4300,"briefTitle":4301,"status":186,"phases":4323,"primaryCompletion":336,"completion":4303,"start":4304,"enrollment":3248,"conditions":4324,"interventions":4325},[87],[17],[4291,4307],{"trials":4327,"activeCount":98},[],{"trials":4329,"activeCount":98},[],{"trials":4331,"activeCount":98},[],{"intervention":4333,"totalTrials":386,"cells":4334},"Methionine",{"EARLY_PHASE1":4335,"PHASE1":4337,"PHASE2":4339,"PHASE3":4356,"PHASE4":4358,"NA":4360},{"trials":4336,"activeCount":98},[],{"trials":4338,"activeCount":98},[],{"trials":4340,"activeCount":386,"soonestReadout":4345},[4341],{"nctId":4342,"briefTitle":4343,"status":167,"phases":4344,"primaryCompletion":4345,"completion":4345,"start":4346,"enrollment":4347,"conditions":4348,"interventions":4355},"NCT00840047","Methionine PET\u002FCT Studies In Patients With Cancer",[87],"2027-07-27","2009-07-20",503,[4349,4350,4351,2479,297,3206,4352,28,4353,1062,526,32,23,4354],"Brain Tumors and\u002For Solid Tumors Including","Brain Stem Glioma","High Grade CNS Tumors","Low Grade CNS Tumors","Non Hodgkin Lymphoma","Other",[4333],{"trials":4357,"activeCount":98},[],{"trials":4359,"activeCount":98},[],{"trials":4361,"activeCount":98},[],{"intervention":227,"totalTrials":386,"cells":4363},{"EARLY_PHASE1":4364,"PHASE1":4366,"PHASE2":4368,"PHASE3":4374,"PHASE4":4376,"NA":4378},{"trials":4365,"activeCount":98},[],{"trials":4367,"activeCount":98},[],{"trials":4369,"activeCount":386,"soonestReadout":63},[4370],{"nctId":61,"briefTitle":62,"status":167,"phases":4371,"primaryCompletion":63,"completion":220,"start":221,"enrollment":222,"conditions":4372,"interventions":4373},[86,87],[14],[64,113,225,226,227,199,228,78,137,136,229,133,139,93],{"trials":4375,"activeCount":98},[],{"trials":4377,"activeCount":98},[],{"trials":4379,"activeCount":98},[],{"intervention":1217,"totalTrials":386,"cells":4381},{"EARLY_PHASE1":4382,"PHASE1":4384,"PHASE2":4386,"PHASE3":4392,"PHASE4":4394,"NA":4396},{"trials":4383,"activeCount":98},[],{"trials":4385,"activeCount":98},[],{"trials":4387,"activeCount":386,"soonestReadout":1211},[4388],{"nctId":1208,"briefTitle":1209,"status":186,"phases":4389,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":4390,"interventions":4391},[87],[14,311],[429,78,544,1217],{"trials":4393,"activeCount":98},[],{"trials":4395,"activeCount":98},[],{"trials":4397,"activeCount":98},[],{"intervention":241,"totalTrials":386,"cells":4399},{"EARLY_PHASE1":4400,"PHASE1":4402,"PHASE2":4404,"PHASE3":4410,"PHASE4":4412,"NA":4414},{"trials":4401,"activeCount":98},[],{"trials":4403,"activeCount":98},[],{"trials":4405,"activeCount":386,"soonestReadout":234},[4406],{"nctId":231,"briefTitle":232,"status":186,"phases":4407,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":4408,"interventions":4409},[87],[32],[93,240,78,241,242,243,244],{"trials":4411,"activeCount":98},[],{"trials":4413,"activeCount":98},[],{"trials":4415,"activeCount":98},[],{"intervention":242,"totalTrials":386,"cells":4417},{"EARLY_PHASE1":4418,"PHASE1":4420,"PHASE2":4422,"PHASE3":4428,"PHASE4":4430,"NA":4432},{"trials":4419,"activeCount":98},[],{"trials":4421,"activeCount":98},[],{"trials":4423,"activeCount":386,"soonestReadout":234},[4424],{"nctId":231,"briefTitle":232,"status":186,"phases":4425,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":4426,"interventions":4427},[87],[32],[93,240,78,241,242,243,244],{"trials":4429,"activeCount":98},[],{"trials":4431,"activeCount":98},[],{"trials":4433,"activeCount":98},[],{"intervention":244,"totalTrials":386,"cells":4435},{"EARLY_PHASE1":4436,"PHASE1":4438,"PHASE2":4440,"PHASE3":4446,"PHASE4":4448,"NA":4450},{"trials":4437,"activeCount":98},[],{"trials":4439,"activeCount":98},[],{"trials":4441,"activeCount":386,"soonestReadout":234},[4442],{"nctId":231,"briefTitle":232,"status":186,"phases":4443,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":4444,"interventions":4445},[87],[32],[93,240,78,241,242,243,244],{"trials":4447,"activeCount":98},[],{"trials":4449,"activeCount":98},[],{"trials":4451,"activeCount":98},[],{"intervention":257,"totalTrials":386,"cells":4453},{"EARLY_PHASE1":4454,"PHASE1":4456,"PHASE2":4458,"PHASE3":4464,"PHASE4":4466,"NA":4468},{"trials":4455,"activeCount":98},[],{"trials":4457,"activeCount":98},[],{"trials":4459,"activeCount":386,"soonestReadout":249},[4460],{"nctId":246,"briefTitle":247,"status":167,"phases":4461,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":4462,"interventions":4463},[87],[32],[93,240,78,255,256,257,114,258,139,259,132,260,261],{"trials":4465,"activeCount":98},[],{"trials":4467,"activeCount":98},[],{"trials":4469,"activeCount":98},[],{"intervention":4471,"totalTrials":386,"cells":4472},"CPX-351",{"EARLY_PHASE1":4473,"PHASE1":4475,"PHASE2":4477,"PHASE3":4490,"PHASE4":4492,"NA":4494},{"trials":4474,"activeCount":98},[],{"trials":4476,"activeCount":98},[],{"trials":4478,"activeCount":386,"soonestReadout":4483},[4479],{"nctId":4480,"briefTitle":4481,"status":167,"phases":4482,"primaryCompletion":4483,"completion":4484,"start":4485,"enrollment":1214,"conditions":4486,"interventions":4488},"NCT05656248","Study of CPX-351 (VYXEOS) in Individuals \u003C 22 Years With Secondary Myeloid Neoplasms",[87],"2025-08-28","2028-08","2023-01-17",[4487],"Myeloid Neoplasm",[4471,4489],"MHA",{"trials":4491,"activeCount":98},[],{"trials":4493,"activeCount":98},[],{"trials":4495,"activeCount":98},[],{"intervention":4489,"totalTrials":386,"cells":4497},{"EARLY_PHASE1":4498,"PHASE1":4500,"PHASE2":4502,"PHASE3":4508,"PHASE4":4510,"NA":4512},{"trials":4499,"activeCount":98},[],{"trials":4501,"activeCount":98},[],{"trials":4503,"activeCount":386,"soonestReadout":4483},[4504],{"nctId":4480,"briefTitle":4481,"status":167,"phases":4505,"primaryCompletion":4483,"completion":4484,"start":4485,"enrollment":1214,"conditions":4506,"interventions":4507},[87],[4487],[4471,4489],{"trials":4509,"activeCount":98},[],{"trials":4511,"activeCount":98},[],{"trials":4513,"activeCount":98},[],{"intervention":4515,"totalTrials":386,"cells":4516},"Mirdametinib",{"EARLY_PHASE1":4517,"PHASE1":4519,"PHASE2":4521,"PHASE3":4535,"PHASE4":4537,"NA":4539},{"trials":4518,"activeCount":98},[],{"trials":4520,"activeCount":98},[],{"trials":4522,"activeCount":386,"soonestReadout":4527},[4523],{"nctId":4524,"briefTitle":4525,"status":186,"phases":4526,"primaryCompletion":4527,"completion":4527,"start":4528,"enrollment":4529,"conditions":4530,"interventions":4534},"NCT04923126","SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma",[86,87],"2031-06","2021-06-21",132,[4531,4532,4533],"Low-Grade Glioma","Recurrent Low-Grade Glioma","Progressive Low-Grade Glioma",[4515],{"trials":4536,"activeCount":98},[],{"trials":4538,"activeCount":98},[],{"trials":4540,"activeCount":98},[],{"intervention":695,"totalTrials":386,"cells":4542},{"EARLY_PHASE1":4543,"PHASE1":4545,"PHASE2":4547,"PHASE3":4553,"PHASE4":4555,"NA":4557},{"trials":4544,"activeCount":98},[],{"trials":4546,"activeCount":98},[],{"trials":4548,"activeCount":386,"soonestReadout":688},[4549],{"nctId":685,"briefTitle":686,"status":167,"phases":4550,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":4551,"interventions":4552},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"trials":4554,"activeCount":98},[],{"trials":4556,"activeCount":98},[],{"trials":4558,"activeCount":98},[],{"intervention":696,"totalTrials":386,"cells":4560},{"EARLY_PHASE1":4561,"PHASE1":4563,"PHASE2":4565,"PHASE3":4571,"PHASE4":4573,"NA":4575},{"trials":4562,"activeCount":98},[],{"trials":4564,"activeCount":98},[],{"trials":4566,"activeCount":386,"soonestReadout":688},[4567],{"nctId":685,"briefTitle":686,"status":167,"phases":4568,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":4569,"interventions":4570},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"trials":4572,"activeCount":98},[],{"trials":4574,"activeCount":98},[],{"trials":4576,"activeCount":98},[],{"intervention":697,"totalTrials":386,"cells":4578},{"EARLY_PHASE1":4579,"PHASE1":4581,"PHASE2":4583,"PHASE3":4589,"PHASE4":4591,"NA":4593},{"trials":4580,"activeCount":98},[],{"trials":4582,"activeCount":98},[],{"trials":4584,"activeCount":386,"soonestReadout":688},[4585],{"nctId":685,"briefTitle":686,"status":167,"phases":4586,"primaryCompletion":688,"completion":689,"start":690,"enrollment":691,"conditions":4587,"interventions":4588},[87],[25,693],[443,695,133,129,139,64,384,429,225,131,256,161,260,696,697],{"trials":4590,"activeCount":98},[],{"trials":4592,"activeCount":98},[],{"trials":4594,"activeCount":98},[],{"intervention":272,"totalTrials":386,"cells":4596},{"EARLY_PHASE1":4597,"PHASE1":4599,"PHASE2":4601,"PHASE3":4607,"PHASE4":4609,"NA":4611},{"trials":4598,"activeCount":98},[],{"trials":4600,"activeCount":98},[],{"trials":4602,"activeCount":386,"soonestReadout":266},[4603],{"nctId":263,"briefTitle":264,"status":186,"phases":4604,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":4605,"interventions":4606},[87],[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],{"trials":4608,"activeCount":98},[],{"trials":4610,"activeCount":98},[],{"trials":4612,"activeCount":98},[],{"intervention":275,"totalTrials":386,"cells":4614},{"EARLY_PHASE1":4615,"PHASE1":4617,"PHASE2":4619,"PHASE3":4625,"PHASE4":4627,"NA":4629},{"trials":4616,"activeCount":98},[],{"trials":4618,"activeCount":98},[],{"trials":4620,"activeCount":386,"soonestReadout":266},[4621],{"nctId":263,"briefTitle":264,"status":186,"phases":4622,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":4623,"interventions":4624},[87],[14,126],[113,93,272,273,198,78,133,136,274,275,129,134],{"trials":4626,"activeCount":98},[],{"trials":4628,"activeCount":98},[],{"trials":4630,"activeCount":98},[],{"intervention":4632,"totalTrials":386,"cells":4633},"Tirzepatide",{"EARLY_PHASE1":4634,"PHASE1":4636,"PHASE2":4638,"PHASE3":4649,"PHASE4":4651,"NA":4653},{"trials":4635,"activeCount":98},[],{"trials":4637,"activeCount":98},[],{"trials":4639,"activeCount":386,"soonestReadout":1269},[4640],{"nctId":4641,"briefTitle":4642,"status":186,"phases":4643,"primaryCompletion":1269,"completion":4644,"start":4645,"enrollment":94,"conditions":4646,"interventions":4648},"NCT07228741","Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity",[87],"2028-11","2026-04-23",[14,4647],"Obesity",[4632],{"trials":4650,"activeCount":98},[],{"trials":4652,"activeCount":98},[],{"trials":4654,"activeCount":98},[],{"intervention":1276,"totalTrials":386,"cells":4656},{"EARLY_PHASE1":4657,"PHASE1":4659,"PHASE2":4661,"PHASE3":4667,"PHASE4":4669,"NA":4671},{"trials":4658,"activeCount":98},[],{"trials":4660,"activeCount":98},[],{"trials":4662,"activeCount":386,"soonestReadout":1269},[4663],{"nctId":1266,"briefTitle":1267,"status":186,"phases":4664,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":4665,"interventions":4666},[87],[1274,1033],[1276,78,139,354,161,356],{"trials":4668,"activeCount":98},[],{"trials":4670,"activeCount":98},[],{"trials":4672,"activeCount":98},[],{"intervention":4674,"totalTrials":386,"cells":4675},"VST",{"EARLY_PHASE1":4676,"PHASE1":4678,"PHASE2":4680,"PHASE3":4693,"PHASE4":4695,"NA":4697},{"trials":4677,"activeCount":98},[],{"trials":4679,"activeCount":98},[],{"trials":4681,"activeCount":386,"soonestReadout":4686},[4682],{"nctId":4683,"briefTitle":4684,"status":186,"phases":4685,"primaryCompletion":4686,"completion":4687,"start":4688,"enrollment":406,"conditions":4689,"interventions":4692},"NCT05664126","Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation",[87],"2028-12-31","2029-12-31","2023-08-01",[4690,4691],"Cytomegalovirus","Adenovirus",[4674],{"trials":4694,"activeCount":98},[],{"trials":4696,"activeCount":98},[],{"trials":4698,"activeCount":98},[],{"intervention":1287,"totalTrials":386,"cells":4700},{"EARLY_PHASE1":4701,"PHASE1":4703,"PHASE2":4705,"PHASE3":4711,"PHASE4":4713,"NA":4715},{"trials":4702,"activeCount":98},[],{"trials":4704,"activeCount":98},[],{"trials":4706,"activeCount":386,"soonestReadout":1281},[4707],{"nctId":1278,"briefTitle":1279,"status":186,"phases":4708,"primaryCompletion":1281,"completion":1005,"start":1282,"enrollment":1021,"conditions":4709,"interventions":4710},[87],[1284,1285],[1136,429,78,544,161,1287,1288],{"trials":4712,"activeCount":98},[],{"trials":4714,"activeCount":98},[],{"trials":4716,"activeCount":98},[],{"intervention":54,"totalTrials":386,"cells":4718},{"EARLY_PHASE1":4719,"PHASE1":4721,"PHASE2":4723,"PHASE3":4732,"PHASE4":4734,"NA":4736},{"trials":4720,"activeCount":98},[],{"trials":4722,"activeCount":98},[],{"trials":4724,"activeCount":386,"soonestReadout":53},[4725],{"nctId":51,"briefTitle":52,"status":167,"phases":4726,"primaryCompletion":53,"completion":4727,"start":4728,"enrollment":4729,"conditions":4730,"interventions":4731},[87],"2028-10","2009-06-05",88,[28],[54],{"trials":4733,"activeCount":98},[],{"trials":4735,"activeCount":98},[],{"trials":4737,"activeCount":98},[],{"intervention":300,"totalTrials":386,"cells":4739},{"EARLY_PHASE1":4740,"PHASE1":4742,"PHASE2":4744,"PHASE3":4750,"PHASE4":4752,"NA":4754},{"trials":4741,"activeCount":98},[],{"trials":4743,"activeCount":98},[],{"trials":4745,"activeCount":386,"soonestReadout":292},[4746],{"nctId":289,"briefTitle":290,"status":167,"phases":4747,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":4748,"interventions":4749},[87],[297],[78,299,93,300,301,302],{"trials":4751,"activeCount":98},[],{"trials":4753,"activeCount":98},[],{"trials":4755,"activeCount":98},[],{"intervention":301,"totalTrials":386,"cells":4757},{"EARLY_PHASE1":4758,"PHASE1":4760,"PHASE2":4762,"PHASE3":4768,"PHASE4":4770,"NA":4772},{"trials":4759,"activeCount":98},[],{"trials":4761,"activeCount":98},[],{"trials":4763,"activeCount":386,"soonestReadout":292},[4764],{"nctId":289,"briefTitle":290,"status":167,"phases":4765,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":4766,"interventions":4767},[87],[297],[78,299,93,300,301,302],{"trials":4769,"activeCount":98},[],{"trials":4771,"activeCount":98},[],{"trials":4773,"activeCount":98},[],{"intervention":1303,"totalTrials":386,"cells":4775},{"EARLY_PHASE1":4776,"PHASE1":4778,"PHASE2":4780,"PHASE3":4786,"PHASE4":4788,"NA":4790},{"trials":4777,"activeCount":98},[],{"trials":4779,"activeCount":98},[],{"trials":4781,"activeCount":386,"soonestReadout":58},[4782],{"nctId":56,"briefTitle":57,"status":167,"phases":4783,"primaryCompletion":58,"completion":266,"start":1295,"enrollment":1296,"conditions":4784,"interventions":4785},[87],[1298,1299,1300],[59,154,1302,155,150,1303,284],{"trials":4787,"activeCount":98},[],{"trials":4789,"activeCount":98},[],{"trials":4791,"activeCount":98},[],{"intervention":314,"totalTrials":386,"cells":4793},{"EARLY_PHASE1":4794,"PHASE1":4796,"PHASE2":4798,"PHASE3":4804,"PHASE4":4806,"NA":4808},{"trials":4795,"activeCount":98},[],{"trials":4797,"activeCount":98},[],{"trials":4799,"activeCount":386,"soonestReadout":307},[4800],{"nctId":304,"briefTitle":305,"status":167,"phases":4801,"primaryCompletion":307,"completion":308,"start":309,"enrollment":18,"conditions":4802,"interventions":4803},[86,87],[311,312],[83,314,113,93,315,198,133,273,136,137,78,139,316,317,226,131],{"trials":4805,"activeCount":98},[],{"trials":4807,"activeCount":98},[],{"trials":4809,"activeCount":98},[],{"intervention":2562,"totalTrials":386,"cells":4811},{"EARLY_PHASE1":4812,"PHASE1":4814,"PHASE2":4816,"PHASE3":4822,"PHASE4":4824,"NA":4826},{"trials":4813,"activeCount":98},[],{"trials":4815,"activeCount":98},[],{"trials":4817,"activeCount":386,"soonestReadout":2556},[4818],{"nctId":2553,"briefTitle":2554,"status":2525,"phases":4819,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":2559,"conditions":4820,"interventions":4821},[87],[17],[2562,2563,1397,2564,549,215,1173,2565],{"trials":4823,"activeCount":98},[],{"trials":4825,"activeCount":98},[],{"trials":4827,"activeCount":98},[],{"intervention":2563,"totalTrials":386,"cells":4829},{"EARLY_PHASE1":4830,"PHASE1":4832,"PHASE2":4834,"PHASE3":4840,"PHASE4":4842,"NA":4844},{"trials":4831,"activeCount":98},[],{"trials":4833,"activeCount":98},[],{"trials":4835,"activeCount":386,"soonestReadout":2556},[4836],{"nctId":2553,"briefTitle":2554,"status":2525,"phases":4837,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":2559,"conditions":4838,"interventions":4839},[87],[17],[2562,2563,1397,2564,549,215,1173,2565],{"trials":4841,"activeCount":98},[],{"trials":4843,"activeCount":98},[],{"trials":4845,"activeCount":98},[],{"intervention":2565,"totalTrials":386,"cells":4847},{"EARLY_PHASE1":4848,"PHASE1":4850,"PHASE2":4852,"PHASE3":4858,"PHASE4":4860,"NA":4862},{"trials":4849,"activeCount":98},[],{"trials":4851,"activeCount":98},[],{"trials":4853,"activeCount":386,"soonestReadout":2556},[4854],{"nctId":2553,"briefTitle":2554,"status":2525,"phases":4855,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":2559,"conditions":4856,"interventions":4857},[87],[17],[2562,2563,1397,2564,549,215,1173,2565],{"trials":4859,"activeCount":98},[],{"trials":4861,"activeCount":98},[],{"trials":4863,"activeCount":98},[],{"intervention":1313,"totalTrials":386,"cells":4865},{"EARLY_PHASE1":4866,"PHASE1":4868,"PHASE2":4870,"PHASE3":4876,"PHASE4":4878,"NA":4880},{"trials":4867,"activeCount":98},[],{"trials":4869,"activeCount":98},[],{"trials":4871,"activeCount":386,"soonestReadout":77},[4872],{"nctId":75,"briefTitle":76,"status":167,"phases":4873,"primaryCompletion":77,"completion":1163,"start":1310,"enrollment":171,"conditions":4874,"interventions":4875},[86,87],[796,986],[78,429,544,1313],{"trials":4877,"activeCount":98},[],{"trials":4879,"activeCount":98},[],{"trials":4881,"activeCount":98},[],{"intervention":49,"totalTrials":386,"cells":4883},{"EARLY_PHASE1":4884,"PHASE1":4886,"PHASE2":4888,"PHASE3":4900,"PHASE4":4902,"NA":4904},{"trials":4885,"activeCount":98},[],{"trials":4887,"activeCount":98},[],{"trials":4889,"activeCount":386,"soonestReadout":48},[4890],{"nctId":46,"briefTitle":47,"status":167,"phases":4891,"primaryCompletion":48,"completion":4892,"start":4893,"enrollment":4894,"conditions":4895,"interventions":4896},[87],"2029-04","2007-12-17",293,[369],[49,4897,4898,4899],"Low-Risk Therapy","High-Risk Therapy","Intermediate-Risk Therapy",{"trials":4901,"activeCount":98},[],{"trials":4903,"activeCount":98},[],{"trials":4905,"activeCount":98},[],{"intervention":4897,"totalTrials":386,"cells":4907},{"EARLY_PHASE1":4908,"PHASE1":4910,"PHASE2":4912,"PHASE3":4918,"PHASE4":4920,"NA":4922},{"trials":4909,"activeCount":98},[],{"trials":4911,"activeCount":98},[],{"trials":4913,"activeCount":386,"soonestReadout":48},[4914],{"nctId":46,"briefTitle":47,"status":167,"phases":4915,"primaryCompletion":48,"completion":4892,"start":4893,"enrollment":4894,"conditions":4916,"interventions":4917},[87],[369],[49,4897,4898,4899],{"trials":4919,"activeCount":98},[],{"trials":4921,"activeCount":98},[],{"trials":4923,"activeCount":98},[],{"intervention":4898,"totalTrials":386,"cells":4925},{"EARLY_PHASE1":4926,"PHASE1":4928,"PHASE2":4930,"PHASE3":4936,"PHASE4":4938,"NA":4940},{"trials":4927,"activeCount":98},[],{"trials":4929,"activeCount":98},[],{"trials":4931,"activeCount":386,"soonestReadout":48},[4932],{"nctId":46,"briefTitle":47,"status":167,"phases":4933,"primaryCompletion":48,"completion":4892,"start":4893,"enrollment":4894,"conditions":4934,"interventions":4935},[87],[369],[49,4897,4898,4899],{"trials":4937,"activeCount":98},[],{"trials":4939,"activeCount":98},[],{"trials":4941,"activeCount":98},[],{"intervention":4899,"totalTrials":386,"cells":4943},{"EARLY_PHASE1":4944,"PHASE1":4946,"PHASE2":4948,"PHASE3":4954,"PHASE4":4956,"NA":4958},{"trials":4945,"activeCount":98},[],{"trials":4947,"activeCount":98},[],{"trials":4949,"activeCount":386,"soonestReadout":48},[4950],{"nctId":46,"briefTitle":47,"status":167,"phases":4951,"primaryCompletion":48,"completion":4892,"start":4893,"enrollment":4894,"conditions":4952,"interventions":4953},[87],[369],[49,4897,4898,4899],{"trials":4955,"activeCount":98},[],{"trials":4957,"activeCount":98},[],{"trials":4959,"activeCount":98},[],{"intervention":2775,"totalTrials":386,"cells":4961},{"EARLY_PHASE1":4962,"PHASE1":4964,"PHASE2":4966,"PHASE3":4972,"PHASE4":4974,"NA":4976},{"trials":4963,"activeCount":98},[],{"trials":4965,"activeCount":98},[],{"trials":4967,"activeCount":386,"soonestReadout":2748},[4968],{"nctId":2745,"briefTitle":2746,"status":186,"phases":4969,"primaryCompletion":2748,"completion":2748,"start":2749,"enrollment":2750,"conditions":4970,"interventions":4971},[86,87],[2752,2753,2754,2755,2756,2757,2758,2759,2760,2761,2762,2763,2764,2765,2766,2767,2768,2769,2770,2771,2772,2773],[2775,2456,243],{"trials":4973,"activeCount":98},[],{"trials":4975,"activeCount":98},[],{"trials":4977,"activeCount":98},[],{"intervention":1629,"totalTrials":386,"cells":4979},{"EARLY_PHASE1":4980,"PHASE1":4982,"PHASE2":4984,"PHASE3":4990,"PHASE4":4992,"NA":4994},{"trials":4981,"activeCount":98},[],{"trials":4983,"activeCount":98},[],{"trials":4985,"activeCount":386,"soonestReadout":1615},[4986],{"nctId":1612,"briefTitle":1613,"status":186,"phases":4987,"primaryCompletion":1615,"completion":1333,"start":1616,"enrollment":1617,"conditions":4988,"interventions":4989},[86,87],[1619,1620,1621,1622,1623,1624,1625,1626,1627],[1629,258,132,428],{"trials":4991,"activeCount":98},[],{"trials":4993,"activeCount":98},[],{"trials":4995,"activeCount":98},[],{"intervention":1343,"totalTrials":386,"cells":4997},{"EARLY_PHASE1":4998,"PHASE1":5000,"PHASE2":5002,"PHASE3":5008,"PHASE4":5010,"NA":5012},{"trials":4999,"activeCount":98},[],{"trials":5001,"activeCount":98},[],{"trials":5003,"activeCount":386,"soonestReadout":1332},[5004],{"nctId":1329,"briefTitle":1330,"status":186,"phases":5005,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":5006,"interventions":5007},[86,87],[1337,1338,1339,1340,1112,1341],[1343,256,255,78],{"trials":5009,"activeCount":98},[],{"trials":5011,"activeCount":98},[],{"trials":5013,"activeCount":98},[],{"intervention":5015,"totalTrials":386,"cells":5016},"Dasatinib plus Quercetin",{"EARLY_PHASE1":5017,"PHASE1":5019,"PHASE2":5021,"PHASE3":5033,"PHASE4":5035,"NA":5037},{"trials":5018,"activeCount":98},[],{"trials":5020,"activeCount":98},[],{"trials":5022,"activeCount":386,"soonestReadout":249},[5023],{"nctId":5024,"briefTitle":5025,"status":167,"phases":5026,"primaryCompletion":249,"completion":188,"start":5027,"enrollment":5028,"conditions":5029,"interventions":5031},"NCT04733534","An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer",[87],"2022-06-06",110,[5030,30],"Frailty",[5015,5032],"Fisetin",{"trials":5034,"activeCount":98},[],{"trials":5036,"activeCount":98},[],{"trials":5038,"activeCount":98},[],{"intervention":5032,"totalTrials":386,"cells":5040},{"EARLY_PHASE1":5041,"PHASE1":5043,"PHASE2":5045,"PHASE3":5051,"PHASE4":5053,"NA":5055},{"trials":5042,"activeCount":98},[],{"trials":5044,"activeCount":98},[],{"trials":5046,"activeCount":386,"soonestReadout":249},[5047],{"nctId":5024,"briefTitle":5025,"status":167,"phases":5048,"primaryCompletion":249,"completion":188,"start":5027,"enrollment":5028,"conditions":5049,"interventions":5050},[87],[5030,30],[5015,5032],{"trials":5052,"activeCount":98},[],{"trials":5054,"activeCount":98},[],{"trials":5056,"activeCount":98},[],{"intervention":1372,"totalTrials":386,"cells":5058},{"EARLY_PHASE1":5059,"PHASE1":5061,"PHASE2":5063,"PHASE3":5069,"PHASE4":5071,"NA":5073},{"trials":5060,"activeCount":98},[],{"trials":5062,"activeCount":98},[],{"trials":5064,"activeCount":386,"soonestReadout":1362},[5065],{"nctId":1359,"briefTitle":1360,"status":167,"phases":5066,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":5067,"interventions":5068},[87],[622,621,1367,1368,28,1369,1169,1168],[78,429,549,639,1371,544,1372,273,1373,1374,1288],{"trials":5070,"activeCount":98},[],{"trials":5072,"activeCount":98},[],{"trials":5074,"activeCount":98},[],{"intervention":1373,"totalTrials":386,"cells":5076},{"EARLY_PHASE1":5077,"PHASE1":5079,"PHASE2":5081,"PHASE3":5087,"PHASE4":5089,"NA":5091},{"trials":5078,"activeCount":98},[],{"trials":5080,"activeCount":98},[],{"trials":5082,"activeCount":386,"soonestReadout":1362},[5083],{"nctId":1359,"briefTitle":1360,"status":167,"phases":5084,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":5085,"interventions":5086},[87],[622,621,1367,1368,28,1369,1169,1168],[78,429,549,639,1371,544,1372,273,1373,1374,1288],{"trials":5088,"activeCount":98},[],{"trials":5090,"activeCount":98},[],{"trials":5092,"activeCount":98},[],{"intervention":1374,"totalTrials":386,"cells":5094},{"EARLY_PHASE1":5095,"PHASE1":5097,"PHASE2":5099,"PHASE3":5105,"PHASE4":5107,"NA":5109},{"trials":5096,"activeCount":98},[],{"trials":5098,"activeCount":98},[],{"trials":5100,"activeCount":386,"soonestReadout":1362},[5101],{"nctId":1359,"briefTitle":1360,"status":167,"phases":5102,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":1365,"conditions":5103,"interventions":5104},[87],[622,621,1367,1368,28,1369,1169,1168],[78,429,549,639,1371,544,1372,273,1373,1374,1288],{"trials":5106,"activeCount":98},[],{"trials":5108,"activeCount":98},[],{"trials":5110,"activeCount":98},[],{"intervention":343,"totalTrials":386,"cells":5112},{"EARLY_PHASE1":5113,"PHASE1":5115,"PHASE2":5117,"PHASE3":5123,"PHASE4":5125,"NA":5127},{"trials":5114,"activeCount":98},[],{"trials":5116,"activeCount":98},[],{"trials":5118,"activeCount":386,"soonestReadout":335},[5119],{"nctId":332,"briefTitle":333,"status":167,"phases":5120,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":5121,"interventions":5122},[87],[340,341],[343,344,153,286,150,154,151,44],{"trials":5124,"activeCount":98},[],{"trials":5126,"activeCount":98},[],{"trials":5128,"activeCount":98},[],{"intervention":2787,"totalTrials":386,"cells":5130},{"EARLY_PHASE1":5131,"PHASE1":5133,"PHASE2":5135,"PHASE3":5141,"PHASE4":5143,"NA":5145},{"trials":5132,"activeCount":98},[],{"trials":5134,"activeCount":98},[],{"trials":5136,"activeCount":386,"soonestReadout":2780},[5137],{"nctId":2777,"briefTitle":2778,"status":186,"phases":5138,"primaryCompletion":2780,"completion":2781,"start":2782,"enrollment":2783,"conditions":5139,"interventions":5140},[87],[2785],[243,114,152,2787,2788],{"trials":5142,"activeCount":98},[],{"trials":5144,"activeCount":98},[],{"trials":5146,"activeCount":98},[],{"intervention":2788,"totalTrials":386,"cells":5148},{"EARLY_PHASE1":5149,"PHASE1":5151,"PHASE2":5153,"PHASE3":5159,"PHASE4":5161,"NA":5163},{"trials":5150,"activeCount":98},[],{"trials":5152,"activeCount":98},[],{"trials":5154,"activeCount":386,"soonestReadout":2780},[5155],{"nctId":2777,"briefTitle":2778,"status":186,"phases":5156,"primaryCompletion":2780,"completion":2781,"start":2782,"enrollment":2783,"conditions":5157,"interventions":5158},[87],[2785],[243,114,152,2787,2788],{"trials":5160,"activeCount":98},[],{"trials":5162,"activeCount":98},[],{"trials":5164,"activeCount":98},[],{"intervention":5166,"totalTrials":386,"cells":5167},"Metformin",{"EARLY_PHASE1":5168,"PHASE1":5170,"PHASE2":5172,"PHASE3":5186,"PHASE4":5188,"NA":5190},{"trials":5169,"activeCount":98},[],{"trials":5171,"activeCount":98},[],{"trials":5173,"activeCount":386,"soonestReadout":5178},[5174],{"nctId":5175,"briefTitle":5176,"status":167,"phases":5177,"primaryCompletion":5178,"completion":5179,"start":5180,"enrollment":5181,"conditions":5182,"interventions":5185},"NCT04742751","An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer",[87],"2026-01-16","2027-03","2022-03-02",96,[5183,5184],"PreDiabetes","Adult Children",[5166],{"trials":5187,"activeCount":98},[],{"trials":5189,"activeCount":98},[],{"trials":5191,"activeCount":98},[],{"intervention":749,"totalTrials":494,"cells":5193},{"EARLY_PHASE1":5194,"PHASE1":5196,"PHASE2":5215,"PHASE3":5228,"PHASE4":5230,"NA":5232},{"trials":5195,"activeCount":98},[],{"trials":5197,"activeCount":445,"soonestReadout":2527},[5198,5202,5206],{"nctId":3275,"briefTitle":3276,"status":186,"phases":5199,"primaryCompletion":3278,"completion":3279,"start":3280,"enrollment":1214,"conditions":5200,"interventions":5201},[86],[17],[749,548,3283,3284],{"nctId":2523,"briefTitle":2524,"status":2525,"phases":5203,"primaryCompletion":2527,"completion":1281,"start":1319,"enrollment":357,"conditions":5204,"interventions":5205},[86],[1285],[215,749],{"nctId":5207,"briefTitle":5208,"status":104,"phases":5209,"primaryCompletion":5210,"completion":5210,"start":5211,"enrollment":357,"conditions":5212,"interventions":5214},"NCT01068301","A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation",[86],"2013-10","2010-05",[14,25,5213,566,1075],"Chronic Myeloid Leukemia",[749],{"trials":5216,"activeCount":98},[5217,5224],{"nctId":5218,"briefTitle":5219,"status":3387,"phases":5220,"primaryCompletion":5221,"completion":5221,"start":5221,"enrollment":98,"conditions":5222,"interventions":5223},"NCT04817345","Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor",[87],"2023-04",[17],[749],{"nctId":739,"briefTitle":740,"status":490,"phases":5225,"primaryCompletion":619,"completion":619,"start":742,"enrollment":743,"conditions":5226,"interventions":5227},[87],[14,564,565,745,566,746,747],[470,474,156,749,150,750,751,752,753],{"trials":5229,"activeCount":98},[],{"trials":5231,"activeCount":98},[],{"trials":5233,"activeCount":98},[],{"intervention":5235,"totalTrials":445,"cells":5236},"B7-H3-CAR T cells",{"EARLY_PHASE1":5237,"PHASE1":5239,"PHASE2":5254,"PHASE3":5256,"PHASE4":5258,"NA":5260},{"trials":5238,"activeCount":98},[],{"trials":5240,"activeCount":445,"soonestReadout":5245},[5241,5250],{"nctId":5242,"briefTitle":5243,"status":186,"phases":5244,"primaryCompletion":5245,"completion":5245,"start":5246,"enrollment":1072,"conditions":5247,"interventions":5249},"NCT05835687","Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors",[86],"2028-03","2023-04-27",[2474,2473,5248,2479,1274,2480,297],"Diffuse Midline Glioma, H3 K27M-Mutant",[5235],{"nctId":1051,"briefTitle":1052,"status":186,"phases":5251,"primaryCompletion":1054,"completion":1055,"start":1056,"enrollment":406,"conditions":5252,"interventions":5253},[86],[1058,1059,1060,1061,1062],[429,78,1064],{"trials":5255,"activeCount":98},[],{"trials":5257,"activeCount":98},[],{"trials":5259,"activeCount":98},[],{"trials":5261,"activeCount":98},[],{"intervention":5263,"totalTrials":445,"cells":5264},"Indocyanine Green",{"EARLY_PHASE1":5265,"PHASE1":5275,"PHASE2":5287,"PHASE3":5289,"PHASE4":5291,"NA":5293},{"trials":5266,"activeCount":386,"soonestReadout":249},[5267],{"nctId":5268,"briefTitle":5269,"status":186,"phases":5270,"primaryCompletion":249,"completion":249,"start":5271,"enrollment":1214,"conditions":5272,"interventions":5274},"NCT05645523","Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors",[85],"2023-10-24",[5273],"Solid Tumor",[5263],{"trials":5276,"activeCount":386,"soonestReadout":829},[5277],{"nctId":5278,"briefTitle":5279,"status":186,"phases":5280,"primaryCompletion":829,"completion":5281,"start":5282,"enrollment":5283,"conditions":5284,"interventions":5286},"NCT04084067","Indocyanine Green (ICG) Guided Tumor Resection",[86],"2027-12-31","2020-02-07",230,[5285,5273],"Neoplastic Disease",[5263],{"trials":5288,"activeCount":98},[],{"trials":5290,"activeCount":98},[],{"trials":5292,"activeCount":98},[],{"trials":5294,"activeCount":98},[],{"intervention":3284,"totalTrials":445,"cells":5296},{"EARLY_PHASE1":5297,"PHASE1":5299,"PHASE2":5313,"PHASE3":5315,"PHASE4":5317,"NA":5319},{"trials":5298,"activeCount":98},[],{"trials":5300,"activeCount":445,"soonestReadout":278},[5301,5305],{"nctId":3275,"briefTitle":3276,"status":186,"phases":5302,"primaryCompletion":3278,"completion":3279,"start":3280,"enrollment":1214,"conditions":5303,"interventions":5304},[86],[17],[749,548,3283,3284],{"nctId":5306,"briefTitle":5307,"status":186,"phases":5308,"primaryCompletion":278,"completion":5309,"start":5310,"enrollment":783,"conditions":5311,"interventions":5312},"NCT06442761","SCD Stem Cell Mobilization and Apheresis Using Motixafortide",[86],"2028-07","2024-11-14",[17],[3284],{"trials":5314,"activeCount":98},[],{"trials":5316,"activeCount":98},[],{"trials":5318,"activeCount":98},[],{"trials":5320,"activeCount":98},[],{"intervention":430,"totalTrials":539,"cells":5322},{"EARLY_PHASE1":5323,"PHASE1":5325,"PHASE2":5335,"PHASE3":5341,"PHASE4":5343,"NA":5345},{"trials":5324,"activeCount":98},[],{"trials":5326,"activeCount":386,"soonestReadout":82},[5327,5331],{"nctId":80,"briefTitle":81,"status":167,"phases":5328,"primaryCompletion":82,"completion":336,"start":420,"enrollment":421,"conditions":5329,"interventions":5330},[86],[423,424,425,426],[83,428,133,429,215,136,430],{"nctId":616,"briefTitle":617,"status":104,"phases":5332,"primaryCompletion":619,"completion":619,"start":521,"enrollment":9,"conditions":5333,"interventions":5334},[86],[621,622,623,624],[428,429,133,430],{"trials":5336,"activeCount":98},[5337],{"nctId":703,"briefTitle":704,"status":490,"phases":5338,"primaryCompletion":706,"completion":706,"start":707,"enrollment":421,"conditions":5339,"interventions":5340},[87],[621],[428,429,133,430],{"trials":5342,"activeCount":98},[],{"trials":5344,"activeCount":98},[],{"trials":5346,"activeCount":98},[],{"intervention":989,"totalTrials":386,"cells":5348},{"EARLY_PHASE1":5349,"PHASE1":5351,"PHASE2":5357,"PHASE3":5359,"PHASE4":5361,"NA":5363},{"trials":5350,"activeCount":98},[],{"trials":5352,"activeCount":386,"soonestReadout":982},[5353],{"nctId":979,"briefTitle":980,"status":186,"phases":5354,"primaryCompletion":982,"completion":207,"start":983,"enrollment":984,"conditions":5355,"interventions":5356},[86],[796,986,987],[989,78,429,544],{"trials":5358,"activeCount":98},[],{"trials":5360,"activeCount":98},[],{"trials":5362,"activeCount":98},[],{"trials":5364,"activeCount":98},[],{"intervention":1000,"totalTrials":386,"cells":5366},{"EARLY_PHASE1":5367,"PHASE1":5369,"PHASE2":5375,"PHASE3":5377,"PHASE4":5379,"NA":5381},{"trials":5368,"activeCount":98},[],{"trials":5370,"activeCount":386,"soonestReadout":994},[5371],{"nctId":991,"briefTitle":992,"status":186,"phases":5372,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":5373,"interventions":5374},[86],[541],[1000,78,429,549,639,544,215,273],{"trials":5376,"activeCount":98},[],{"trials":5378,"activeCount":98},[],{"trials":5380,"activeCount":98},[],{"trials":5382,"activeCount":98},[],{"intervention":5384,"totalTrials":386,"cells":5385},"Dalbavancin",{"EARLY_PHASE1":5386,"PHASE1":5388,"PHASE2":5401,"PHASE3":5403,"PHASE4":5405,"NA":5407},{"trials":5387,"activeCount":98},[],{"trials":5389,"activeCount":386,"soonestReadout":5394},[5390],{"nctId":5391,"briefTitle":5392,"status":186,"phases":5393,"primaryCompletion":5394,"completion":5395,"start":5396,"enrollment":2725,"conditions":5397,"interventions":5399},"NCT06810583","A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia",[86],"2030-09","2031-09","2025-05-22",[1087,25,5398],"Lymphoblastic Leukemia in Children",[5384,5400],"Fluoroquinolone",{"trials":5402,"activeCount":98},[],{"trials":5404,"activeCount":98},[],{"trials":5406,"activeCount":98},[],{"trials":5408,"activeCount":98},[],{"intervention":5400,"totalTrials":386,"cells":5410},{"EARLY_PHASE1":5411,"PHASE1":5413,"PHASE2":5419,"PHASE3":5421,"PHASE4":5423,"NA":5425},{"trials":5412,"activeCount":98},[],{"trials":5414,"activeCount":386,"soonestReadout":5394},[5415],{"nctId":5391,"briefTitle":5392,"status":186,"phases":5416,"primaryCompletion":5394,"completion":5395,"start":5396,"enrollment":2725,"conditions":5417,"interventions":5418},[86],[1087,25,5398],[5384,5400],{"trials":5420,"activeCount":98},[],{"trials":5422,"activeCount":98},[],{"trials":5424,"activeCount":98},[],{"trials":5426,"activeCount":98},[],{"intervention":1013,"totalTrials":386,"cells":5428},{"EARLY_PHASE1":5429,"PHASE1":5431,"PHASE2":5437,"PHASE3":5439,"PHASE4":5441,"NA":5443},{"trials":5430,"activeCount":98},[],{"trials":5432,"activeCount":386,"soonestReadout":1005},[5433],{"nctId":1002,"briefTitle":1003,"status":186,"phases":5434,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":412,"conditions":5435,"interventions":5436},[86],[541,1009,1010,634,1011],[429,78,1013,544],{"trials":5438,"activeCount":98},[],{"trials":5440,"activeCount":98},[],{"trials":5442,"activeCount":98},[],{"trials":5444,"activeCount":98},[],{"intervention":3283,"totalTrials":386,"cells":5446},{"EARLY_PHASE1":5447,"PHASE1":5449,"PHASE2":5455,"PHASE3":5457,"PHASE4":5459,"NA":5461},{"trials":5448,"activeCount":98},[],{"trials":5450,"activeCount":386,"soonestReadout":3278},[5451],{"nctId":3275,"briefTitle":3276,"status":186,"phases":5452,"primaryCompletion":3278,"completion":3279,"start":3280,"enrollment":1214,"conditions":5453,"interventions":5454},[86],[17],[749,548,3283,3284],{"trials":5456,"activeCount":98},[],{"trials":5458,"activeCount":98},[],{"trials":5460,"activeCount":98},[],{"trials":5462,"activeCount":98},[],{"intervention":5464,"totalTrials":386,"cells":5465},"Extended-Release Methylphenidate",{"EARLY_PHASE1":5466,"PHASE1":5468,"PHASE2":5482,"PHASE3":5484,"PHASE4":5486,"NA":5488},{"trials":5467,"activeCount":98},[],{"trials":5469,"activeCount":386,"soonestReadout":5474},[5470],{"nctId":5471,"briefTitle":5472,"status":186,"phases":5473,"primaryCompletion":5474,"completion":4484,"start":5475,"enrollment":5476,"conditions":5477,"interventions":5481},"NCT07226219","Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease",[86],"2027-07","2025-11-25",72,[17,5478,5479,5480],"Executive Dysfunction","Cognitive Impairment","Attention Deficit\u002FHyperactivity Disorder (ADHD)",[5464],{"trials":5483,"activeCount":98},[],{"trials":5485,"activeCount":98},[],{"trials":5487,"activeCount":98},[],{"trials":5489,"activeCount":98},[],{"intervention":442,"totalTrials":386,"cells":5491},{"EARLY_PHASE1":5492,"PHASE1":5494,"PHASE2":5500,"PHASE3":5502,"PHASE4":5504,"NA":5506},{"trials":5493,"activeCount":98},[],{"trials":5495,"activeCount":386,"soonestReadout":435},[5496],{"nctId":432,"briefTitle":433,"status":186,"phases":5497,"primaryCompletion":435,"completion":436,"start":437,"enrollment":171,"conditions":5498,"interventions":5499},[86],[426,439,440],[442,83,443,444,133,136],{"trials":5501,"activeCount":98},[],{"trials":5503,"activeCount":98},[],{"trials":5505,"activeCount":98},[],{"trials":5507,"activeCount":98},[],{"intervention":444,"totalTrials":386,"cells":5509},{"EARLY_PHASE1":5510,"PHASE1":5512,"PHASE2":5518,"PHASE3":5520,"PHASE4":5522,"NA":5524},{"trials":5511,"activeCount":98},[],{"trials":5513,"activeCount":386,"soonestReadout":435},[5514],{"nctId":432,"briefTitle":433,"status":186,"phases":5515,"primaryCompletion":435,"completion":436,"start":437,"enrollment":171,"conditions":5516,"interventions":5517},[86],[426,439,440],[442,83,443,444,133,136],{"trials":5519,"activeCount":98},[],{"trials":5521,"activeCount":98},[],{"trials":5523,"activeCount":98},[],{"trials":5525,"activeCount":98},[],{"intervention":1102,"totalTrials":386,"cells":5527},{"EARLY_PHASE1":5528,"PHASE1":5530,"PHASE2":5536,"PHASE3":5538,"PHASE4":5540,"NA":5542},{"trials":5529,"activeCount":98},[],{"trials":5531,"activeCount":386,"soonestReadout":1093},[5532],{"nctId":1090,"briefTitle":1091,"status":186,"phases":5533,"primaryCompletion":1093,"completion":1094,"start":793,"enrollment":1095,"conditions":5534,"interventions":5535},[86],[1097,1098,1099,1100],[1102,78,429,544,1103],{"trials":5537,"activeCount":98},[],{"trials":5539,"activeCount":98},[],{"trials":5541,"activeCount":98},[],{"trials":5543,"activeCount":98},[],{"intervention":1124,"totalTrials":386,"cells":5545},{"EARLY_PHASE1":5546,"PHASE1":5548,"PHASE2":5554,"PHASE3":5556,"PHASE4":5558,"NA":5560},{"trials":5547,"activeCount":98},[],{"trials":5549,"activeCount":386,"soonestReadout":1108},[5550],{"nctId":1105,"briefTitle":1106,"status":186,"phases":5551,"primaryCompletion":1108,"completion":1109,"start":1110,"enrollment":1072,"conditions":5552,"interventions":5553},[86],[1112,526,32,23,1062,1113,1114,173,1115,1116,1117,1118,1119,1120,1121,1122],[429,78,287,1124],{"trials":5555,"activeCount":98},[],{"trials":5557,"activeCount":98},[],{"trials":5559,"activeCount":98},[],{"trials":5561,"activeCount":98},[],{"intervention":5563,"totalTrials":386,"cells":5564},"Fecal microbiota transplant",{"EARLY_PHASE1":5565,"PHASE1":5567,"PHASE2":5577,"PHASE3":5579,"PHASE4":5581,"NA":5583},{"trials":5566,"activeCount":98},[],{"trials":5568,"activeCount":386,"soonestReadout":2748},[5569],{"nctId":5570,"briefTitle":5571,"status":186,"phases":5572,"primaryCompletion":2748,"completion":4686,"start":5573,"enrollment":831,"conditions":5574,"interventions":5576},"NCT05664113","Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).",[86],"2025-07-07",[5575],"Gastro-Intestinal Disorder",[5563],{"trials":5578,"activeCount":98},[],{"trials":5580,"activeCount":98},[],{"trials":5582,"activeCount":98},[],{"trials":5584,"activeCount":98},[],{"intervention":5586,"totalTrials":386,"cells":5587},"18F-DA",{"EARLY_PHASE1":5588,"PHASE1":5597,"PHASE2":5599,"PHASE3":5601,"PHASE4":5603,"NA":5605},{"trials":5589,"activeCount":386,"soonestReadout":206},[5590],{"nctId":5591,"briefTitle":5592,"status":167,"phases":5593,"primaryCompletion":206,"completion":207,"start":706,"enrollment":33,"conditions":5594,"interventions":5596},"NCT03541720","18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma",[85],[23,5595],"Pheochromocytoma",[5586],{"trials":5598,"activeCount":98},[],{"trials":5600,"activeCount":98},[],{"trials":5602,"activeCount":98},[],{"trials":5604,"activeCount":98},[],{"trials":5606,"activeCount":98},[],{"intervention":5608,"totalTrials":386,"cells":5609},"[18F]-fluoromannitol",{"EARLY_PHASE1":5610,"PHASE1":5621,"PHASE2":5623,"PHASE3":5625,"PHASE4":5627,"NA":5629},{"trials":5611,"activeCount":386,"soonestReadout":2723},[5612],{"nctId":5613,"briefTitle":5614,"status":186,"phases":5615,"primaryCompletion":2723,"completion":5616,"start":5617,"enrollment":831,"conditions":5618,"interventions":5620},"NCT07110519","Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol",[85],"2027-05","2025-09-17",[5619],"Healthy",[5608],{"trials":5622,"activeCount":98},[],{"trials":5624,"activeCount":98},[],{"trials":5626,"activeCount":98},[],{"trials":5628,"activeCount":98},[],{"trials":5630,"activeCount":98},[],{"intervention":5632,"totalTrials":386,"cells":5633},"Methylphenidate",{"EARLY_PHASE1":5634,"PHASE1":5636,"PHASE2":5638,"PHASE3":5640,"PHASE4":5642,"NA":5654},{"trials":5635,"activeCount":98},[],{"trials":5637,"activeCount":98},[],{"trials":5639,"activeCount":98},[],{"trials":5641,"activeCount":98},[],{"trials":5643,"activeCount":98},[5644],{"nctId":5645,"briefTitle":5646,"status":104,"phases":5647,"primaryCompletion":5648,"completion":5648,"start":5649,"enrollment":5650,"conditions":5651,"interventions":5653},"NCT00576472","Learning Impairments Among Survivors of Childhood Cancer",[89],"2010-03","2000-01",469,[14,5652],"Brain Tumors",[5632],{"trials":5655,"activeCount":98},[],{"intervention":5657,"totalTrials":445,"cells":5658},"Chemotherapy and antibodies",{"EARLY_PHASE1":5659,"PHASE1":5661,"PHASE2":5663,"PHASE3":5677,"PHASE4":5690,"NA":5692},{"trials":5660,"activeCount":98},[],{"trials":5662,"activeCount":98},[],{"trials":5664,"activeCount":98},[5665],{"nctId":5666,"briefTitle":5667,"status":104,"phases":5668,"primaryCompletion":5669,"completion":5670,"start":5671,"enrollment":3248,"conditions":5672,"interventions":5676},"NCT00145626","HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies",[87],"2015-03","2016-07","2004-05",[25,5673,5674,5213,5675],"Acute Lymphocytic Leukemia","Myelodysplasia","Histiocytosis",[5657],{"trials":5678,"activeCount":98},[5679],{"nctId":5680,"briefTitle":5681,"status":104,"phases":5682,"primaryCompletion":5683,"completion":106,"start":5684,"enrollment":5685,"conditions":5686,"interventions":5689},"NCT00152139","Stem Cell Transplantation for Patients With Hematologic Malignancies",[88],"2005-06","2002-05",33,[5687,564,5213,745,566,5688,807],"Acute Lymphoblastic Leukemias","Hemoglobinuria, Paroxysmal",[5657],{"trials":5691,"activeCount":98},[],{"trials":5693,"activeCount":98},[],{"intervention":5695,"totalTrials":386,"cells":5696},"Vincristine, Carboplatin",{"EARLY_PHASE1":5697,"PHASE1":5699,"PHASE2":5701,"PHASE3":5703,"PHASE4":5720,"NA":5722},{"trials":5698,"activeCount":98},[],{"trials":5700,"activeCount":98},[],{"trials":5702,"activeCount":98},[],{"trials":5704,"activeCount":98},[5705],{"nctId":5706,"briefTitle":5707,"status":104,"phases":5708,"primaryCompletion":5709,"completion":5710,"start":5711,"enrollment":5712,"conditions":5713,"interventions":5715},"NCT00186888","Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma",[88],"2013-11","2024-11-12","2005-04-07",107,[282,5714],"Retinal Neoplasm",[5695,5716,5717,5718,5719],"Vincristine and Topotecan","Vincristine + Carboplatin + Etoposide","vincristine, cyclophosphamide, and doxorubicin","Vincristine, Carboplatin and Etoposide",{"trials":5721,"activeCount":98},[],{"trials":5723,"activeCount":98},[],{"intervention":5716,"totalTrials":386,"cells":5725},{"EARLY_PHASE1":5726,"PHASE1":5728,"PHASE2":5730,"PHASE3":5732,"PHASE4":5738,"NA":5740},{"trials":5727,"activeCount":98},[],{"trials":5729,"activeCount":98},[],{"trials":5731,"activeCount":98},[],{"trials":5733,"activeCount":98},[5734],{"nctId":5706,"briefTitle":5707,"status":104,"phases":5735,"primaryCompletion":5709,"completion":5710,"start":5711,"enrollment":5712,"conditions":5736,"interventions":5737},[88],[282,5714],[5695,5716,5717,5718,5719],{"trials":5739,"activeCount":98},[],{"trials":5741,"activeCount":98},[],{"intervention":5717,"totalTrials":386,"cells":5743},{"EARLY_PHASE1":5744,"PHASE1":5746,"PHASE2":5748,"PHASE3":5750,"PHASE4":5756,"NA":5758},{"trials":5745,"activeCount":98},[],{"trials":5747,"activeCount":98},[],{"trials":5749,"activeCount":98},[],{"trials":5751,"activeCount":98},[5752],{"nctId":5706,"briefTitle":5707,"status":104,"phases":5753,"primaryCompletion":5709,"completion":5710,"start":5711,"enrollment":5712,"conditions":5754,"interventions":5755},[88],[282,5714],[5695,5716,5717,5718,5719],{"trials":5757,"activeCount":98},[],{"trials":5759,"activeCount":98},[],{"intervention":5718,"totalTrials":386,"cells":5761},{"EARLY_PHASE1":5762,"PHASE1":5764,"PHASE2":5766,"PHASE3":5768,"PHASE4":5774,"NA":5776},{"trials":5763,"activeCount":98},[],{"trials":5765,"activeCount":98},[],{"trials":5767,"activeCount":98},[],{"trials":5769,"activeCount":98},[5770],{"nctId":5706,"briefTitle":5707,"status":104,"phases":5771,"primaryCompletion":5709,"completion":5710,"start":5711,"enrollment":5712,"conditions":5772,"interventions":5773},[88],[282,5714],[5695,5716,5717,5718,5719],{"trials":5775,"activeCount":98},[],{"trials":5777,"activeCount":98},[],{"intervention":5719,"totalTrials":386,"cells":5779},{"EARLY_PHASE1":5780,"PHASE1":5782,"PHASE2":5784,"PHASE3":5786,"PHASE4":5792,"NA":5794},{"trials":5781,"activeCount":98},[],{"trials":5783,"activeCount":98},[],{"trials":5785,"activeCount":98},[],{"trials":5787,"activeCount":98},[5788],{"nctId":5706,"briefTitle":5707,"status":104,"phases":5789,"primaryCompletion":5709,"completion":5710,"start":5711,"enrollment":5712,"conditions":5790,"interventions":5791},[88],[282,5714],[5695,5716,5717,5718,5719],{"trials":5793,"activeCount":98},[],{"trials":5795,"activeCount":98},[],{"intervention":5797,"totalTrials":386,"cells":5798},"ethanol",{"EARLY_PHASE1":5799,"PHASE1":5801,"PHASE2":5803,"PHASE3":5805,"PHASE4":5818,"NA":5820},{"trials":5800,"activeCount":98},[],{"trials":5802,"activeCount":98},[],{"trials":5804,"activeCount":98},[],{"trials":5806,"activeCount":98},[5807],{"nctId":5808,"briefTitle":5809,"status":104,"phases":5810,"primaryCompletion":5811,"completion":5811,"start":5812,"enrollment":5813,"conditions":5814,"interventions":5816},"NCT01472965","Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection",[88],"2016-11-11","2011-12-29",95,[5815],"Central Line-Associated Bloodstream Infection",[5797,5817],"heparin-saline placebo",{"trials":5819,"activeCount":98},[],{"trials":5821,"activeCount":98},[],{"intervention":5817,"totalTrials":386,"cells":5823},{"EARLY_PHASE1":5824,"PHASE1":5826,"PHASE2":5828,"PHASE3":5830,"PHASE4":5836,"NA":5838},{"trials":5825,"activeCount":98},[],{"trials":5827,"activeCount":98},[],{"trials":5829,"activeCount":98},[],{"trials":5831,"activeCount":98},[5832],{"nctId":5808,"briefTitle":5809,"status":104,"phases":5833,"primaryCompletion":5811,"completion":5811,"start":5812,"enrollment":5813,"conditions":5834,"interventions":5835},[88],[5815],[5797,5817],{"trials":5837,"activeCount":98},[],{"trials":5839,"activeCount":98},[],{"intervention":5841,"totalTrials":386,"cells":5842},"TBI, systemic chemotherapy and antibodies as follows:",{"EARLY_PHASE1":5843,"PHASE1":5845,"PHASE2":5847,"PHASE3":5849,"PHASE4":5859,"NA":5861},{"trials":5844,"activeCount":98},[],{"trials":5846,"activeCount":98},[],{"trials":5848,"activeCount":98},[],{"trials":5850,"activeCount":98},[5851],{"nctId":5852,"briefTitle":5853,"status":104,"phases":5854,"primaryCompletion":1259,"completion":106,"start":3733,"enrollment":5855,"conditions":5856,"interventions":5858},"NCT00186823","Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies",[88],57,[1388,1389,1390,5857,1391,1392,623],"Juvenile Myelomonocytic Leukemia(JMML)",[5841],{"trials":5860,"activeCount":98},[],{"trials":5862,"activeCount":98},[],{"intervention":5864,"totalTrials":386,"cells":5865},"Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase",{"EARLY_PHASE1":5866,"PHASE1":5868,"PHASE2":5870,"PHASE3":5872,"PHASE4":5883,"NA":5885},{"trials":5867,"activeCount":98},[],{"trials":5869,"activeCount":98},[],{"trials":5871,"activeCount":98},[],{"trials":5873,"activeCount":98},[5874],{"nctId":5875,"briefTitle":5876,"status":490,"phases":5877,"primaryCompletion":5878,"completion":5878,"start":5879,"enrollment":2740,"conditions":5880,"interventions":5881},"NCT00187005","Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia",[88],"2002-07","1998-07",[14],[5864,5882],"L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine",{"trials":5884,"activeCount":98},[],{"trials":5886,"activeCount":98},[],{"intervention":5882,"totalTrials":386,"cells":5888},{"EARLY_PHASE1":5889,"PHASE1":5891,"PHASE2":5893,"PHASE3":5895,"PHASE4":5901,"NA":5903},{"trials":5890,"activeCount":98},[],{"trials":5892,"activeCount":98},[],{"trials":5894,"activeCount":98},[],{"trials":5896,"activeCount":98},[5897],{"nctId":5875,"briefTitle":5876,"status":490,"phases":5898,"primaryCompletion":5878,"completion":5878,"start":5879,"enrollment":2740,"conditions":5899,"interventions":5900},[88],[14],[5864,5882],{"trials":5902,"activeCount":98},[],{"trials":5904,"activeCount":98},[],{"intervention":5906,"totalTrials":386,"cells":5907},"Calcium carbonate (Tums), vitamin D",{"EARLY_PHASE1":5908,"PHASE1":5910,"PHASE2":5912,"PHASE3":5914,"PHASE4":5927,"NA":5929},{"trials":5909,"activeCount":98},[],{"trials":5911,"activeCount":98},[],{"trials":5913,"activeCount":98},[],{"trials":5915,"activeCount":98},[5916],{"nctId":5917,"briefTitle":5918,"status":104,"phases":5919,"primaryCompletion":5920,"completion":5921,"start":1042,"enrollment":5922,"conditions":5923,"interventions":5926},"NCT00186901","A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors",[88],"2009-06","2011-09",429,[5924,5925],"Leukemia, Lymphoblastic, Acute","Osteoporosis",[5906],{"trials":5928,"activeCount":98},[],{"trials":5930,"activeCount":98},[],{"intervention":5932,"totalTrials":386,"cells":5933},"Fentanyl",{"EARLY_PHASE1":5934,"PHASE1":5936,"PHASE2":5938,"PHASE3":5940,"PHASE4":5955,"NA":5957},{"trials":5935,"activeCount":98},[],{"trials":5937,"activeCount":98},[],{"trials":5939,"activeCount":98},[],{"trials":5941,"activeCount":98},[5942],{"nctId":5943,"briefTitle":5944,"status":490,"phases":5945,"primaryCompletion":5946,"completion":5946,"start":3733,"enrollment":5947,"conditions":5948,"interventions":5951},"NCT00187135","Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration",[88],"2008-08",168,[5949,5950],"Bone Marrow Disease","Pain",[5932,5952,5953,5954],"EMLA","L.M.X4","Propofol",{"trials":5956,"activeCount":98},[],{"trials":5958,"activeCount":98},[],{"intervention":5952,"totalTrials":386,"cells":5960},{"EARLY_PHASE1":5961,"PHASE1":5963,"PHASE2":5965,"PHASE3":5967,"PHASE4":5973,"NA":5975},{"trials":5962,"activeCount":98},[],{"trials":5964,"activeCount":98},[],{"trials":5966,"activeCount":98},[],{"trials":5968,"activeCount":98},[5969],{"nctId":5943,"briefTitle":5944,"status":490,"phases":5970,"primaryCompletion":5946,"completion":5946,"start":3733,"enrollment":5947,"conditions":5971,"interventions":5972},[88],[5949,5950],[5932,5952,5953,5954],{"trials":5974,"activeCount":98},[],{"trials":5976,"activeCount":98},[],{"intervention":5953,"totalTrials":386,"cells":5978},{"EARLY_PHASE1":5979,"PHASE1":5981,"PHASE2":5983,"PHASE3":5985,"PHASE4":5991,"NA":5993},{"trials":5980,"activeCount":98},[],{"trials":5982,"activeCount":98},[],{"trials":5984,"activeCount":98},[],{"trials":5986,"activeCount":98},[5987],{"nctId":5943,"briefTitle":5944,"status":490,"phases":5988,"primaryCompletion":5946,"completion":5946,"start":3733,"enrollment":5947,"conditions":5989,"interventions":5990},[88],[5949,5950],[5932,5952,5953,5954],{"trials":5992,"activeCount":98},[],{"trials":5994,"activeCount":98},[],{"intervention":5954,"totalTrials":386,"cells":5996},{"EARLY_PHASE1":5997,"PHASE1":5999,"PHASE2":6001,"PHASE3":6003,"PHASE4":6009,"NA":6011},{"trials":5998,"activeCount":98},[],{"trials":6000,"activeCount":98},[],{"trials":6002,"activeCount":98},[],{"trials":6004,"activeCount":98},[6005],{"nctId":5943,"briefTitle":5944,"status":490,"phases":6006,"primaryCompletion":5946,"completion":5946,"start":3733,"enrollment":5947,"conditions":6007,"interventions":6008},[88],[5949,5950],[5932,5952,5953,5954],{"trials":6010,"activeCount":98},[],{"trials":6012,"activeCount":98},[],{"intervention":6014,"totalTrials":386,"cells":6015},"Tranexamic Acid",{"EARLY_PHASE1":6016,"PHASE1":6018,"PHASE2":6020,"PHASE3":6022,"PHASE4":6034,"NA":6036},{"trials":6017,"activeCount":98},[],{"trials":6019,"activeCount":98},[],{"trials":6021,"activeCount":98},[],{"trials":6023,"activeCount":98},[6024],{"nctId":6025,"briefTitle":6026,"status":490,"phases":6027,"primaryCompletion":6028,"completion":6028,"start":6029,"enrollment":783,"conditions":6030,"interventions":6033},"NCT04410042","Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure",[88],"2024-01-16","2021-01-29",[6031,6032],"Cancer of the Bone","Limb Salvage",[6014],{"trials":6035,"activeCount":98},[],{"trials":6037,"activeCount":98},[],{"intervention":6039,"totalTrials":386,"cells":6040},"melatonin",{"EARLY_PHASE1":6041,"PHASE1":6043,"PHASE2":6045,"PHASE3":6047,"PHASE4":6059,"NA":6061},{"trials":6042,"activeCount":98},[],{"trials":6044,"activeCount":98},[],{"trials":6046,"activeCount":98},[],{"trials":6048,"activeCount":98},[6049],{"nctId":6050,"briefTitle":6051,"status":104,"phases":6052,"primaryCompletion":6053,"completion":6053,"start":6054,"enrollment":6055,"conditions":6056,"interventions":6058},"NCT01700959","Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort",[88],"2017-04-19","2013-02-06",911,[6057],"Cancer Malignancies",[6039],{"trials":6060,"activeCount":98},[],{"trials":6062,"activeCount":98},[],{"intervention":568,"totalTrials":386,"cells":6064},{"EARLY_PHASE1":6065,"PHASE1":6067,"PHASE2":6069,"PHASE3":6071,"PHASE4":6077,"NA":6079},{"trials":6066,"activeCount":98},[],{"trials":6068,"activeCount":98},[],{"trials":6070,"activeCount":98},[],{"trials":6072,"activeCount":98},[6073],{"nctId":558,"briefTitle":559,"status":104,"phases":6074,"primaryCompletion":561,"completion":561,"start":562,"enrollment":554,"conditions":6075,"interventions":6076},[88],[14,564,565,111,566],[136,568],{"trials":6078,"activeCount":98},[],{"trials":6080,"activeCount":98},[],{"intervention":6082,"totalTrials":386,"cells":6083},"Prednisone, Dexamethasone, Vincristine, Daunorubicin",{"EARLY_PHASE1":6084,"PHASE1":6086,"PHASE2":6088,"PHASE3":6090,"PHASE4":6106,"NA":6108},{"trials":6085,"activeCount":98},[],{"trials":6087,"activeCount":98},[],{"trials":6089,"activeCount":98},[],{"trials":6091,"activeCount":98},[6092],{"nctId":6093,"briefTitle":6094,"status":104,"phases":6095,"primaryCompletion":6096,"completion":6097,"start":6098,"enrollment":6099,"conditions":6100,"interventions":6102},"NCT00137111","Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia",[88],"2010-11","2014-04","2000-07-08",501,[6101],"Lymphoblastic Leukemia, Acute",[6082,6103,6104,6105],"Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase","Methotrexate, Cyclophosphamide, Cytarabine, Etoposide","Mercaptopurine, Imatinib",{"trials":6107,"activeCount":98},[],{"trials":6109,"activeCount":98},[],{"intervention":6103,"totalTrials":386,"cells":6111},{"EARLY_PHASE1":6112,"PHASE1":6114,"PHASE2":6116,"PHASE3":6118,"PHASE4":6124,"NA":6126},{"trials":6113,"activeCount":98},[],{"trials":6115,"activeCount":98},[],{"trials":6117,"activeCount":98},[],{"trials":6119,"activeCount":98},[6120],{"nctId":6093,"briefTitle":6094,"status":104,"phases":6121,"primaryCompletion":6096,"completion":6097,"start":6098,"enrollment":6099,"conditions":6122,"interventions":6123},[88],[6101],[6082,6103,6104,6105],{"trials":6125,"activeCount":98},[],{"trials":6127,"activeCount":98},[],{"intervention":6104,"totalTrials":386,"cells":6129},{"EARLY_PHASE1":6130,"PHASE1":6132,"PHASE2":6134,"PHASE3":6136,"PHASE4":6142,"NA":6144},{"trials":6131,"activeCount":98},[],{"trials":6133,"activeCount":98},[],{"trials":6135,"activeCount":98},[],{"trials":6137,"activeCount":98},[6138],{"nctId":6093,"briefTitle":6094,"status":104,"phases":6139,"primaryCompletion":6096,"completion":6097,"start":6098,"enrollment":6099,"conditions":6140,"interventions":6141},[88],[6101],[6082,6103,6104,6105],{"trials":6143,"activeCount":98},[],{"trials":6145,"activeCount":98},[],{"intervention":6105,"totalTrials":386,"cells":6147},{"EARLY_PHASE1":6148,"PHASE1":6150,"PHASE2":6152,"PHASE3":6154,"PHASE4":6160,"NA":6162},{"trials":6149,"activeCount":98},[],{"trials":6151,"activeCount":98},[],{"trials":6153,"activeCount":98},[],{"trials":6155,"activeCount":98},[6156],{"nctId":6093,"briefTitle":6094,"status":104,"phases":6157,"primaryCompletion":6096,"completion":6097,"start":6098,"enrollment":6099,"conditions":6158,"interventions":6159},[88],[6101],[6082,6103,6104,6105],{"trials":6161,"activeCount":98},[],{"trials":6163,"activeCount":98},[],{"intervention":6165,"totalTrials":386,"cells":6166},"Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine",{"EARLY_PHASE1":6167,"PHASE1":6169,"PHASE2":6171,"PHASE3":6173,"PHASE4":6186,"NA":6188},{"trials":6168,"activeCount":98},[],{"trials":6170,"activeCount":98},[],{"trials":6172,"activeCount":98},[],{"trials":6174,"activeCount":98},[6175],{"nctId":6176,"briefTitle":6177,"status":104,"phases":6178,"primaryCompletion":6179,"completion":6180,"start":6181,"enrollment":6182,"conditions":6183,"interventions":6184},"NCT00549848","Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia",[88],"2020-09-26","2022-03-26","2007-10-29",600,[14],[6165,6185],"Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib",{"trials":6187,"activeCount":98},[],{"trials":6189,"activeCount":98},[],{"intervention":6185,"totalTrials":386,"cells":6191},{"EARLY_PHASE1":6192,"PHASE1":6194,"PHASE2":6196,"PHASE3":6198,"PHASE4":6204,"NA":6206},{"trials":6193,"activeCount":98},[],{"trials":6195,"activeCount":98},[],{"trials":6197,"activeCount":98},[],{"trials":6199,"activeCount":98},[6200],{"nctId":6176,"briefTitle":6177,"status":104,"phases":6201,"primaryCompletion":6179,"completion":6180,"start":6181,"enrollment":6182,"conditions":6202,"interventions":6203},[88],[14],[6165,6185],{"trials":6205,"activeCount":98},[],{"trials":6207,"activeCount":98},[],{"intervention":6209,"totalTrials":386,"cells":6210},"Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone",{"EARLY_PHASE1":6211,"PHASE1":6213,"PHASE2":6215,"PHASE3":6217,"PHASE4":6230,"NA":6232},{"trials":6212,"activeCount":98},[],{"trials":6214,"activeCount":98},[],{"trials":6216,"activeCount":98},[],{"trials":6218,"activeCount":98},[6219],{"nctId":6220,"briefTitle":6221,"status":104,"phases":6222,"primaryCompletion":3089,"completion":6223,"start":6224,"enrollment":6225,"conditions":6226,"interventions":6228},"NCT00136084","Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia",[88],"2012-06","2002-08",238,[6227],"Leukemia, Myelocytic, Acute",[6209,6229],"Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine",{"trials":6231,"activeCount":98},[],{"trials":6233,"activeCount":98},[],{"intervention":6229,"totalTrials":386,"cells":6235},{"EARLY_PHASE1":6236,"PHASE1":6238,"PHASE2":6240,"PHASE3":6242,"PHASE4":6248,"NA":6250},{"trials":6237,"activeCount":98},[],{"trials":6239,"activeCount":98},[],{"trials":6241,"activeCount":98},[],{"trials":6243,"activeCount":98},[6244],{"nctId":6220,"briefTitle":6221,"status":104,"phases":6245,"primaryCompletion":3089,"completion":6223,"start":6224,"enrollment":6225,"conditions":6246,"interventions":6247},[88],[6227],[6209,6229],{"trials":6249,"activeCount":98},[],{"trials":6251,"activeCount":98},[],{"intervention":3251,"totalTrials":386,"cells":6253},{"EARLY_PHASE1":6254,"PHASE1":6256,"PHASE2":6258,"PHASE3":6260,"PHASE4":6266,"NA":6268},{"trials":6255,"activeCount":98},[],{"trials":6257,"activeCount":98},[],{"trials":6259,"activeCount":98},[],{"trials":6261,"activeCount":98},[6262],{"nctId":3243,"briefTitle":3244,"status":104,"phases":6263,"primaryCompletion":3246,"completion":3246,"start":3247,"enrollment":3248,"conditions":6264,"interventions":6265},[88],[14],[3251,3252,3253,3254,3255],{"trials":6267,"activeCount":98},[],{"trials":6269,"activeCount":98},[],{"intervention":3252,"totalTrials":386,"cells":6271},{"EARLY_PHASE1":6272,"PHASE1":6274,"PHASE2":6276,"PHASE3":6278,"PHASE4":6284,"NA":6286},{"trials":6273,"activeCount":98},[],{"trials":6275,"activeCount":98},[],{"trials":6277,"activeCount":98},[],{"trials":6279,"activeCount":98},[6280],{"nctId":3243,"briefTitle":3244,"status":104,"phases":6281,"primaryCompletion":3246,"completion":3246,"start":3247,"enrollment":3248,"conditions":6282,"interventions":6283},[88],[14],[3251,3252,3253,3254,3255],{"trials":6285,"activeCount":98},[],{"trials":6287,"activeCount":98},[],{"intervention":3254,"totalTrials":386,"cells":6289},{"EARLY_PHASE1":6290,"PHASE1":6292,"PHASE2":6294,"PHASE3":6296,"PHASE4":6302,"NA":6304},{"trials":6291,"activeCount":98},[],{"trials":6293,"activeCount":98},[],{"trials":6295,"activeCount":98},[],{"trials":6297,"activeCount":98},[6298],{"nctId":3243,"briefTitle":3244,"status":104,"phases":6299,"primaryCompletion":3246,"completion":3246,"start":3247,"enrollment":3248,"conditions":6300,"interventions":6301},[88],[14],[3251,3252,3253,3254,3255],{"trials":6303,"activeCount":98},[],{"trials":6305,"activeCount":98},[],{"intervention":3255,"totalTrials":386,"cells":6307},{"EARLY_PHASE1":6308,"PHASE1":6310,"PHASE2":6312,"PHASE3":6314,"PHASE4":6320,"NA":6322},{"trials":6309,"activeCount":98},[],{"trials":6311,"activeCount":98},[],{"trials":6313,"activeCount":98},[],{"trials":6315,"activeCount":98},[6316],{"nctId":3243,"briefTitle":3244,"status":104,"phases":6317,"primaryCompletion":3246,"completion":3246,"start":3247,"enrollment":3248,"conditions":6318,"interventions":6319},[88],[14],[3251,3252,3253,3254,3255],{"trials":6321,"activeCount":98},[],{"trials":6323,"activeCount":98},[],{"intervention":1253,"totalTrials":494,"cells":6325},{"EARLY_PHASE1":6326,"PHASE1":6328,"PHASE2":6334,"PHASE3":6352,"PHASE4":6354,"NA":6356},{"trials":6327,"activeCount":98},[],{"trials":6329,"activeCount":98},[6330],{"nctId":2052,"briefTitle":2053,"status":104,"phases":6331,"primaryCompletion":2055,"completion":364,"start":106,"enrollment":743,"conditions":6332,"interventions":6333},[86],[2057],[135,549,639,1253,1103],{"trials":6335,"activeCount":98},[6336,6340,6344,6348],{"nctId":1245,"briefTitle":1246,"status":490,"phases":6337,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":171,"conditions":6338,"interventions":6339},[87],[1251],[78,549,429,639,544,161,1253,752,500,1254],{"nctId":739,"briefTitle":740,"status":490,"phases":6341,"primaryCompletion":619,"completion":619,"start":742,"enrollment":743,"conditions":6342,"interventions":6343},[87],[14,564,565,745,566,746,747],[470,474,156,749,150,750,751,752,753],{"nctId":1380,"briefTitle":1381,"status":104,"phases":6345,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":6346,"interventions":6347},[87],[1388,1389,1390,1169,1391,28,1392,623],[429,1394,1395,1253,1396,1397,78,545,161,1398],{"nctId":1408,"briefTitle":1409,"status":104,"phases":6349,"primaryCompletion":1411,"completion":1412,"start":1413,"enrollment":1414,"conditions":6350,"interventions":6351},[87],[1087,634],[429,78,549,639,1172,1417,161,544,1253],{"trials":6353,"activeCount":98},[],{"trials":6355,"activeCount":98},[],{"trials":6357,"activeCount":98},[],{"intervention":1078,"totalTrials":108,"cells":6359},{"EARLY_PHASE1":6360,"PHASE1":6362,"PHASE2":6376,"PHASE3":6386,"PHASE4":6388,"NA":6390},{"trials":6361,"activeCount":98},[],{"trials":6363,"activeCount":98},[6364,6372],{"nctId":6365,"briefTitle":6366,"status":104,"phases":6367,"primaryCompletion":6368,"completion":1043,"start":6369,"enrollment":171,"conditions":6370,"interventions":6371},"NCT00186862","Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed\u002FRefractory Neuroblastoma",[86],"2000-04","1998-08",[23],[1078],{"nctId":1066,"briefTitle":1067,"status":104,"phases":6373,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":6374,"interventions":6375},[86],[14,1074,745,566,1075],[1077,1078,135,78,139],{"trials":6377,"activeCount":98},[6378,6382],{"nctId":141,"briefTitle":142,"status":104,"phases":6379,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":6380,"interventions":6381},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":1187,"briefTitle":1188,"status":490,"phases":6383,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":357,"conditions":6384,"interventions":6385},[87],[622,621,1167,1194,1169,623,1170],[78,429,161,1078,639,549,1103,1196,1197,1198],{"trials":6387,"activeCount":98},[],{"trials":6389,"activeCount":98},[],{"trials":6391,"activeCount":98},[],{"intervention":138,"totalTrials":539,"cells":6393},{"EARLY_PHASE1":6394,"PHASE1":6396,"PHASE2":6398,"PHASE3":6412,"PHASE4":6414,"NA":6416},{"trials":6395,"activeCount":98},[],{"trials":6397,"activeCount":98},[],{"trials":6399,"activeCount":98},[6400,6404,6408],{"nctId":118,"briefTitle":119,"status":104,"phases":6401,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":6402,"interventions":6403},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":488,"briefTitle":489,"status":490,"phases":6405,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":6406,"interventions":6407},[87],[14],[497,136,138,133,498,499,500],{"nctId":506,"briefTitle":507,"status":490,"phases":6409,"primaryCompletion":509,"completion":509,"start":510,"enrollment":357,"conditions":6410,"interventions":6411},[87],[512,25,513],[199,228,225,133,136,138,515,516,113,137,132],{"trials":6413,"activeCount":98},[],{"trials":6415,"activeCount":98},[],{"trials":6417,"activeCount":98},[],{"intervention":468,"totalTrials":539,"cells":6419},{"EARLY_PHASE1":6420,"PHASE1":6422,"PHASE2":6424,"PHASE3":6438,"PHASE4":6440,"NA":6442},{"trials":6421,"activeCount":98},[],{"trials":6423,"activeCount":98},[],{"trials":6425,"activeCount":98},[6426,6430,6434],{"nctId":2875,"briefTitle":2876,"status":104,"phases":6427,"primaryCompletion":2878,"completion":2878,"start":2879,"enrollment":1214,"conditions":6428,"interventions":6429},[87],[282],[286,468],{"nctId":457,"briefTitle":458,"status":104,"phases":6431,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":6432,"interventions":6433},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"nctId":1345,"briefTitle":1346,"status":104,"phases":6435,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":6436,"interventions":6437},[87],[369],[284,1353,153,150,468],{"trials":6439,"activeCount":98},[],{"trials":6441,"activeCount":98},[],{"trials":6443,"activeCount":98},[],{"intervention":130,"totalTrials":445,"cells":6445},{"EARLY_PHASE1":6446,"PHASE1":6448,"PHASE2":6450,"PHASE3":6460,"PHASE4":6462,"NA":6464},{"trials":6447,"activeCount":98},[],{"trials":6449,"activeCount":98},[],{"trials":6451,"activeCount":98},[6452,6456],{"nctId":118,"briefTitle":119,"status":104,"phases":6453,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":6454,"interventions":6455},[87],[126],[128,93,129,130,131,132,78,133,134,135,136,137,113,138,139],{"nctId":856,"briefTitle":857,"status":490,"phases":6457,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":6458,"interventions":6459},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"trials":6461,"activeCount":98},[],{"trials":6463,"activeCount":98},[],{"trials":6465,"activeCount":98},[],{"intervention":159,"totalTrials":445,"cells":6467},{"EARLY_PHASE1":6468,"PHASE1":6470,"PHASE2":6472,"PHASE3":6482,"PHASE4":6484,"NA":6486},{"trials":6469,"activeCount":98},[],{"trials":6471,"activeCount":98},[],{"trials":6473,"activeCount":98},[6474,6478],{"nctId":141,"briefTitle":142,"status":104,"phases":6475,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":6476,"interventions":6477},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"nctId":457,"briefTitle":458,"status":104,"phases":6479,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":6480,"interventions":6481},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"trials":6483,"activeCount":98},[],{"trials":6485,"activeCount":98},[],{"trials":6487,"activeCount":98},[],{"intervention":160,"totalTrials":445,"cells":6489},{"EARLY_PHASE1":6490,"PHASE1":6492,"PHASE2":6498,"PHASE3":6504,"PHASE4":6506,"NA":6508},{"trials":6491,"activeCount":98},[],{"trials":6493,"activeCount":98},[6494],{"nctId":627,"briefTitle":628,"status":104,"phases":6495,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":6496,"interventions":6497},[86],[23,634,635],[637,638,152,548,639,160,640,139,133,354,161,641],{"trials":6499,"activeCount":98},[6500],{"nctId":141,"briefTitle":142,"status":104,"phases":6501,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":6502,"interventions":6503},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"trials":6505,"activeCount":98},[],{"trials":6507,"activeCount":98},[],{"trials":6509,"activeCount":98},[],{"intervention":6511,"totalTrials":445,"cells":6512},"gabapentin",{"EARLY_PHASE1":6513,"PHASE1":6515,"PHASE2":6517,"PHASE3":6538,"PHASE4":6540,"NA":6542},{"trials":6514,"activeCount":98},[],{"trials":6516,"activeCount":98},[],{"trials":6518,"activeCount":98},[6519,6529],{"nctId":6520,"briefTitle":6521,"status":104,"phases":6522,"primaryCompletion":6523,"completion":6523,"start":6524,"enrollment":962,"conditions":6525,"interventions":6528},"NCT01506453","Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)",[87],"2018-01-02","2012-01-24",[14,6526,6527],"Neuropathy","Neuropathic Pain",[6511],{"nctId":6530,"briefTitle":6531,"status":104,"phases":6532,"primaryCompletion":6533,"completion":6533,"start":6534,"enrollment":2750,"conditions":6535,"interventions":6536},"NCT01954927","Pain Management in Children and Young Adults With Sickle Cell Disease",[87],"2018-01-03","2013-10-07",[17],[6537],"Gabapentin",{"trials":6539,"activeCount":98},[],{"trials":6541,"activeCount":98},[],{"trials":6543,"activeCount":98},[],{"intervention":603,"totalTrials":445,"cells":6545},{"EARLY_PHASE1":6546,"PHASE1":6548,"PHASE2":6554,"PHASE3":6560,"PHASE4":6562,"NA":6564},{"trials":6547,"activeCount":98},[],{"trials":6549,"activeCount":98},[6550],{"nctId":596,"briefTitle":597,"status":490,"phases":6551,"primaryCompletion":599,"completion":599,"start":600,"enrollment":9,"conditions":6552,"interventions":6553},[86],[25,566],[603,429,133,317,316],{"trials":6555,"activeCount":98},[6556],{"nctId":856,"briefTitle":857,"status":490,"phases":6557,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":6558,"interventions":6559},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"trials":6561,"activeCount":98},[],{"trials":6563,"activeCount":98},[],{"trials":6565,"activeCount":98},[],{"intervention":500,"totalTrials":445,"cells":6567},{"EARLY_PHASE1":6568,"PHASE1":6570,"PHASE2":6572,"PHASE3":6582,"PHASE4":6584,"NA":6586},{"trials":6569,"activeCount":98},[],{"trials":6571,"activeCount":98},[],{"trials":6573,"activeCount":98},[6574,6578],{"nctId":1245,"briefTitle":1246,"status":490,"phases":6575,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":171,"conditions":6576,"interventions":6577},[87],[1251],[78,549,429,639,544,161,1253,752,500,1254],{"nctId":488,"briefTitle":489,"status":490,"phases":6579,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":6580,"interventions":6581},[87],[14],[497,136,138,133,498,499,500],{"trials":6583,"activeCount":98},[],{"trials":6585,"activeCount":98},[],{"trials":6587,"activeCount":98},[],{"intervention":2743,"totalTrials":445,"cells":6589},{"EARLY_PHASE1":6590,"PHASE1":6592,"PHASE2":6594,"PHASE3":6604,"PHASE4":6606,"NA":6608},{"trials":6591,"activeCount":98},[],{"trials":6593,"activeCount":98},[],{"trials":6595,"activeCount":98},[6596,6600],{"nctId":4078,"briefTitle":4079,"status":104,"phases":6597,"primaryCompletion":4081,"completion":4081,"start":4082,"enrollment":357,"conditions":6598,"interventions":6599},[87],[4084,4085,4086,4087],[4089,2743,4090],{"nctId":2735,"briefTitle":2736,"status":104,"phases":6601,"primaryCompletion":2738,"completion":2738,"start":2739,"enrollment":2740,"conditions":6602,"interventions":6603},[87],[369],[2743,179],{"trials":6605,"activeCount":98},[],{"trials":6607,"activeCount":98},[],{"trials":6609,"activeCount":98},[],{"intervention":751,"totalTrials":445,"cells":6611},{"EARLY_PHASE1":6612,"PHASE1":6614,"PHASE2":6620,"PHASE3":6626,"PHASE4":6628,"NA":6630},{"trials":6613,"activeCount":98},[],{"trials":6615,"activeCount":98},[6616],{"nctId":2254,"briefTitle":2255,"status":104,"phases":6617,"primaryCompletion":2257,"completion":2257,"start":2258,"enrollment":124,"conditions":6618,"interventions":6619},[86],[1062,2260,2261,2262,634,1113,1116,2263,2264,1119,23,32,2265],[2267,2268,2269,548,157,751],{"trials":6621,"activeCount":98},[6622],{"nctId":739,"briefTitle":740,"status":490,"phases":6623,"primaryCompletion":619,"completion":619,"start":742,"enrollment":743,"conditions":6624,"interventions":6625},[87],[14,564,565,745,566,746,747],[470,474,156,749,150,750,751,752,753],{"trials":6627,"activeCount":98},[],{"trials":6629,"activeCount":98},[],{"trials":6631,"activeCount":98},[],{"intervention":6633,"totalTrials":386,"cells":6634},"Influenza virus vaccine",{"EARLY_PHASE1":6635,"PHASE1":6637,"PHASE2":6639,"PHASE3":6651,"PHASE4":6653,"NA":6655},{"trials":6636,"activeCount":98},[],{"trials":6638,"activeCount":98},[],{"trials":6640,"activeCount":98},[6641],{"nctId":6642,"briefTitle":6643,"status":104,"phases":6644,"primaryCompletion":6645,"completion":6645,"start":6646,"enrollment":6647,"conditions":6648,"interventions":6650},"NCT02649192","Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children",[87],"2018-06-29","2016-01-21",87,[6649],"Healthy Participants",[6633],{"trials":6652,"activeCount":98},[],{"trials":6654,"activeCount":98},[],{"trials":6656,"activeCount":98},[],{"intervention":158,"totalTrials":386,"cells":6658},{"EARLY_PHASE1":6659,"PHASE1":6661,"PHASE2":6663,"PHASE3":6669,"PHASE4":6671,"NA":6673},{"trials":6660,"activeCount":98},[],{"trials":6662,"activeCount":98},[],{"trials":6664,"activeCount":98},[6665],{"nctId":141,"briefTitle":142,"status":104,"phases":6666,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":6667,"interventions":6668},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"trials":6670,"activeCount":98},[],{"trials":6672,"activeCount":98},[],{"trials":6674,"activeCount":98},[],{"intervention":163,"totalTrials":386,"cells":6676},{"EARLY_PHASE1":6677,"PHASE1":6679,"PHASE2":6681,"PHASE3":6687,"PHASE4":6689,"NA":6691},{"trials":6678,"activeCount":98},[],{"trials":6680,"activeCount":98},[],{"trials":6682,"activeCount":98},[6683],{"nctId":141,"briefTitle":142,"status":104,"phases":6684,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":6685,"interventions":6686},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"trials":6688,"activeCount":98},[],{"trials":6690,"activeCount":98},[],{"trials":6692,"activeCount":98},[],{"intervention":165,"totalTrials":386,"cells":6694},{"EARLY_PHASE1":6695,"PHASE1":6697,"PHASE2":6699,"PHASE3":6705,"PHASE4":6707,"NA":6709},{"trials":6696,"activeCount":98},[],{"trials":6698,"activeCount":98},[],{"trials":6700,"activeCount":98},[6701],{"nctId":141,"briefTitle":142,"status":104,"phases":6702,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":6703,"interventions":6704},[87],[23],[150,151,152,153,154,155,44,156,157,158,159,160,161,162,163,164,165],{"trials":6706,"activeCount":98},[],{"trials":6708,"activeCount":98},[],{"trials":6710,"activeCount":98},[],{"intervention":3309,"totalTrials":386,"cells":6712},{"EARLY_PHASE1":6713,"PHASE1":6715,"PHASE2":6717,"PHASE3":6723,"PHASE4":6725,"NA":6727},{"trials":6714,"activeCount":98},[],{"trials":6716,"activeCount":98},[],{"trials":6718,"activeCount":98},[6719],{"nctId":3300,"briefTitle":3301,"status":721,"phases":6720,"primaryCompletion":829,"completion":3303,"start":3304,"enrollment":3305,"conditions":6721,"interventions":6722},[86,87],[3307],[3309,548],{"trials":6724,"activeCount":98},[],{"trials":6726,"activeCount":98},[],{"trials":6728,"activeCount":98},[],{"intervention":6730,"totalTrials":386,"cells":6731},"Etoposide, cytarabine, vincristine, dexamethasone",{"EARLY_PHASE1":6732,"PHASE1":6734,"PHASE2":6736,"PHASE3":6751,"PHASE4":6753,"NA":6755},{"trials":6733,"activeCount":98},[],{"trials":6735,"activeCount":98},[],{"trials":6737,"activeCount":98},[6738],{"nctId":6739,"briefTitle":6740,"status":104,"phases":6741,"primaryCompletion":6742,"completion":6742,"start":6743,"enrollment":6744,"conditions":6745,"interventions":6747},"NCT00186875","Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia",[87],"2016-08","2003-11",47,[14,6746],"Lymphoma, Lymphoblastic",[6730,6748,6749,6750],"methotrexate, teniposide, PEG-asparaginase","mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine","L-asparaginase, erwinia asparaginase",{"trials":6752,"activeCount":98},[],{"trials":6754,"activeCount":98},[],{"trials":6756,"activeCount":98},[],{"intervention":6748,"totalTrials":386,"cells":6758},{"EARLY_PHASE1":6759,"PHASE1":6761,"PHASE2":6763,"PHASE3":6769,"PHASE4":6771,"NA":6773},{"trials":6760,"activeCount":98},[],{"trials":6762,"activeCount":98},[],{"trials":6764,"activeCount":98},[6765],{"nctId":6739,"briefTitle":6740,"status":104,"phases":6766,"primaryCompletion":6742,"completion":6742,"start":6743,"enrollment":6744,"conditions":6767,"interventions":6768},[87],[14,6746],[6730,6748,6749,6750],{"trials":6770,"activeCount":98},[],{"trials":6772,"activeCount":98},[],{"trials":6774,"activeCount":98},[],{"intervention":6749,"totalTrials":386,"cells":6776},{"EARLY_PHASE1":6777,"PHASE1":6779,"PHASE2":6781,"PHASE3":6787,"PHASE4":6789,"NA":6791},{"trials":6778,"activeCount":98},[],{"trials":6780,"activeCount":98},[],{"trials":6782,"activeCount":98},[6783],{"nctId":6739,"briefTitle":6740,"status":104,"phases":6784,"primaryCompletion":6742,"completion":6742,"start":6743,"enrollment":6744,"conditions":6785,"interventions":6786},[87],[14,6746],[6730,6748,6749,6750],{"trials":6788,"activeCount":98},[],{"trials":6790,"activeCount":98},[],{"trials":6792,"activeCount":98},[],{"intervention":6750,"totalTrials":386,"cells":6794},{"EARLY_PHASE1":6795,"PHASE1":6797,"PHASE2":6799,"PHASE3":6805,"PHASE4":6807,"NA":6809},{"trials":6796,"activeCount":98},[],{"trials":6798,"activeCount":98},[],{"trials":6800,"activeCount":98},[6801],{"nctId":6739,"briefTitle":6740,"status":104,"phases":6802,"primaryCompletion":6742,"completion":6742,"start":6743,"enrollment":6744,"conditions":6803,"interventions":6804},[87],[14,6746],[6730,6748,6749,6750],{"trials":6806,"activeCount":98},[],{"trials":6808,"activeCount":98},[],{"trials":6810,"activeCount":98},[],{"intervention":6812,"totalTrials":386,"cells":6813},"Busulfan, Cyclophosphamide, Horse ATG",{"EARLY_PHASE1":6814,"PHASE1":6816,"PHASE2":6818,"PHASE3":6828,"PHASE4":6830,"NA":6832},{"trials":6815,"activeCount":98},[],{"trials":6817,"activeCount":98},[],{"trials":6819,"activeCount":98},[6820],{"nctId":6821,"briefTitle":6822,"status":104,"phases":6823,"primaryCompletion":6824,"completion":1043,"start":6825,"enrollment":783,"conditions":6826,"interventions":6827},"NCT00186810","Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease",[87],"2006-02","1992-12",[17],[6812],{"trials":6829,"activeCount":98},[],{"trials":6831,"activeCount":98},[],{"trials":6833,"activeCount":98},[],{"intervention":6835,"totalTrials":386,"cells":6836},"Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin",{"EARLY_PHASE1":6837,"PHASE1":6839,"PHASE2":6841,"PHASE3":6851,"PHASE4":6853,"NA":6855},{"trials":6838,"activeCount":98},[],{"trials":6840,"activeCount":98},[],{"trials":6842,"activeCount":98},[6843],{"nctId":6844,"briefTitle":6845,"status":104,"phases":6846,"primaryCompletion":6847,"completion":6847,"start":6848,"enrollment":997,"conditions":6849,"interventions":6850},"NCT00186849","Therapy for Children With Advanced Stage High Risk Neuroblastoma",[87],"2001-04","1997-10",[23],[6835],{"trials":6852,"activeCount":98},[],{"trials":6854,"activeCount":98},[],{"trials":6856,"activeCount":98},[],{"intervention":1196,"totalTrials":386,"cells":6858},{"EARLY_PHASE1":6859,"PHASE1":6861,"PHASE2":6863,"PHASE3":6869,"PHASE4":6871,"NA":6873},{"trials":6860,"activeCount":98},[],{"trials":6862,"activeCount":98},[],{"trials":6864,"activeCount":98},[6865],{"nctId":1187,"briefTitle":1188,"status":490,"phases":6866,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":357,"conditions":6867,"interventions":6868},[87],[622,621,1167,1194,1169,623,1170],[78,429,161,1078,639,549,1103,1196,1197,1198],{"trials":6870,"activeCount":98},[],{"trials":6872,"activeCount":98},[],{"trials":6874,"activeCount":98},[],{"intervention":1197,"totalTrials":386,"cells":6876},{"EARLY_PHASE1":6877,"PHASE1":6879,"PHASE2":6881,"PHASE3":6887,"PHASE4":6889,"NA":6891},{"trials":6878,"activeCount":98},[],{"trials":6880,"activeCount":98},[],{"trials":6882,"activeCount":98},[6883],{"nctId":1187,"briefTitle":1188,"status":490,"phases":6884,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":357,"conditions":6885,"interventions":6886},[87],[622,621,1167,1194,1169,623,1170],[78,429,161,1078,639,549,1103,1196,1197,1198],{"trials":6888,"activeCount":98},[],{"trials":6890,"activeCount":98},[],{"trials":6892,"activeCount":98},[],{"intervention":1198,"totalTrials":386,"cells":6894},{"EARLY_PHASE1":6895,"PHASE1":6897,"PHASE2":6899,"PHASE3":6905,"PHASE4":6907,"NA":6909},{"trials":6896,"activeCount":98},[],{"trials":6898,"activeCount":98},[],{"trials":6900,"activeCount":98},[6901],{"nctId":1187,"briefTitle":1188,"status":490,"phases":6902,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":357,"conditions":6903,"interventions":6904},[87],[622,621,1167,1194,1169,623,1170],[78,429,161,1078,639,549,1103,1196,1197,1198],{"trials":6906,"activeCount":98},[],{"trials":6908,"activeCount":98},[],{"trials":6910,"activeCount":98},[],{"intervention":675,"totalTrials":386,"cells":6912},{"EARLY_PHASE1":6913,"PHASE1":6915,"PHASE2":6917,"PHASE3":6923,"PHASE4":6925,"NA":6927},{"trials":6914,"activeCount":98},[],{"trials":6916,"activeCount":98},[],{"trials":6918,"activeCount":98},[6919],{"nctId":668,"briefTitle":669,"status":490,"phases":6920,"primaryCompletion":671,"completion":671,"start":672,"enrollment":108,"conditions":6921,"interventions":6922},[87],[621,623],[133,317,675],{"trials":6924,"activeCount":98},[],{"trials":6926,"activeCount":98},[],{"trials":6928,"activeCount":98},[],{"intervention":6930,"totalTrials":386,"cells":6931},"Erlotinib hydrochloride",{"EARLY_PHASE1":6932,"PHASE1":6934,"PHASE2":6936,"PHASE3":6947,"PHASE4":6949,"NA":6951},{"trials":6933,"activeCount":98},[],{"trials":6935,"activeCount":98},[],{"trials":6937,"activeCount":98},[6938],{"nctId":6939,"briefTitle":6940,"status":104,"phases":6941,"primaryCompletion":6942,"completion":6943,"start":6944,"enrollment":611,"conditions":6945,"interventions":6946},"NCT00124657","Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma",[86,87],"2012-07","2014-09","2005-03",[369],[6930],{"trials":6948,"activeCount":98},[],{"trials":6950,"activeCount":98},[],{"trials":6952,"activeCount":98},[],{"intervention":471,"totalTrials":386,"cells":6954},{"EARLY_PHASE1":6955,"PHASE1":6957,"PHASE2":6959,"PHASE3":6965,"PHASE4":6967,"NA":6969},{"trials":6956,"activeCount":98},[],{"trials":6958,"activeCount":98},[],{"trials":6960,"activeCount":98},[6961],{"nctId":457,"briefTitle":458,"status":104,"phases":6962,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":6963,"interventions":6964},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"trials":6966,"activeCount":98},[],{"trials":6968,"activeCount":98},[],{"trials":6970,"activeCount":98},[],{"intervention":476,"totalTrials":386,"cells":6972},{"EARLY_PHASE1":6973,"PHASE1":6975,"PHASE2":6977,"PHASE3":6983,"PHASE4":6985,"NA":6987},{"trials":6974,"activeCount":98},[],{"trials":6976,"activeCount":98},[],{"trials":6978,"activeCount":98},[6979],{"nctId":457,"briefTitle":458,"status":104,"phases":6980,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":6981,"interventions":6982},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"trials":6984,"activeCount":98},[],{"trials":6986,"activeCount":98},[],{"trials":6988,"activeCount":98},[],{"intervention":478,"totalTrials":386,"cells":6990},{"EARLY_PHASE1":6991,"PHASE1":6993,"PHASE2":6995,"PHASE3":7001,"PHASE4":7003,"NA":7005},{"trials":6992,"activeCount":98},[],{"trials":6994,"activeCount":98},[],{"trials":6996,"activeCount":98},[6997],{"nctId":457,"briefTitle":458,"status":104,"phases":6998,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":6999,"interventions":7000},[87],[464,465],[467,468,469,470,150,154,471,472,344,473,474,475,476,477,159,478],{"trials":7002,"activeCount":98},[],{"trials":7004,"activeCount":98},[],{"trials":7006,"activeCount":98},[],{"intervention":7008,"totalTrials":386,"cells":7009},"Glutamine",{"EARLY_PHASE1":7010,"PHASE1":7012,"PHASE2":7014,"PHASE3":7023,"PHASE4":7025,"NA":7027},{"trials":7011,"activeCount":98},[],{"trials":7013,"activeCount":98},[],{"trials":7015,"activeCount":98},[7016],{"nctId":7017,"briefTitle":7018,"status":490,"phases":7019,"primaryCompletion":7020,"completion":7020,"start":5671,"enrollment":1441,"conditions":7021,"interventions":7022},"NCT00131508","Trial of Oral Glutamine in Patients With Sickle Cell Anemia",[87],"2009-04",[3754],[7008],{"trials":7024,"activeCount":98},[],{"trials":7026,"activeCount":98},[],{"trials":7028,"activeCount":98},[],{"intervention":7030,"totalTrials":386,"cells":7031},"Avelumab",{"EARLY_PHASE1":7032,"PHASE1":7034,"PHASE2":7036,"PHASE3":7046,"PHASE4":7048,"NA":7050},{"trials":7033,"activeCount":98},[],{"trials":7035,"activeCount":98},[],{"trials":7037,"activeCount":98},[7038],{"nctId":7039,"briefTitle":7040,"status":104,"phases":7041,"primaryCompletion":7042,"completion":7042,"start":7043,"enrollment":9,"conditions":7044,"interventions":7045},"NCT03006848","A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma",[87],"2020-03-18","2017-02-16",[526],[7030],{"trials":7047,"activeCount":98},[],{"trials":7049,"activeCount":98},[],{"trials":7051,"activeCount":98},[],{"intervention":7053,"totalTrials":386,"cells":7054},"hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus",{"EARLY_PHASE1":7055,"PHASE1":7057,"PHASE2":7059,"PHASE3":7071,"PHASE4":7073,"NA":7075},{"trials":7056,"activeCount":98},[],{"trials":7058,"activeCount":98},[],{"trials":7060,"activeCount":98},[7061],{"nctId":7062,"briefTitle":7063,"status":721,"phases":7064,"primaryCompletion":7065,"completion":7066,"start":7067,"enrollment":3248,"conditions":7068,"interventions":7069},"NCT04362293","Reduced Intensity Transplantation for Severe Sickle Cell Disease",[87],"2026-08-01","2029-08-01","2020-04-30",[17],[7053,7070],"hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus",{"trials":7072,"activeCount":98},[],{"trials":7074,"activeCount":98},[],{"trials":7076,"activeCount":98},[],{"intervention":7070,"totalTrials":386,"cells":7078},{"EARLY_PHASE1":7079,"PHASE1":7081,"PHASE2":7083,"PHASE3":7089,"PHASE4":7091,"NA":7093},{"trials":7080,"activeCount":98},[],{"trials":7082,"activeCount":98},[],{"trials":7084,"activeCount":98},[7085],{"nctId":7062,"briefTitle":7063,"status":721,"phases":7086,"primaryCompletion":7065,"completion":7066,"start":7067,"enrollment":3248,"conditions":7087,"interventions":7088},[87],[17],[7053,7070],{"trials":7090,"activeCount":98},[],{"trials":7092,"activeCount":98},[],{"trials":7094,"activeCount":98},[],{"intervention":3728,"totalTrials":386,"cells":7096},{"EARLY_PHASE1":7097,"PHASE1":7099,"PHASE2":7101,"PHASE3":7107,"PHASE4":7109,"NA":7111},{"trials":7098,"activeCount":98},[],{"trials":7100,"activeCount":98},[],{"trials":7102,"activeCount":98},[7103],{"nctId":3719,"briefTitle":3720,"status":490,"phases":7104,"primaryCompletion":3722,"completion":3723,"start":3724,"enrollment":647,"conditions":7105,"interventions":7106},[87],[3726],[2564,3728],{"trials":7108,"activeCount":98},[],{"trials":7110,"activeCount":98},[],{"trials":7112,"activeCount":98},[],{"intervention":1231,"totalTrials":386,"cells":7114},{"EARLY_PHASE1":7115,"PHASE1":7117,"PHASE2":7119,"PHASE3":7125,"PHASE4":7127,"NA":7129},{"trials":7116,"activeCount":98},[],{"trials":7118,"activeCount":98},[],{"trials":7120,"activeCount":98},[7121],{"nctId":1223,"briefTitle":1224,"status":490,"phases":7122,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":108,"conditions":7123,"interventions":7124},[87],[23],[1230,114,78,132,139,299,355,1231],{"trials":7126,"activeCount":98},[],{"trials":7128,"activeCount":98},[],{"trials":7130,"activeCount":98},[],{"intervention":7132,"totalTrials":386,"cells":7133},"Recombinant Human Thrombopoietin",{"EARLY_PHASE1":7134,"PHASE1":7136,"PHASE2":7138,"PHASE3":7150,"PHASE4":7152,"NA":7154},{"trials":7135,"activeCount":98},[],{"trials":7137,"activeCount":98},[],{"trials":7139,"activeCount":98},[7140],{"nctId":7141,"briefTitle":7142,"status":104,"phases":7143,"primaryCompletion":7144,"completion":7144,"start":7145,"enrollment":3248,"conditions":7146,"interventions":7149},"NCT00187109","Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy",[86,87],"2007-02","2000-06",[7147,7148,23,526,32],"Germ Cell Tumors","Hepatic Cancer",[7132],{"trials":7151,"activeCount":98},[],{"trials":7153,"activeCount":98},[],{"trials":7155,"activeCount":98},[],{"intervention":7157,"totalTrials":386,"cells":7158},"Systematic chemotherapy and antibodies",{"EARLY_PHASE1":7159,"PHASE1":7161,"PHASE2":7163,"PHASE3":7174,"PHASE4":7176,"NA":7178},{"trials":7160,"activeCount":98},[],{"trials":7162,"activeCount":98},[],{"trials":7164,"activeCount":98},[7165],{"nctId":7166,"briefTitle":7167,"status":104,"phases":7168,"primaryCompletion":7169,"completion":106,"start":7170,"enrollment":975,"conditions":7171,"interventions":7173},"NCT00143559","Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies",[87],"2006-07","2005-08",[1087,14,25,5213,745,566,7172,327,807],"Paroxysmal Nocturnal Hemoglobinuria",[7157],{"trials":7175,"activeCount":98},[],{"trials":7177,"activeCount":98},[],{"trials":7179,"activeCount":98},[],{"intervention":7181,"totalTrials":386,"cells":7182},"Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid",{"EARLY_PHASE1":7183,"PHASE1":7185,"PHASE2":7187,"PHASE3":7195,"PHASE4":7197,"NA":7199},{"trials":7184,"activeCount":98},[],{"trials":7186,"activeCount":98},[],{"trials":7188,"activeCount":98},[7189],{"nctId":7190,"briefTitle":7191,"status":104,"phases":7192,"primaryCompletion":1348,"completion":1348,"start":7170,"enrollment":124,"conditions":7193,"interventions":7194},"NCT00135135","Therapy for Children With Neuroblastoma",[87],[23],[7181],{"trials":7196,"activeCount":98},[],{"trials":7198,"activeCount":98},[],{"trials":7200,"activeCount":98},[],{"intervention":1254,"totalTrials":386,"cells":7202},{"EARLY_PHASE1":7203,"PHASE1":7205,"PHASE2":7207,"PHASE3":7213,"PHASE4":7215,"NA":7217},{"trials":7204,"activeCount":98},[],{"trials":7206,"activeCount":98},[],{"trials":7208,"activeCount":98},[7209],{"nctId":1245,"briefTitle":1246,"status":490,"phases":7210,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":171,"conditions":7211,"interventions":7212},[87],[1251],[78,549,429,639,544,161,1253,752,500,1254],{"trials":7214,"activeCount":98},[],{"trials":7216,"activeCount":98},[],{"trials":7218,"activeCount":98},[],{"intervention":1263,"totalTrials":386,"cells":7220},{"EARLY_PHASE1":7221,"PHASE1":7223,"PHASE2":7225,"PHASE3":7231,"PHASE4":7233,"NA":7235},{"trials":7222,"activeCount":98},[],{"trials":7224,"activeCount":98},[],{"trials":7226,"activeCount":98},[7227],{"nctId":1256,"briefTitle":1257,"status":104,"phases":7228,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":108,"conditions":7229,"interventions":7230},[87],[282],[284,286,150,1263,154,1264],{"trials":7232,"activeCount":98},[],{"trials":7234,"activeCount":98},[],{"trials":7236,"activeCount":98},[],{"intervention":1264,"totalTrials":386,"cells":7238},{"EARLY_PHASE1":7239,"PHASE1":7241,"PHASE2":7243,"PHASE3":7249,"PHASE4":7251,"NA":7253},{"trials":7240,"activeCount":98},[],{"trials":7242,"activeCount":98},[],{"trials":7244,"activeCount":98},[7245],{"nctId":1256,"briefTitle":1257,"status":104,"phases":7246,"primaryCompletion":1259,"completion":1259,"start":1260,"enrollment":108,"conditions":7247,"interventions":7248},[87],[282],[284,286,150,1263,154,1264],{"trials":7250,"activeCount":98},[],{"trials":7252,"activeCount":98},[],{"trials":7254,"activeCount":98},[],{"intervention":497,"totalTrials":386,"cells":7256},{"EARLY_PHASE1":7257,"PHASE1":7259,"PHASE2":7261,"PHASE3":7267,"PHASE4":7269,"NA":7271},{"trials":7258,"activeCount":98},[],{"trials":7260,"activeCount":98},[],{"trials":7262,"activeCount":98},[7263],{"nctId":488,"briefTitle":489,"status":490,"phases":7264,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":7265,"interventions":7266},[87],[14],[497,136,138,133,498,499,500],{"trials":7268,"activeCount":98},[],{"trials":7270,"activeCount":98},[],{"trials":7272,"activeCount":98},[],{"intervention":498,"totalTrials":386,"cells":7274},{"EARLY_PHASE1":7275,"PHASE1":7277,"PHASE2":7279,"PHASE3":7285,"PHASE4":7287,"NA":7289},{"trials":7276,"activeCount":98},[],{"trials":7278,"activeCount":98},[],{"trials":7280,"activeCount":98},[7281],{"nctId":488,"briefTitle":489,"status":490,"phases":7282,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":7283,"interventions":7284},[87],[14],[497,136,138,133,498,499,500],{"trials":7286,"activeCount":98},[],{"trials":7288,"activeCount":98},[],{"trials":7290,"activeCount":98},[],{"intervention":499,"totalTrials":386,"cells":7292},{"EARLY_PHASE1":7293,"PHASE1":7295,"PHASE2":7297,"PHASE3":7303,"PHASE4":7305,"NA":7307},{"trials":7294,"activeCount":98},[],{"trials":7296,"activeCount":98},[],{"trials":7298,"activeCount":98},[7299],{"nctId":488,"briefTitle":489,"status":490,"phases":7300,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":7301,"interventions":7302},[87],[14],[497,136,138,133,498,499,500],{"trials":7304,"activeCount":98},[],{"trials":7306,"activeCount":98},[],{"trials":7308,"activeCount":98},[],{"intervention":4089,"totalTrials":386,"cells":7310},{"EARLY_PHASE1":7311,"PHASE1":7313,"PHASE2":7315,"PHASE3":7321,"PHASE4":7323,"NA":7325},{"trials":7312,"activeCount":98},[],{"trials":7314,"activeCount":98},[],{"trials":7316,"activeCount":98},[7317],{"nctId":4078,"briefTitle":4079,"status":104,"phases":7318,"primaryCompletion":4081,"completion":4081,"start":4082,"enrollment":357,"conditions":7319,"interventions":7320},[87],[4084,4085,4086,4087],[4089,2743,4090],{"trials":7322,"activeCount":98},[],{"trials":7324,"activeCount":98},[],{"trials":7326,"activeCount":98},[],{"intervention":7328,"totalTrials":386,"cells":7329},"Preparative Regimen",{"EARLY_PHASE1":7330,"PHASE1":7332,"PHASE2":7334,"PHASE3":7347,"PHASE4":7349,"NA":7351},{"trials":7331,"activeCount":98},[],{"trials":7333,"activeCount":98},[],{"trials":7335,"activeCount":98},[7336],{"nctId":7337,"briefTitle":7338,"status":104,"phases":7339,"primaryCompletion":7340,"completion":7340,"start":7341,"enrollment":7342,"conditions":7343,"interventions":7346},"NCT01328496","Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen",[87],"2016-10-31","2011-06-15",14,[2057,7344,7345],"Disorder Related to Transplantation","Hematopoietic Malignancy",[7328],{"trials":7348,"activeCount":98},[],{"trials":7350,"activeCount":98},[],{"trials":7352,"activeCount":98},[],{"intervention":7354,"totalTrials":386,"cells":7355},"Topotecan, Filgrastim (G-CSF), Pegfilgrastim",{"EARLY_PHASE1":7356,"PHASE1":7358,"PHASE2":7360,"PHASE3":7369,"PHASE4":7371,"NA":7373},{"trials":7357,"activeCount":98},[],{"trials":7359,"activeCount":98},[],{"trials":7361,"activeCount":98},[7362],{"nctId":7363,"briefTitle":7364,"status":104,"phases":7365,"completion":1043,"start":7366,"enrollment":421,"conditions":7367,"interventions":7368},"NCT00187031","A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor",[87],"2002-11",[1113],[7354],{"trials":7370,"activeCount":98},[],{"trials":7372,"activeCount":98},[],{"trials":7374,"activeCount":98},[],{"intervention":7376,"totalTrials":386,"cells":7377},"12 Week Stanford V Chemotherapy",{"EARLY_PHASE1":7378,"PHASE1":7380,"PHASE2":7382,"PHASE3":7397,"PHASE4":7399,"NA":7401},{"trials":7379,"activeCount":98},[],{"trials":7381,"activeCount":98},[],{"trials":7383,"activeCount":98},[7384],{"nctId":7385,"briefTitle":7386,"status":104,"phases":7387,"primaryCompletion":7388,"completion":7389,"start":7390,"enrollment":7391,"conditions":7392,"interventions":7393},"NCT00145600","Therapy for Pediatric Hodgkin Lymphoma",[87],"2012-05-31","2021-11-05","2000-03-02",296,[28],[7376,7394,7395,7396],"4 cycles of VAMP chemotherapy","2 alternating cycles of VAMP\u002FCOP chemotherapy","3 alternating cycles of VAMP\u002FCOP chemotherapy",{"trials":7398,"activeCount":98},[],{"trials":7400,"activeCount":98},[],{"trials":7402,"activeCount":98},[],{"intervention":7394,"totalTrials":386,"cells":7404},{"EARLY_PHASE1":7405,"PHASE1":7407,"PHASE2":7409,"PHASE3":7415,"PHASE4":7417,"NA":7419},{"trials":7406,"activeCount":98},[],{"trials":7408,"activeCount":98},[],{"trials":7410,"activeCount":98},[7411],{"nctId":7385,"briefTitle":7386,"status":104,"phases":7412,"primaryCompletion":7388,"completion":7389,"start":7390,"enrollment":7391,"conditions":7413,"interventions":7414},[87],[28],[7376,7394,7395,7396],{"trials":7416,"activeCount":98},[],{"trials":7418,"activeCount":98},[],{"trials":7420,"activeCount":98},[],{"intervention":7395,"totalTrials":386,"cells":7422},{"EARLY_PHASE1":7423,"PHASE1":7425,"PHASE2":7427,"PHASE3":7433,"PHASE4":7435,"NA":7437},{"trials":7424,"activeCount":98},[],{"trials":7426,"activeCount":98},[],{"trials":7428,"activeCount":98},[7429],{"nctId":7385,"briefTitle":7386,"status":104,"phases":7430,"primaryCompletion":7388,"completion":7389,"start":7390,"enrollment":7391,"conditions":7431,"interventions":7432},[87],[28],[7376,7394,7395,7396],{"trials":7434,"activeCount":98},[],{"trials":7436,"activeCount":98},[],{"trials":7438,"activeCount":98},[],{"intervention":7396,"totalTrials":386,"cells":7440},{"EARLY_PHASE1":7441,"PHASE1":7443,"PHASE2":7445,"PHASE3":7451,"PHASE4":7453,"NA":7455},{"trials":7442,"activeCount":98},[],{"trials":7444,"activeCount":98},[],{"trials":7446,"activeCount":98},[7447],{"nctId":7385,"briefTitle":7386,"status":104,"phases":7448,"primaryCompletion":7388,"completion":7389,"start":7390,"enrollment":7391,"conditions":7449,"interventions":7450},[87],[28],[7376,7394,7395,7396],{"trials":7452,"activeCount":98},[],{"trials":7454,"activeCount":98},[],{"trials":7456,"activeCount":98},[],{"intervention":7458,"totalTrials":386,"cells":7459},"Fluzone High Dose Vaccine",{"EARLY_PHASE1":7460,"PHASE1":7462,"PHASE2":7464,"PHASE3":7475,"PHASE4":7477,"NA":7479},{"trials":7461,"activeCount":98},[],{"trials":7463,"activeCount":98},[],{"trials":7465,"activeCount":98},[7466],{"nctId":7467,"briefTitle":7468,"status":104,"phases":7469,"primaryCompletion":805,"completion":805,"start":562,"enrollment":7470,"conditions":7471,"interventions":7473},"NCT01205581","Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV",[87],85,[7472,20],"HIV",[7458,7474],"Fluzone Standard Dose Vaccine",{"trials":7476,"activeCount":98},[],{"trials":7478,"activeCount":98},[],{"trials":7480,"activeCount":98},[],{"intervention":7474,"totalTrials":386,"cells":7482},{"EARLY_PHASE1":7483,"PHASE1":7485,"PHASE2":7487,"PHASE3":7493,"PHASE4":7495,"NA":7497},{"trials":7484,"activeCount":98},[],{"trials":7486,"activeCount":98},[],{"trials":7488,"activeCount":98},[7489],{"nctId":7467,"briefTitle":7468,"status":104,"phases":7490,"primaryCompletion":805,"completion":805,"start":562,"enrollment":7470,"conditions":7491,"interventions":7492},[87],[7472,20],[7458,7474],{"trials":7494,"activeCount":98},[],{"trials":7496,"activeCount":98},[],{"trials":7498,"activeCount":98},[],{"intervention":728,"totalTrials":386,"cells":7500},{"EARLY_PHASE1":7501,"PHASE1":7503,"PHASE2":7505,"PHASE3":7511,"PHASE4":7513,"NA":7515},{"trials":7502,"activeCount":98},[],{"trials":7504,"activeCount":98},[],{"trials":7506,"activeCount":98},[7507],{"nctId":719,"briefTitle":720,"status":721,"phases":7508,"primaryCompletion":249,"completion":723,"start":724,"enrollment":725,"conditions":7509,"interventions":7510},[87],[25],[83,443,133,728,729,730,731,732,139,733],{"trials":7512,"activeCount":98},[],{"trials":7514,"activeCount":98},[],{"trials":7516,"activeCount":98},[],{"intervention":729,"totalTrials":386,"cells":7518},{"EARLY_PHASE1":7519,"PHASE1":7521,"PHASE2":7523,"PHASE3":7529,"PHASE4":7531,"NA":7533},{"trials":7520,"activeCount":98},[],{"trials":7522,"activeCount":98},[],{"trials":7524,"activeCount":98},[7525],{"nctId":719,"briefTitle":720,"status":721,"phases":7526,"primaryCompletion":249,"completion":723,"start":724,"enrollment":725,"conditions":7527,"interventions":7528},[87],[25],[83,443,133,728,729,730,731,732,139,733],{"trials":7530,"activeCount":98},[],{"trials":7532,"activeCount":98},[],{"trials":7534,"activeCount":98},[],{"intervention":730,"totalTrials":386,"cells":7536},{"EARLY_PHASE1":7537,"PHASE1":7539,"PHASE2":7541,"PHASE3":7547,"PHASE4":7549,"NA":7551},{"trials":7538,"activeCount":98},[],{"trials":7540,"activeCount":98},[],{"trials":7542,"activeCount":98},[7543],{"nctId":719,"briefTitle":720,"status":721,"phases":7544,"primaryCompletion":249,"completion":723,"start":724,"enrollment":725,"conditions":7545,"interventions":7546},[87],[25],[83,443,133,728,729,730,731,732,139,733],{"trials":7548,"activeCount":98},[],{"trials":7550,"activeCount":98},[],{"trials":7552,"activeCount":98},[],{"intervention":731,"totalTrials":386,"cells":7554},{"EARLY_PHASE1":7555,"PHASE1":7557,"PHASE2":7559,"PHASE3":7565,"PHASE4":7567,"NA":7569},{"trials":7556,"activeCount":98},[],{"trials":7558,"activeCount":98},[],{"trials":7560,"activeCount":98},[7561],{"nctId":719,"briefTitle":720,"status":721,"phases":7562,"primaryCompletion":249,"completion":723,"start":724,"enrollment":725,"conditions":7563,"interventions":7564},[87],[25],[83,443,133,728,729,730,731,732,139,733],{"trials":7566,"activeCount":98},[],{"trials":7568,"activeCount":98},[],{"trials":7570,"activeCount":98},[],{"intervention":732,"totalTrials":386,"cells":7572},{"EARLY_PHASE1":7573,"PHASE1":7575,"PHASE2":7577,"PHASE3":7583,"PHASE4":7585,"NA":7587},{"trials":7574,"activeCount":98},[],{"trials":7576,"activeCount":98},[],{"trials":7578,"activeCount":98},[7579],{"nctId":719,"briefTitle":720,"status":721,"phases":7580,"primaryCompletion":249,"completion":723,"start":724,"enrollment":725,"conditions":7581,"interventions":7582},[87],[25],[83,443,133,728,729,730,731,732,139,733],{"trials":7584,"activeCount":98},[],{"trials":7586,"activeCount":98},[],{"trials":7588,"activeCount":98},[],{"intervention":733,"totalTrials":386,"cells":7590},{"EARLY_PHASE1":7591,"PHASE1":7593,"PHASE2":7595,"PHASE3":7601,"PHASE4":7603,"NA":7605},{"trials":7592,"activeCount":98},[],{"trials":7594,"activeCount":98},[],{"trials":7596,"activeCount":98},[7597],{"nctId":719,"briefTitle":720,"status":721,"phases":7598,"primaryCompletion":249,"completion":723,"start":724,"enrollment":725,"conditions":7599,"interventions":7600},[87],[25],[83,443,133,728,729,730,731,732,139,733],{"trials":7602,"activeCount":98},[],{"trials":7604,"activeCount":98},[],{"trials":7606,"activeCount":98},[],{"intervention":515,"totalTrials":386,"cells":7608},{"EARLY_PHASE1":7609,"PHASE1":7611,"PHASE2":7613,"PHASE3":7619,"PHASE4":7621,"NA":7623},{"trials":7610,"activeCount":98},[],{"trials":7612,"activeCount":98},[],{"trials":7614,"activeCount":98},[7615],{"nctId":506,"briefTitle":507,"status":490,"phases":7616,"primaryCompletion":509,"completion":509,"start":510,"enrollment":357,"conditions":7617,"interventions":7618},[87],[512,25,513],[199,228,225,133,136,138,515,516,113,137,132],{"trials":7620,"activeCount":98},[],{"trials":7622,"activeCount":98},[],{"trials":7624,"activeCount":98},[],{"intervention":516,"totalTrials":386,"cells":7626},{"EARLY_PHASE1":7627,"PHASE1":7629,"PHASE2":7631,"PHASE3":7637,"PHASE4":7639,"NA":7641},{"trials":7628,"activeCount":98},[],{"trials":7630,"activeCount":98},[],{"trials":7632,"activeCount":98},[7633],{"nctId":506,"briefTitle":507,"status":490,"phases":7634,"primaryCompletion":509,"completion":509,"start":510,"enrollment":357,"conditions":7635,"interventions":7636},[87],[512,25,513],[199,228,225,133,136,138,515,516,113,137,132],{"trials":7638,"activeCount":98},[],{"trials":7640,"activeCount":98},[],{"trials":7642,"activeCount":98},[],{"intervention":7644,"totalTrials":386,"cells":7645},"Memantine",{"EARLY_PHASE1":7646,"PHASE1":7648,"PHASE2":7650,"PHASE3":7661,"PHASE4":7663,"NA":7665},{"trials":7647,"activeCount":98},[],{"trials":7649,"activeCount":98},[],{"trials":7651,"activeCount":98},[7652],{"nctId":7653,"briefTitle":7654,"status":104,"phases":7655,"primaryCompletion":7656,"completion":7656,"start":7657,"enrollment":743,"conditions":7658,"interventions":7660},"NCT03194906","Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors",[87],"2023-06-28","2017-11-07",[7659,3206,2479,2261],"Glioma of Brain",[7644],{"trials":7662,"activeCount":98},[],{"trials":7664,"activeCount":98},[],{"trials":7666,"activeCount":98},[],{"intervention":750,"totalTrials":386,"cells":7668},{"EARLY_PHASE1":7669,"PHASE1":7671,"PHASE2":7673,"PHASE3":7679,"PHASE4":7681,"NA":7683},{"trials":7670,"activeCount":98},[],{"trials":7672,"activeCount":98},[],{"trials":7674,"activeCount":98},[7675],{"nctId":739,"briefTitle":740,"status":490,"phases":7676,"primaryCompletion":619,"completion":619,"start":742,"enrollment":743,"conditions":7677,"interventions":7678},[87],[14,564,565,745,566,746,747],[470,474,156,749,150,750,751,752,753],{"trials":7680,"activeCount":98},[],{"trials":7682,"activeCount":98},[],{"trials":7684,"activeCount":98},[],{"intervention":7686,"totalTrials":386,"cells":7687},"Ifosfamide, Carboplatin, Doxorubicin",{"EARLY_PHASE1":7688,"PHASE1":7690,"PHASE2":7692,"PHASE3":7702,"PHASE4":7704,"NA":7706},{"trials":7689,"activeCount":98},[],{"trials":7691,"activeCount":98},[],{"trials":7693,"activeCount":98},[7694],{"nctId":7695,"briefTitle":7696,"status":104,"phases":7697,"primaryCompletion":7698,"completion":7698,"start":7699,"enrollment":462,"conditions":7700,"interventions":7701},"NCT00145639","Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma",[87],"2006-05","1999-05",[526],[7686],{"trials":7703,"activeCount":98},[],{"trials":7705,"activeCount":98},[],{"trials":7707,"activeCount":98},[],{"intervention":1353,"totalTrials":386,"cells":7709},{"EARLY_PHASE1":7710,"PHASE1":7712,"PHASE2":7714,"PHASE3":7720,"PHASE4":7722,"NA":7724},{"trials":7711,"activeCount":98},[],{"trials":7713,"activeCount":98},[],{"trials":7715,"activeCount":98},[7716],{"nctId":1345,"briefTitle":1346,"status":104,"phases":7717,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":7718,"interventions":7719},[87],[369],[284,1353,153,150,468],{"trials":7721,"activeCount":98},[],{"trials":7723,"activeCount":98},[],{"trials":7725,"activeCount":98},[],{"intervention":866,"totalTrials":386,"cells":7727},{"EARLY_PHASE1":7728,"PHASE1":7730,"PHASE2":7732,"PHASE3":7738,"PHASE4":7740,"NA":7742},{"trials":7729,"activeCount":98},[],{"trials":7731,"activeCount":98},[],{"trials":7733,"activeCount":98},[7734],{"nctId":856,"briefTitle":857,"status":490,"phases":7735,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":7736,"interventions":7737},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"trials":7739,"activeCount":98},[],{"trials":7741,"activeCount":98},[],{"trials":7743,"activeCount":98},[],{"intervention":868,"totalTrials":386,"cells":7745},{"EARLY_PHASE1":7746,"PHASE1":7748,"PHASE2":7750,"PHASE3":7756,"PHASE4":7758,"NA":7760},{"trials":7747,"activeCount":98},[],{"trials":7749,"activeCount":98},[],{"trials":7751,"activeCount":98},[7752],{"nctId":856,"briefTitle":857,"status":490,"phases":7753,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":7754,"interventions":7755},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"trials":7757,"activeCount":98},[],{"trials":7759,"activeCount":98},[],{"trials":7761,"activeCount":98},[],{"intervention":869,"totalTrials":386,"cells":7763},{"EARLY_PHASE1":7764,"PHASE1":7766,"PHASE2":7768,"PHASE3":7774,"PHASE4":7776,"NA":7778},{"trials":7765,"activeCount":98},[],{"trials":7767,"activeCount":98},[],{"trials":7769,"activeCount":98},[7770],{"nctId":856,"briefTitle":857,"status":490,"phases":7771,"primaryCompletion":859,"completion":859,"start":860,"enrollment":539,"conditions":7772,"interventions":7773},[87],[14,862,863,864],[113,603,866,225,867,199,317,868,274,869,201,78,139,135],{"trials":7775,"activeCount":98},[],{"trials":7777,"activeCount":98},[],{"trials":7779,"activeCount":98},[],{"intervention":7781,"totalTrials":386,"cells":7782},"Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin",{"EARLY_PHASE1":7783,"PHASE1":7785,"PHASE2":7787,"PHASE3":7797,"PHASE4":7799,"NA":7801},{"trials":7784,"activeCount":98},[],{"trials":7786,"activeCount":98},[],{"trials":7788,"activeCount":98},[7789],{"nctId":7790,"briefTitle":7791,"status":104,"phases":7792,"completion":3724,"start":7793,"enrollment":2465,"conditions":7794,"interventions":7796},"NCT00187161","Treatment of Burkitt Lymphoma\u002FLeukemia and B Large Cell NHL",[87],"1994-11",[807,7795],"Acute Lymphoblastic Leukemia, Mature B-Cell",[7781],{"trials":7798,"activeCount":98},[],{"trials":7800,"activeCount":98},[],{"trials":7802,"activeCount":98},[],{"intervention":329,"totalTrials":386,"cells":7804},{"EARLY_PHASE1":7805,"PHASE1":7807,"PHASE2":7809,"PHASE3":7815,"PHASE4":7817,"NA":7819},{"trials":7806,"activeCount":98},[],{"trials":7808,"activeCount":98},[],{"trials":7810,"activeCount":98},[7811],{"nctId":319,"briefTitle":320,"status":104,"phases":7812,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":7813,"interventions":7814},[87],[327],[329,214,330,78,93,213,139,128,161],{"trials":7816,"activeCount":98},[],{"trials":7818,"activeCount":98},[],{"trials":7820,"activeCount":98},[],{"intervention":330,"totalTrials":386,"cells":7822},{"EARLY_PHASE1":7823,"PHASE1":7825,"PHASE2":7827,"PHASE3":7833,"PHASE4":7835,"NA":7837},{"trials":7824,"activeCount":98},[],{"trials":7826,"activeCount":98},[],{"trials":7828,"activeCount":98},[7829],{"nctId":319,"briefTitle":320,"status":104,"phases":7830,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":7831,"interventions":7832},[87],[327],[329,214,330,78,93,213,139,128,161],{"trials":7834,"activeCount":98},[],{"trials":7836,"activeCount":98},[],{"trials":7838,"activeCount":98},[],{"intervention":1394,"totalTrials":386,"cells":7840},{"EARLY_PHASE1":7841,"PHASE1":7843,"PHASE2":7845,"PHASE3":7851,"PHASE4":7853,"NA":7855},{"trials":7842,"activeCount":98},[],{"trials":7844,"activeCount":98},[],{"trials":7846,"activeCount":98},[7847],{"nctId":1380,"briefTitle":1381,"status":104,"phases":7848,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":7849,"interventions":7850},[87],[1388,1389,1390,1169,1391,28,1392,623],[429,1394,1395,1253,1396,1397,78,545,161,1398],{"trials":7852,"activeCount":98},[],{"trials":7854,"activeCount":98},[],{"trials":7856,"activeCount":98},[],{"intervention":1395,"totalTrials":386,"cells":7858},{"EARLY_PHASE1":7859,"PHASE1":7861,"PHASE2":7863,"PHASE3":7869,"PHASE4":7871,"NA":7873},{"trials":7860,"activeCount":98},[],{"trials":7862,"activeCount":98},[],{"trials":7864,"activeCount":98},[7865],{"nctId":1380,"briefTitle":1381,"status":104,"phases":7866,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":7867,"interventions":7868},[87],[1388,1389,1390,1169,1391,28,1392,623],[429,1394,1395,1253,1396,1397,78,545,161,1398],{"trials":7870,"activeCount":98},[],{"trials":7872,"activeCount":98},[],{"trials":7874,"activeCount":98},[],{"intervention":1396,"totalTrials":386,"cells":7876},{"EARLY_PHASE1":7877,"PHASE1":7879,"PHASE2":7881,"PHASE3":7887,"PHASE4":7889,"NA":7891},{"trials":7878,"activeCount":98},[],{"trials":7880,"activeCount":98},[],{"trials":7882,"activeCount":98},[7883],{"nctId":1380,"briefTitle":1381,"status":104,"phases":7884,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":7885,"interventions":7886},[87],[1388,1389,1390,1169,1391,28,1392,623],[429,1394,1395,1253,1396,1397,78,545,161,1398],{"trials":7888,"activeCount":98},[],{"trials":7890,"activeCount":98},[],{"trials":7892,"activeCount":98},[],{"intervention":1398,"totalTrials":386,"cells":7894},{"EARLY_PHASE1":7895,"PHASE1":7897,"PHASE2":7899,"PHASE3":7905,"PHASE4":7907,"NA":7909},{"trials":7896,"activeCount":98},[],{"trials":7898,"activeCount":98},[],{"trials":7900,"activeCount":98},[7901],{"nctId":1380,"briefTitle":1381,"status":104,"phases":7902,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":7903,"interventions":7904},[87],[1388,1389,1390,1169,1391,28,1392,623],[429,1394,1395,1253,1396,1397,78,545,161,1398],{"trials":7906,"activeCount":98},[],{"trials":7908,"activeCount":98},[],{"trials":7910,"activeCount":98},[],{"intervention":546,"totalTrials":386,"cells":7912},{"EARLY_PHASE1":7913,"PHASE1":7915,"PHASE2":7917,"PHASE3":7923,"PHASE4":7925,"NA":7927},{"trials":7914,"activeCount":98},[],{"trials":7916,"activeCount":98},[],{"trials":7918,"activeCount":98},[7919],{"nctId":534,"briefTitle":535,"status":490,"phases":7920,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":7921,"interventions":7922},[87],[541,542],[383,544,545,546,78,429,136,547,548,549],{"trials":7924,"activeCount":98},[],{"trials":7926,"activeCount":98},[],{"trials":7928,"activeCount":98},[],{"intervention":547,"totalTrials":386,"cells":7930},{"EARLY_PHASE1":7931,"PHASE1":7933,"PHASE2":7935,"PHASE3":7941,"PHASE4":7943,"NA":7945},{"trials":7932,"activeCount":98},[],{"trials":7934,"activeCount":98},[],{"trials":7936,"activeCount":98},[7937],{"nctId":534,"briefTitle":535,"status":490,"phases":7938,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":7939,"interventions":7940},[87],[541,542],[383,544,545,546,78,429,136,547,548,549],{"trials":7942,"activeCount":98},[],{"trials":7944,"activeCount":98},[],{"trials":7946,"activeCount":98},[],{"intervention":7948,"totalTrials":386,"cells":7949},"Intensive Antihypertensive Therapy",{"EARLY_PHASE1":7950,"PHASE1":7952,"PHASE2":7954,"PHASE3":7969,"PHASE4":7971,"NA":7973},{"trials":7951,"activeCount":98},[],{"trials":7953,"activeCount":98},[],{"trials":7955,"activeCount":98},[7956],{"nctId":7957,"briefTitle":7958,"status":104,"phases":7959,"primaryCompletion":7960,"completion":7961,"start":7962,"enrollment":962,"conditions":7963,"interventions":7967},"NCT04401267","Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia\u002FLymphoma",[87],"2023-09-25","2025-10-07","2020-10-15",[7964,7965,7966],"Hypertension","Osteonecrosis","Osteonecrosis Due to Drug",[7948,7968],"Conventional Antihypertensive Therapy",{"trials":7970,"activeCount":98},[],{"trials":7972,"activeCount":98},[],{"trials":7974,"activeCount":98},[],{"intervention":7968,"totalTrials":386,"cells":7976},{"EARLY_PHASE1":7977,"PHASE1":7979,"PHASE2":7981,"PHASE3":7987,"PHASE4":7989,"NA":7991},{"trials":7978,"activeCount":98},[],{"trials":7980,"activeCount":98},[],{"trials":7982,"activeCount":98},[7983],{"nctId":7957,"briefTitle":7958,"status":104,"phases":7984,"primaryCompletion":7960,"completion":7961,"start":7962,"enrollment":962,"conditions":7985,"interventions":7986},[87],[7964,7965,7966],[7948,7968],{"trials":7988,"activeCount":98},[],{"trials":7990,"activeCount":98},[],{"trials":7992,"activeCount":98},[],{"intervention":1417,"totalTrials":386,"cells":7994},{"EARLY_PHASE1":7995,"PHASE1":7997,"PHASE2":7999,"PHASE3":8005,"PHASE4":8007,"NA":8009},{"trials":7996,"activeCount":98},[],{"trials":7998,"activeCount":98},[],{"trials":8000,"activeCount":98},[8001],{"nctId":1408,"briefTitle":1409,"status":104,"phases":8002,"primaryCompletion":1411,"completion":1412,"start":1413,"enrollment":1414,"conditions":8003,"interventions":8004},[87],[1087,634],[429,78,549,639,1172,1417,161,544,1253],{"trials":8006,"activeCount":98},[],{"trials":8008,"activeCount":98},[],{"trials":8010,"activeCount":98},[],{"intervention":2922,"totalTrials":445,"cells":8012},{"EARLY_PHASE1":8013,"PHASE1":8015,"PHASE2":8031,"PHASE3":8033,"PHASE4":8035,"NA":8037},{"trials":8014,"activeCount":98},[],{"trials":8016,"activeCount":98},[8017,8027],{"nctId":8018,"briefTitle":8019,"status":104,"phases":8020,"primaryCompletion":6943,"completion":8021,"start":8022,"enrollment":8023,"conditions":8024,"interventions":8026},"NCT01393912","PDGFR Inhibitor Crenolanib in Children\u002FYoung Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma",[86],"2016-10","2011-07",55,[1701,8025],"Progressive or Refractory High-Grade Glioma",[2922],{"nctId":2915,"briefTitle":2916,"status":104,"phases":8028,"primaryCompletion":2918,"completion":2918,"start":2919,"enrollment":831,"conditions":8029,"interventions":8030},[86],[25],[2922,256,2923],{"trials":8032,"activeCount":98},[],{"trials":8034,"activeCount":98},[],{"trials":8036,"activeCount":98},[],{"trials":8038,"activeCount":98},[],{"intervention":3094,"totalTrials":445,"cells":8040},{"EARLY_PHASE1":8041,"PHASE1":8043,"PHASE2":8059,"PHASE3":8061,"PHASE4":8063,"NA":8065},{"trials":8042,"activeCount":98},[],{"trials":8044,"activeCount":98},[8045,8055],{"nctId":8046,"briefTitle":8047,"status":104,"phases":8048,"primaryCompletion":8049,"completion":8049,"start":8050,"enrollment":1320,"conditions":8051,"interventions":8054},"NCT00187174","Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors",[86],"2008-10","2004-10",[8052,5652,32,8053],"Tumors","Sarcoma, Soft Tissue",[3094],{"nctId":3085,"briefTitle":3086,"status":104,"phases":8056,"primaryCompletion":3088,"completion":3088,"start":3089,"enrollment":26,"conditions":8057,"interventions":8058},[86],[3091,3092],[255,3094],{"trials":8060,"activeCount":98},[],{"trials":8062,"activeCount":98},[],{"trials":8064,"activeCount":98},[],{"trials":8066,"activeCount":98},[],{"intervention":8068,"totalTrials":445,"cells":8069},"Chemotherapy",{"EARLY_PHASE1":8070,"PHASE1":8072,"PHASE2":8095,"PHASE3":8097,"PHASE4":8099,"NA":8101},{"trials":8071,"activeCount":98},[],{"trials":8073,"activeCount":98},[8074,8085],{"nctId":8075,"briefTitle":8076,"status":104,"phases":8077,"primaryCompletion":6097,"completion":6097,"start":8078,"enrollment":21,"conditions":8079,"interventions":8084},"NCT00640796","Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors",[86],"2008-09",[8080,8081,8082,8083,566],"Leukemia, Myeloid, Acute","Leukemia, Lymphocytic, Acute, T-Cell","Juvenile Myelomonocytic Leukemia Lymphoblastic","T-cell Lymphoblastic Lymphoma",[8068],{"nctId":8086,"briefTitle":8087,"status":104,"phases":8088,"primaryCompletion":1192,"completion":8089,"start":8090,"enrollment":743,"conditions":8091,"interventions":8092},"NCT01576692","Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma",[86],"2018-10-17","2012-04",[23],[8093,8068,8094],"Humanized anti-GD2 antibody","Natural killer cells",{"trials":8096,"activeCount":98},[],{"trials":8098,"activeCount":98},[],{"trials":8100,"activeCount":98},[],{"trials":8102,"activeCount":98},[],{"intervention":8104,"totalTrials":386,"cells":8105},"GDC-0084",{"EARLY_PHASE1":8106,"PHASE1":8108,"PHASE2":8119,"PHASE3":8121,"PHASE4":8123,"NA":8125},{"trials":8107,"activeCount":98},[],{"trials":8109,"activeCount":98},[8110],{"nctId":8111,"briefTitle":8112,"status":104,"phases":8113,"primaryCompletion":8114,"completion":8115,"start":8116,"enrollment":1441,"conditions":8117,"interventions":8118},"NCT03696355","Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas",[86],"2021-04-02","2022-09-04","2018-11-19",[369],[8104],{"trials":8120,"activeCount":98},[],{"trials":8122,"activeCount":98},[],{"trials":8124,"activeCount":98},[],{"trials":8126,"activeCount":98},[],{"intervention":8128,"totalTrials":386,"cells":8129},"PolyEnv1 vaccine",{"EARLY_PHASE1":8130,"PHASE1":8132,"PHASE2":8143,"PHASE3":8145,"PHASE4":8147,"NA":8149},{"trials":8131,"activeCount":98},[],{"trials":8133,"activeCount":98},[8134],{"nctId":8135,"briefTitle":8136,"status":104,"phases":8137,"primaryCompletion":8138,"completion":8138,"start":6848,"enrollment":412,"conditions":8139,"interventions":8142},"NCT00187044","Evaluation of the Safety of a Polyvalent Virus in Healthy Adults",[86],"2009-10",[8140,8141],"HIV Infection","Human Immunodeficiency Virus",[8128],{"trials":8144,"activeCount":98},[],{"trials":8146,"activeCount":98},[],{"trials":8148,"activeCount":98},[],{"trials":8150,"activeCount":98},[],{"intervention":8152,"totalTrials":386,"cells":8153},"Magnesium Pidolate, Hydroxyurea",{"EARLY_PHASE1":8154,"PHASE1":8156,"PHASE2":8165,"PHASE3":8167,"PHASE4":8169,"NA":8171},{"trials":8155,"activeCount":98},[],{"trials":8157,"activeCount":98},[8158],{"nctId":8159,"briefTitle":8160,"status":104,"phases":8161,"primaryCompletion":973,"completion":973,"start":8162,"enrollment":26,"conditions":8163,"interventions":8164},"NCT00143572","Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease",[86],"2004-11",[3754],[8152],{"trials":8166,"activeCount":98},[],{"trials":8168,"activeCount":98},[],{"trials":8170,"activeCount":98},[],{"trials":8172,"activeCount":98},[],{"intervention":8174,"totalTrials":386,"cells":8175},"Optison",{"EARLY_PHASE1":8176,"PHASE1":8178,"PHASE2":8190,"PHASE3":8192,"PHASE4":8194,"NA":8196},{"trials":8177,"activeCount":98},[],{"trials":8179,"activeCount":98},[8180],{"nctId":8181,"briefTitle":8182,"status":104,"phases":8183,"primaryCompletion":8184,"completion":8184,"start":8185,"enrollment":7342,"conditions":8186,"interventions":8189},"NCT00186953","Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors",[86],"2004-08","2002-06",[8187,8188],"Abdominal Neoplasms","Pelvic Neoplasms",[8174],{"trials":8191,"activeCount":98},[],{"trials":8193,"activeCount":98},[],{"trials":8195,"activeCount":98},[],{"trials":8197,"activeCount":98},[],{"intervention":8199,"totalTrials":386,"cells":8200},"vandetanib and dasatinib",{"EARLY_PHASE1":8201,"PHASE1":8203,"PHASE2":8212,"PHASE3":8214,"PHASE4":8216,"NA":8218},{"trials":8202,"activeCount":98},[],{"trials":8204,"activeCount":98},[8205],{"nctId":8206,"briefTitle":8207,"status":104,"phases":8208,"primaryCompletion":8090,"completion":8209,"start":8138,"enrollment":1214,"conditions":8210,"interventions":8211},"NCT00996723","Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)",[86],"2014-06",[1701],[8199],{"trials":8213,"activeCount":98},[],{"trials":8215,"activeCount":98},[],{"trials":8217,"activeCount":98},[],{"trials":8219,"activeCount":98},[],{"intervention":799,"totalTrials":386,"cells":8221},{"EARLY_PHASE1":8222,"PHASE1":8224,"PHASE2":8230,"PHASE3":8232,"PHASE4":8234,"NA":8236},{"trials":8223,"activeCount":98},[],{"trials":8225,"activeCount":98},[8226],{"nctId":790,"briefTitle":791,"status":490,"phases":8227,"primaryCompletion":793,"completion":793,"start":794,"enrollment":357,"conditions":8228,"interventions":8229},[86],[796,797],[799,614,113,199,198,132,383],{"trials":8231,"activeCount":98},[],{"trials":8233,"activeCount":98},[],{"trials":8235,"activeCount":98},[],{"trials":8237,"activeCount":98},[],{"intervention":2867,"totalTrials":386,"cells":8239},{"EARLY_PHASE1":8240,"PHASE1":8242,"PHASE2":8248,"PHASE3":8250,"PHASE4":8252,"NA":8254},{"trials":8241,"activeCount":98},[],{"trials":8243,"activeCount":98},[8244],{"nctId":2860,"briefTitle":2861,"status":104,"phases":8245,"primaryCompletion":2863,"completion":2863,"start":2864,"enrollment":632,"conditions":8246,"interventions":8247},[86],[282],[354,2867],{"trials":8249,"activeCount":98},[],{"trials":8251,"activeCount":98},[],{"trials":8253,"activeCount":98},[],{"trials":8255,"activeCount":98},[],{"intervention":8257,"totalTrials":386,"cells":8258},"Palifermin",{"EARLY_PHASE1":8259,"PHASE1":8261,"PHASE2":8272,"PHASE3":8274,"PHASE4":8276,"NA":8278},{"trials":8260,"activeCount":98},[],{"trials":8262,"activeCount":98},[8263],{"nctId":8264,"briefTitle":8265,"status":104,"phases":8266,"primaryCompletion":5921,"completion":561,"start":8267,"enrollment":9,"conditions":8268,"interventions":8271},"NCT00701688","Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation",[86],"2007-09",[8269,8270],"Oral Mucositis","Hematopoietic Stem Cell Transplantation",[8257],{"trials":8273,"activeCount":98},[],{"trials":8275,"activeCount":98},[],{"trials":8277,"activeCount":98},[],{"trials":8279,"activeCount":98},[],{"intervention":1036,"totalTrials":386,"cells":8281},{"EARLY_PHASE1":8282,"PHASE1":8284,"PHASE2":8290,"PHASE3":8292,"PHASE4":8294,"NA":8296},{"trials":8283,"activeCount":98},[],{"trials":8285,"activeCount":98},[8286],{"nctId":1015,"briefTitle":1016,"status":104,"phases":8287,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":1021,"conditions":8288,"interventions":8289},[86],[1023,1024,1025,1026,297,1027,1028,1029,1030,1031,1032,1033,1034],[1036,78,302,284,1037],{"trials":8291,"activeCount":98},[],{"trials":8293,"activeCount":98},[],{"trials":8295,"activeCount":98},[],{"trials":8297,"activeCount":98},[],{"intervention":1049,"totalTrials":386,"cells":8299},{"EARLY_PHASE1":8300,"PHASE1":8302,"PHASE2":8308,"PHASE3":8310,"PHASE4":8312,"NA":8314},{"trials":8301,"activeCount":98},[],{"trials":8303,"activeCount":98},[8304],{"nctId":1039,"briefTitle":1040,"status":104,"phases":8305,"primaryCompletion":1042,"completion":1043,"start":1044,"enrollment":1045,"conditions":8306,"interventions":8307},[86],[1047],[78,1049,548],{"trials":8309,"activeCount":98},[],{"trials":8311,"activeCount":98},[],{"trials":8313,"activeCount":98},[],{"trials":8315,"activeCount":98},[],{"intervention":8317,"totalTrials":386,"cells":8318},"Filgrastim, Alemtuzumab",{"EARLY_PHASE1":8319,"PHASE1":8321,"PHASE2":8331,"PHASE3":8333,"PHASE4":8335,"NA":8337},{"trials":8320,"activeCount":98},[],{"trials":8322,"activeCount":98},[8323],{"nctId":8324,"briefTitle":8325,"status":104,"phases":8326,"primaryCompletion":8327,"completion":8327,"start":8328,"enrollment":108,"conditions":8329,"interventions":8330},"NCT00152100","Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome",[86],"2007-08","2004-02",[2286],[8317],{"trials":8332,"activeCount":98},[],{"trials":8334,"activeCount":98},[],{"trials":8336,"activeCount":98},[],{"trials":8338,"activeCount":98},[],{"intervention":8340,"totalTrials":386,"cells":8341},"Vitamin A supplementation",{"EARLY_PHASE1":8342,"PHASE1":8344,"PHASE2":8355,"PHASE3":8357,"PHASE4":8359,"NA":8361},{"trials":8343,"activeCount":98},[],{"trials":8345,"activeCount":98},[8346],{"nctId":8347,"briefTitle":8348,"status":490,"phases":8349,"primaryCompletion":8350,"completion":8350,"start":8351,"enrollment":21,"conditions":8352,"interventions":8353},"NCT03859687","Trial of Antibody Responses by Vitamin Supplementation",[86],"2025-07-10","2019-08-19",[6649],[8340,8354],"No vitamin A supplementation",{"trials":8356,"activeCount":98},[],{"trials":8358,"activeCount":98},[],{"trials":8360,"activeCount":98},[],{"trials":8362,"activeCount":98},[],{"intervention":8354,"totalTrials":386,"cells":8364},{"EARLY_PHASE1":8365,"PHASE1":8367,"PHASE2":8373,"PHASE3":8375,"PHASE4":8377,"NA":8379},{"trials":8366,"activeCount":98},[],{"trials":8368,"activeCount":98},[8369],{"nctId":8347,"briefTitle":8348,"status":490,"phases":8370,"primaryCompletion":8350,"completion":8350,"start":8351,"enrollment":21,"conditions":8371,"interventions":8372},[86],[6649],[8340,8354],{"trials":8374,"activeCount":98},[],{"trials":8376,"activeCount":98},[],{"trials":8378,"activeCount":98},[],{"trials":8380,"activeCount":98},[],{"intervention":8382,"totalTrials":386,"cells":8383},"Marrow stromal cell",{"EARLY_PHASE1":8384,"PHASE1":8386,"PHASE2":8397,"PHASE3":8399,"PHASE4":8401,"NA":8403},{"trials":8385,"activeCount":98},[],{"trials":8387,"activeCount":98},[8388],{"nctId":8389,"briefTitle":8390,"status":104,"phases":8391,"primaryCompletion":8392,"completion":973,"start":8393,"enrollment":632,"conditions":8394,"interventions":8396},"NCT00186914","Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation",[86],"2001-11","1999-07",[8395],"Osteodysplasia",[8382],{"trials":8398,"activeCount":98},[],{"trials":8400,"activeCount":98},[],{"trials":8402,"activeCount":98},[],{"trials":8404,"activeCount":98},[],{"intervention":8406,"totalTrials":386,"cells":8407},"EnvDNA, PolyEnv1, EnvPro",{"EARLY_PHASE1":8408,"PHASE1":8410,"PHASE2":8420,"PHASE3":8422,"PHASE4":8424,"NA":8426},{"trials":8409,"activeCount":98},[],{"trials":8411,"activeCount":98},[8412],{"nctId":8413,"briefTitle":8414,"status":490,"phases":8415,"primaryCompletion":973,"completion":973,"start":8416,"enrollment":539,"conditions":8417,"interventions":8419},"NCT00623753","Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults",[86],"2007-05",[8418],"HIV Infections",[8406],{"trials":8421,"activeCount":98},[],{"trials":8423,"activeCount":98},[],{"trials":8425,"activeCount":98},[],{"trials":8427,"activeCount":98},[],{"intervention":8429,"totalTrials":386,"cells":8430},"gene-modified tumor cell vaccine therapy",{"EARLY_PHASE1":8431,"PHASE1":8433,"PHASE2":8443,"PHASE3":8445,"PHASE4":8447,"NA":8449},{"trials":8432,"activeCount":98},[],{"trials":8434,"activeCount":98},[8435],{"nctId":8436,"briefTitle":8437,"status":104,"phases":8438,"primaryCompletion":8327,"completion":8327,"start":8439,"enrollment":15,"conditions":8440,"interventions":8441},"NCT00002748","Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma",[86],"1991-12",[23],[8429,8442],"interleukin-2 gene",{"trials":8444,"activeCount":98},[],{"trials":8446,"activeCount":98},[],{"trials":8448,"activeCount":98},[],{"trials":8450,"activeCount":98},[],{"intervention":8442,"totalTrials":386,"cells":8452},{"EARLY_PHASE1":8453,"PHASE1":8455,"PHASE2":8461,"PHASE3":8463,"PHASE4":8465,"NA":8467},{"trials":8454,"activeCount":98},[],{"trials":8456,"activeCount":98},[8457],{"nctId":8436,"briefTitle":8437,"status":104,"phases":8458,"primaryCompletion":8327,"completion":8327,"start":8439,"enrollment":15,"conditions":8459,"interventions":8460},[86],[23],[8429,8442],{"trials":8462,"activeCount":98},[],{"trials":8464,"activeCount":98},[],{"trials":8466,"activeCount":98},[],{"trials":8468,"activeCount":98},[],{"intervention":8470,"totalTrials":386,"cells":8471},"EnvDNA",{"EARLY_PHASE1":8472,"PHASE1":8474,"PHASE2":8484,"PHASE3":8486,"PHASE4":8488,"NA":8490},{"trials":8473,"activeCount":98},[],{"trials":8475,"activeCount":98},[8476],{"nctId":8477,"briefTitle":8478,"status":104,"phases":8479,"primaryCompletion":8480,"completion":8480,"start":8481,"enrollment":554,"conditions":8482,"interventions":8483},"NCT00187148","Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults",[86],"2009-11","2005-02",[8141,8418],[8470],{"trials":8485,"activeCount":98},[],{"trials":8487,"activeCount":98},[],{"trials":8489,"activeCount":98},[],{"trials":8491,"activeCount":98},[],{"intervention":8493,"totalTrials":386,"cells":8494},"Irinotecan, Cefpodoxime",{"EARLY_PHASE1":8495,"PHASE1":8497,"PHASE2":8509,"PHASE3":8511,"PHASE4":8513,"NA":8515},{"trials":8496,"activeCount":98},[],{"trials":8498,"activeCount":98},[8499],{"nctId":8500,"briefTitle":8501,"status":104,"phases":8502,"primaryCompletion":562,"completion":8503,"start":8504,"enrollment":94,"conditions":8505,"interventions":8508},"NCT00143533","Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors",[86],"2011-06","2003-09",[8506,8507],"Neoplasm","Diarrhea",[8493],{"trials":8510,"activeCount":98},[],{"trials":8512,"activeCount":98},[],{"trials":8514,"activeCount":98},[],{"trials":8516,"activeCount":98},[],{"intervention":2923,"totalTrials":386,"cells":8518},{"EARLY_PHASE1":8519,"PHASE1":8521,"PHASE2":8527,"PHASE3":8529,"PHASE4":8531,"NA":8533},{"trials":8520,"activeCount":98},[],{"trials":8522,"activeCount":98},[8523],{"nctId":2915,"briefTitle":2916,"status":104,"phases":8524,"primaryCompletion":2918,"completion":2918,"start":2919,"enrollment":831,"conditions":8525,"interventions":8526},[86],[25],[2922,256,2923],{"trials":8528,"activeCount":98},[],{"trials":8530,"activeCount":98},[],{"trials":8532,"activeCount":98},[],{"trials":8534,"activeCount":98},[],{"intervention":1077,"totalTrials":386,"cells":8536},{"EARLY_PHASE1":8537,"PHASE1":8539,"PHASE2":8545,"PHASE3":8547,"PHASE4":8549,"NA":8551},{"trials":8538,"activeCount":98},[],{"trials":8540,"activeCount":98},[8541],{"nctId":1066,"briefTitle":1067,"status":104,"phases":8542,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":8543,"interventions":8544},[86],[14,1074,745,566,1075],[1077,1078,135,78,139],{"trials":8546,"activeCount":98},[],{"trials":8548,"activeCount":98},[],{"trials":8550,"activeCount":98},[],{"trials":8552,"activeCount":98},[],{"intervention":1704,"totalTrials":386,"cells":8554},{"EARLY_PHASE1":8555,"PHASE1":8557,"PHASE2":8563,"PHASE3":8565,"PHASE4":8567,"NA":8569},{"trials":8556,"activeCount":98},[],{"trials":8558,"activeCount":98},[8559],{"nctId":1693,"briefTitle":1694,"status":104,"phases":8560,"primaryCompletion":1696,"completion":1697,"start":1698,"enrollment":1699,"conditions":8561,"interventions":8562},[86],[1701,1702],[1704,198],{"trials":8564,"activeCount":98},[],{"trials":8566,"activeCount":98},[],{"trials":8568,"activeCount":98},[],{"trials":8570,"activeCount":98},[],{"intervention":8572,"totalTrials":386,"cells":8573},"Sendai virus vaccine",{"EARLY_PHASE1":8574,"PHASE1":8576,"PHASE2":8587,"PHASE3":8589,"PHASE4":8591,"NA":8593},{"trials":8575,"activeCount":98},[],{"trials":8577,"activeCount":98},[8578],{"nctId":8579,"briefTitle":8580,"status":721,"phases":8581,"primaryCompletion":4200,"completion":278,"start":8582,"enrollment":2783,"conditions":8583,"interventions":8586},"NCT00186927","A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers",[86],"2005-05-05",[8584,8585],"Parainfluenza","Respiratory Viral Infections",[8572],{"trials":8588,"activeCount":98},[],{"trials":8590,"activeCount":98},[],{"trials":8592,"activeCount":98},[],{"trials":8594,"activeCount":98},[],{"intervention":8596,"totalTrials":386,"cells":8597},"See intervention description",{"EARLY_PHASE1":8598,"PHASE1":8600,"PHASE2":8609,"PHASE3":8611,"PHASE4":8613,"NA":8615},{"trials":8599,"activeCount":98},[],{"trials":8601,"activeCount":98},[8602],{"nctId":8603,"briefTitle":8604,"status":104,"phases":8605,"primaryCompletion":1227,"completion":106,"start":8606,"enrollment":494,"conditions":8607,"interventions":8608},"NCT00152113","Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound",[86],"2005-04",[17],[8596],{"trials":8610,"activeCount":98},[],{"trials":8612,"activeCount":98},[],{"trials":8614,"activeCount":98},[],{"trials":8616,"activeCount":98},[],{"intervention":8618,"totalTrials":386,"cells":8619},"Anti-GD2 antibody",{"EARLY_PHASE1":8620,"PHASE1":8622,"PHASE2":8633,"PHASE3":8635,"PHASE4":8637,"NA":8639},{"trials":8621,"activeCount":98},[],{"trials":8623,"activeCount":98},[8624],{"nctId":8625,"briefTitle":8626,"status":104,"phases":8627,"primaryCompletion":8628,"completion":8629,"start":8630,"enrollment":222,"conditions":8631,"interventions":8632},"NCT00743496","A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma",[86],"2014-04-01","2014-04-18","2008-10-08",[23,1119,526,1062],[8618],{"trials":8634,"activeCount":98},[],{"trials":8636,"activeCount":98},[],{"trials":8638,"activeCount":98},[],{"trials":8640,"activeCount":98},[],{"intervention":637,"totalTrials":386,"cells":8642},{"EARLY_PHASE1":8643,"PHASE1":8645,"PHASE2":8651,"PHASE3":8653,"PHASE4":8655,"NA":8657},{"trials":8644,"activeCount":98},[],{"trials":8646,"activeCount":98},[8647],{"nctId":627,"briefTitle":628,"status":104,"phases":8648,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":8649,"interventions":8650},[86],[23,634,635],[637,638,152,548,639,160,640,139,133,354,161,641],{"trials":8652,"activeCount":98},[],{"trials":8654,"activeCount":98},[],{"trials":8656,"activeCount":98},[],{"trials":8658,"activeCount":98},[],{"intervention":638,"totalTrials":386,"cells":8660},{"EARLY_PHASE1":8661,"PHASE1":8663,"PHASE2":8669,"PHASE3":8671,"PHASE4":8673,"NA":8675},{"trials":8662,"activeCount":98},[],{"trials":8664,"activeCount":98},[8665],{"nctId":627,"briefTitle":628,"status":104,"phases":8666,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":8667,"interventions":8668},[86],[23,634,635],[637,638,152,548,639,160,640,139,133,354,161,641],{"trials":8670,"activeCount":98},[],{"trials":8672,"activeCount":98},[],{"trials":8674,"activeCount":98},[],{"trials":8676,"activeCount":98},[],{"intervention":8678,"totalTrials":386,"cells":8679},"Fludarabine, Melphalan, Thiotepa",{"EARLY_PHASE1":8680,"PHASE1":8682,"PHASE2":8693,"PHASE3":8695,"PHASE4":8697,"NA":8699},{"trials":8681,"activeCount":98},[],{"trials":8683,"activeCount":98},[8684],{"nctId":8685,"briefTitle":8686,"status":104,"phases":8687,"primaryCompletion":3089,"completion":8688,"start":8689,"enrollment":108,"conditions":8690,"interventions":8692},"NCT00160355","Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome",[86],"2009-02","2005-05",[8691],"Wiskott-Aldrich Syndrome",[8678],{"trials":8694,"activeCount":98},[],{"trials":8696,"activeCount":98},[],{"trials":8698,"activeCount":98},[],{"trials":8700,"activeCount":98},[],{"intervention":8702,"totalTrials":386,"cells":8703},"oxaliplatin",{"EARLY_PHASE1":8704,"PHASE1":8706,"PHASE2":8714,"PHASE3":8716,"PHASE4":8718,"NA":8720},{"trials":8705,"activeCount":98},[],{"trials":8707,"activeCount":98},[8708],{"nctId":8709,"briefTitle":8710,"status":104,"phases":8711,"primaryCompletion":8267,"completion":8267,"start":6368,"enrollment":2203,"conditions":8712,"interventions":8713},"NCT00005844","Oxaliplatin in Treating Children With Advanced Solid Tumors",[86],[4087],[8702],{"trials":8715,"activeCount":98},[],{"trials":8717,"activeCount":98},[],{"trials":8719,"activeCount":98},[],{"trials":8721,"activeCount":98},[],{"intervention":8723,"totalTrials":386,"cells":8724},"FluMist",{"EARLY_PHASE1":8725,"PHASE1":8727,"PHASE2":8737,"PHASE3":8739,"PHASE4":8741,"NA":8743},{"trials":8726,"activeCount":98},[],{"trials":8728,"activeCount":98},[8729],{"nctId":8730,"briefTitle":8731,"status":104,"phases":8732,"primaryCompletion":8022,"completion":8022,"start":8049,"enrollment":8733,"conditions":8734,"interventions":8735},"NCT00906750","A Study of a Live Intranasal Influenza Vaccine in Children With Cancer",[86],56,[20],[8723,8736],"Inactivated influenza vaccine",{"trials":8738,"activeCount":98},[],{"trials":8740,"activeCount":98},[],{"trials":8742,"activeCount":98},[],{"trials":8744,"activeCount":98},[],{"intervention":8736,"totalTrials":386,"cells":8746},{"EARLY_PHASE1":8747,"PHASE1":8749,"PHASE2":8755,"PHASE3":8757,"PHASE4":8759,"NA":8761},{"trials":8748,"activeCount":98},[],{"trials":8750,"activeCount":98},[8751],{"nctId":8730,"briefTitle":8731,"status":104,"phases":8752,"primaryCompletion":8022,"completion":8022,"start":8049,"enrollment":8733,"conditions":8753,"interventions":8754},[86],[20],[8723,8736],{"trials":8756,"activeCount":98},[],{"trials":8758,"activeCount":98},[],{"trials":8760,"activeCount":98},[],{"trials":8762,"activeCount":98},[],{"intervention":8764,"totalTrials":386,"cells":8765},"Gene Transfer",{"EARLY_PHASE1":8766,"PHASE1":8768,"PHASE2":8780,"PHASE3":8782,"PHASE4":8784,"NA":8786},{"trials":8767,"activeCount":98},[],{"trials":8769,"activeCount":98},[8770],{"nctId":8771,"briefTitle":8772,"status":104,"phases":8773,"primaryCompletion":8774,"completion":8774,"start":8775,"enrollment":7342,"conditions":8776,"interventions":8778},"NCT00979238","Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B",[86],"2026-03-26","2010-02-22",[8777],"Hemophilia B",[8764,8779],"scAAV2\u002F8-LP1-hFIXco",{"trials":8781,"activeCount":98},[],{"trials":8783,"activeCount":98},[],{"trials":8785,"activeCount":98},[],{"trials":8787,"activeCount":98},[],{"intervention":8779,"totalTrials":386,"cells":8789},{"EARLY_PHASE1":8790,"PHASE1":8792,"PHASE2":8798,"PHASE3":8800,"PHASE4":8802,"NA":8804},{"trials":8791,"activeCount":98},[],{"trials":8793,"activeCount":98},[8794],{"nctId":8771,"briefTitle":8772,"status":104,"phases":8795,"primaryCompletion":8774,"completion":8774,"start":8775,"enrollment":7342,"conditions":8796,"interventions":8797},[86],[8777],[8764,8779],{"trials":8799,"activeCount":98},[],{"trials":8801,"activeCount":98},[],{"trials":8803,"activeCount":98},[],{"trials":8805,"activeCount":98},[],{"intervention":8807,"totalTrials":386,"cells":8808},"Erwinase",{"EARLY_PHASE1":8809,"PHASE1":8811,"PHASE2":8822,"PHASE3":8824,"PHASE4":8826,"NA":8828},{"trials":8810,"activeCount":98},[],{"trials":8812,"activeCount":98},[8813],{"nctId":8814,"briefTitle":8815,"status":104,"phases":8816,"primaryCompletion":8817,"completion":8817,"start":8818,"enrollment":6647,"conditions":8819,"interventions":8821},"NCT00693602","Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma",[86],"2011-12","2006-06",[14,8820],"Non Hodgkins Lymphoma",[8807],{"trials":8823,"activeCount":98},[],{"trials":8825,"activeCount":98},[],{"trials":8827,"activeCount":98},[],{"trials":8829,"activeCount":98},[],{"intervention":2519,"totalTrials":386,"cells":8831},{"EARLY_PHASE1":8832,"PHASE1":8834,"PHASE2":8840,"PHASE3":8842,"PHASE4":8844,"NA":8846},{"trials":8833,"activeCount":98},[],{"trials":8835,"activeCount":98},[8836],{"nctId":2459,"briefTitle":2460,"status":104,"phases":8837,"primaryCompletion":2462,"completion":2463,"start":2464,"enrollment":2465,"conditions":8838,"interventions":8839},[86],[2467,2468,2469,2470,2471,2472,2473,1031,1023,2474,2475,2476,2477,1033,2478,2479,2480,2481,2482,297,2483,2484,2485,2486,2487,2488,2489,2490,2491,2492,2493,2494,2495,2496,2497,2498,2499,2500,2501,2502,2503,2504,2505,1028,2506,2507,2508,2509,2510,2511,2512,2513,2514,2515,2516,2517],[302,2519,2520,2521,284],{"trials":8841,"activeCount":98},[],{"trials":8843,"activeCount":98},[],{"trials":8845,"activeCount":98},[],{"trials":8847,"activeCount":98},[],{"intervention":2520,"totalTrials":386,"cells":8849},{"EARLY_PHASE1":8850,"PHASE1":8852,"PHASE2":8858,"PHASE3":8860,"PHASE4":8862,"NA":8864},{"trials":8851,"activeCount":98},[],{"trials":8853,"activeCount":98},[8854],{"nctId":2459,"briefTitle":2460,"status":104,"phases":8855,"primaryCompletion":2462,"completion":2463,"start":2464,"enrollment":2465,"conditions":8856,"interventions":8857},[86],[2467,2468,2469,2470,2471,2472,2473,1031,1023,2474,2475,2476,2477,1033,2478,2479,2480,2481,2482,297,2483,2484,2485,2486,2487,2488,2489,2490,2491,2492,2493,2494,2495,2496,2497,2498,2499,2500,2501,2502,2503,2504,2505,1028,2506,2507,2508,2509,2510,2511,2512,2513,2514,2515,2516,2517],[302,2519,2520,2521,284],{"trials":8859,"activeCount":98},[],{"trials":8861,"activeCount":98},[],{"trials":8863,"activeCount":98},[],{"trials":8865,"activeCount":98},[],{"intervention":2521,"totalTrials":386,"cells":8867},{"EARLY_PHASE1":8868,"PHASE1":8870,"PHASE2":8876,"PHASE3":8878,"PHASE4":8880,"NA":8882},{"trials":8869,"activeCount":98},[],{"trials":8871,"activeCount":98},[8872],{"nctId":2459,"briefTitle":2460,"status":104,"phases":8873,"primaryCompletion":2462,"completion":2463,"start":2464,"enrollment":2465,"conditions":8874,"interventions":8875},[86],[2467,2468,2469,2470,2471,2472,2473,1031,1023,2474,2475,2476,2477,1033,2478,2479,2480,2481,2482,297,2483,2484,2485,2486,2487,2488,2489,2490,2491,2492,2493,2494,2495,2496,2497,2498,2499,2500,2501,2502,2503,2504,2505,1028,2506,2507,2508,2509,2510,2511,2512,2513,2514,2515,2516,2517],[302,2519,2520,2521,284],{"trials":8877,"activeCount":98},[],{"trials":8879,"activeCount":98},[],{"trials":8881,"activeCount":98},[],{"trials":8883,"activeCount":98},[],{"intervention":3395,"totalTrials":386,"cells":8885},{"EARLY_PHASE1":8886,"PHASE1":8888,"PHASE2":8894,"PHASE3":8896,"PHASE4":8898,"NA":8900},{"trials":8887,"activeCount":98},[],{"trials":8889,"activeCount":98},[8890],{"nctId":3385,"briefTitle":3386,"status":3387,"phases":8891,"primaryCompletion":3389,"completion":3390,"start":3391,"enrollment":98,"conditions":8892,"interventions":8893},[86],[1116,2473,3393,1033],[3395,3395,428],{"trials":8895,"activeCount":98},[],{"trials":8897,"activeCount":98},[],{"trials":8899,"activeCount":98},[],{"trials":8901,"activeCount":98},[],{"intervention":8903,"totalTrials":386,"cells":8904},"Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.",{"EARLY_PHASE1":8905,"PHASE1":8907,"PHASE2":8917,"PHASE3":8919,"PHASE4":8921,"NA":8923},{"trials":8906,"activeCount":98},[],{"trials":8908,"activeCount":98},[8909],{"nctId":8910,"briefTitle":8911,"status":104,"phases":8912,"primaryCompletion":5648,"completion":5648,"start":8913,"enrollment":743,"conditions":8914,"interventions":8916},"NCT00186979","Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors",[86],"2003-05",[8915],"Solid Tumors",[8903],{"trials":8918,"activeCount":98},[],{"trials":8920,"activeCount":98},[],{"trials":8922,"activeCount":98},[],{"trials":8924,"activeCount":98},[],{"intervention":8926,"totalTrials":386,"cells":8927},"5-fluorouracil",{"EARLY_PHASE1":8928,"PHASE1":8930,"PHASE2":8940,"PHASE3":8942,"PHASE4":8944,"NA":8946},{"trials":8929,"activeCount":98},[],{"trials":8931,"activeCount":98},[8932],{"nctId":8933,"briefTitle":8934,"status":104,"phases":8935,"primaryCompletion":8936,"completion":8936,"start":8817,"enrollment":2203,"conditions":8937,"interventions":8939},"NCT01498783","Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma",[86],"2014-05",[8938,2479],"Central Nervous System Malignancies",[8926],{"trials":8941,"activeCount":98},[],{"trials":8943,"activeCount":98},[],{"trials":8945,"activeCount":98},[],{"trials":8947,"activeCount":98},[],{"intervention":8949,"totalTrials":386,"cells":8950},"vandetanib",{"EARLY_PHASE1":8951,"PHASE1":8953,"PHASE2":8962,"PHASE3":8964,"PHASE4":8966,"NA":8968},{"trials":8952,"activeCount":98},[],{"trials":8954,"activeCount":98},[8955],{"nctId":8956,"briefTitle":8957,"status":104,"phases":8958,"primaryCompletion":3338,"completion":3338,"start":8959,"enrollment":18,"conditions":8960,"interventions":8961},"NCT00472017","Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma",[86],"2007-04",[369],[8949],{"trials":8963,"activeCount":98},[],{"trials":8965,"activeCount":98},[],{"trials":8967,"activeCount":98},[],{"trials":8969,"activeCount":98},[],{"intervention":8093,"totalTrials":386,"cells":8971},{"EARLY_PHASE1":8972,"PHASE1":8974,"PHASE2":8980,"PHASE3":8982,"PHASE4":8984,"NA":8986},{"trials":8973,"activeCount":98},[],{"trials":8975,"activeCount":98},[8976],{"nctId":8086,"briefTitle":8087,"status":104,"phases":8977,"primaryCompletion":1192,"completion":8089,"start":8090,"enrollment":743,"conditions":8978,"interventions":8979},[86],[23],[8093,8068,8094],{"trials":8981,"activeCount":98},[],{"trials":8983,"activeCount":98},[],{"trials":8985,"activeCount":98},[],{"trials":8987,"activeCount":98},[],{"intervention":8094,"totalTrials":386,"cells":8989},{"EARLY_PHASE1":8990,"PHASE1":8992,"PHASE2":8998,"PHASE3":9000,"PHASE4":9002,"NA":9004},{"trials":8991,"activeCount":98},[],{"trials":8993,"activeCount":98},[8994],{"nctId":8086,"briefTitle":8087,"status":104,"phases":8995,"primaryCompletion":1192,"completion":8089,"start":8090,"enrollment":743,"conditions":8996,"interventions":8997},[86],[23],[8093,8068,8094],{"trials":8999,"activeCount":98},[],{"trials":9001,"activeCount":98},[],{"trials":9003,"activeCount":98},[],{"trials":9005,"activeCount":98},[],{"intervention":9007,"totalTrials":386,"cells":9008},"NK Cell",{"EARLY_PHASE1":9009,"PHASE1":9011,"PHASE2":9019,"PHASE3":9021,"PHASE4":9023,"NA":9025},{"trials":9010,"activeCount":98},[],{"trials":9012,"activeCount":98},[9013],{"nctId":9014,"briefTitle":9015,"status":104,"phases":9016,"primaryCompletion":1070,"completion":8936,"start":8138,"enrollment":7342,"conditions":9017,"interventions":9018},"NCT00995137","Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia",[86],[6101],[9007],{"trials":9020,"activeCount":98},[],{"trials":9022,"activeCount":98},[],{"trials":9024,"activeCount":98},[],{"trials":9026,"activeCount":98},[],{"intervention":9028,"totalTrials":386,"cells":9029},"SJ733",{"EARLY_PHASE1":9030,"PHASE1":9032,"PHASE2":9044,"PHASE3":9046,"PHASE4":9048,"NA":9050},{"trials":9031,"activeCount":98},[],{"trials":9033,"activeCount":98},[9034],{"nctId":9035,"briefTitle":9036,"status":104,"phases":9037,"primaryCompletion":9038,"completion":9038,"start":9039,"enrollment":647,"conditions":9040,"interventions":9042},"NCT02661373","First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor",[86],"2018-03-09","2016-03-01",[9041],"Malaria",[9028,9043],"Cobicistat",{"trials":9045,"activeCount":98},[],{"trials":9047,"activeCount":98},[],{"trials":9049,"activeCount":98},[],{"trials":9051,"activeCount":98},[],{"intervention":9043,"totalTrials":386,"cells":9053},{"EARLY_PHASE1":9054,"PHASE1":9056,"PHASE2":9062,"PHASE3":9064,"PHASE4":9066,"NA":9068},{"trials":9055,"activeCount":98},[],{"trials":9057,"activeCount":98},[9058],{"nctId":9035,"briefTitle":9036,"status":104,"phases":9059,"primaryCompletion":9038,"completion":9038,"start":9039,"enrollment":647,"conditions":9060,"interventions":9061},[86],[9041],[9028,9043],{"trials":9063,"activeCount":98},[],{"trials":9065,"activeCount":98},[],{"trials":9067,"activeCount":98},[],{"trials":9069,"activeCount":98},[],{"intervention":9071,"totalTrials":445,"cells":9072},"Systemic chemotherapy and antibodies",{"EARLY_PHASE1":9073,"PHASE1":9075,"PHASE2":9077,"PHASE3":9091,"PHASE4":9093,"NA":9095},{"trials":9074,"activeCount":98},[],{"trials":9076,"activeCount":98},[],{"trials":9078,"activeCount":98},[9079],{"nctId":9080,"briefTitle":9081,"status":104,"phases":9082,"primaryCompletion":7169,"completion":8688,"start":9083,"enrollment":1214,"conditions":9084,"interventions":9090},"NCT00145613","Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies",[87],"2003-06",[622,621,9085,623,9086,5213,1169,9087,9088,9089],"Secondary AML","Secondary MDS","Paroxysmal Nocturnal Hemoglobinuria (PNH)","Lymphoma, Non-Hodgkin","Hodgkin Disease",[9071],{"trials":9092,"activeCount":98},[],{"trials":9094,"activeCount":98},[],{"trials":9096,"activeCount":98},[9097],{"nctId":9098,"briefTitle":9099,"status":490,"phases":9100,"primaryCompletion":8688,"completion":8688,"start":9101,"enrollment":783,"conditions":9102,"interventions":9104},"NCT00145587","Stem Cell Transplantation for Children Affected With Osteopetrosis",[90],"2004-07",[9103],"Osteopetrosis",[9071],{"intervention":9106,"totalTrials":386,"cells":9107},"Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2",{"EARLY_PHASE1":9108,"PHASE1":9110,"PHASE2":9112,"PHASE3":9114,"PHASE4":9116,"NA":9118},{"trials":9109,"activeCount":98},[],{"trials":9111,"activeCount":98},[],{"trials":9113,"activeCount":98},[],{"trials":9115,"activeCount":98},[],{"trials":9117,"activeCount":98},[],{"trials":9119,"activeCount":98},[9120],{"nctId":9121,"briefTitle":9122,"status":104,"phases":9123,"primaryCompletion":561,"completion":9124,"start":1259,"enrollment":1084,"conditions":9125,"interventions":9126},"NCT00187096","Natural Killer (NK) Cell Transplantation for AML",[90],"2013-03",[25],[9106],{"intervention":9128,"totalTrials":386,"cells":9129},"Rasburicase",{"EARLY_PHASE1":9130,"PHASE1":9132,"PHASE2":9134,"PHASE3":9136,"PHASE4":9138,"NA":9140},{"trials":9131,"activeCount":98},[],{"trials":9133,"activeCount":98},[],{"trials":9135,"activeCount":98},[],{"trials":9137,"activeCount":98},[],{"trials":9139,"activeCount":98},[],{"trials":9141,"activeCount":98},[9142],{"nctId":9143,"briefTitle":9144,"status":104,"phases":9145,"primaryCompletion":9146,"completion":9146,"start":6944,"enrollment":26,"conditions":9147,"interventions":9150},"NCT00186940","Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma\u002FAllergy Patients",[],"2010-02",[1087,634,9148,9149],"Tumor Lysis Syndrome","Hyperuricemia",[9128],{"intervention":9152,"totalTrials":386,"cells":9153},"Busulfan, Melphalan",{"EARLY_PHASE1":9154,"PHASE1":9156,"PHASE2":9158,"PHASE3":9160,"PHASE4":9162,"NA":9164},{"trials":9155,"activeCount":98},[],{"trials":9157,"activeCount":98},[],{"trials":9159,"activeCount":98},[],{"trials":9161,"activeCount":98},[],{"trials":9163,"activeCount":98},[],{"trials":9165,"activeCount":98},[9166],{"nctId":9167,"briefTitle":9168,"status":104,"phases":9169,"primaryCompletion":7170,"completion":8688,"start":366,"enrollment":2203,"conditions":9170,"interventions":9173},"NCT00152126","Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas",[90],[23,9171,9172,1113],"Central Nervous System Tumors","Lymphomas",[9152],{"intervention":9175,"totalTrials":386,"cells":9176},"Bone marrow transplant",{"EARLY_PHASE1":9177,"PHASE1":9179,"PHASE2":9181,"PHASE3":9183,"PHASE4":9185,"NA":9187},{"trials":9178,"activeCount":98},[],{"trials":9180,"activeCount":98},[],{"trials":9182,"activeCount":98},[],{"trials":9184,"activeCount":98},[],{"trials":9186,"activeCount":98},[],{"trials":9188,"activeCount":98},[9189],{"nctId":9190,"briefTitle":9191,"status":104,"phases":9192,"primaryCompletion":8327,"completion":8327,"start":9193,"enrollment":1045,"conditions":9194,"interventions":9195},"NCT00187018","Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study",[90],"2004-03",[1047],[9175],{"intervention":9197,"totalTrials":386,"cells":9198},"Fludarabine, Cyclophosphamide",{"EARLY_PHASE1":9199,"PHASE1":9201,"PHASE2":9203,"PHASE3":9205,"PHASE4":9207,"NA":9209},{"trials":9200,"activeCount":98},[],{"trials":9202,"activeCount":98},[],{"trials":9204,"activeCount":98},[],{"trials":9206,"activeCount":98},[],{"trials":9208,"activeCount":98},[],{"trials":9210,"activeCount":98},[9211],{"nctId":9212,"briefTitle":9213,"status":104,"phases":9214,"primaryCompletion":1259,"completion":8416,"start":9215,"enrollment":3305,"conditions":9216,"interventions":9217},"NCT00186797","Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia",[90],"2002-12",[1284],[9197],{"intervention":9219,"totalTrials":386,"cells":9220},"L-(11C) methionine",{"EARLY_PHASE1":9221,"PHASE1":9223,"PHASE2":9225,"PHASE3":9227,"PHASE4":9229,"NA":9231},{"trials":9222,"activeCount":98},[],{"trials":9224,"activeCount":98},[],{"trials":9226,"activeCount":98},[],{"trials":9228,"activeCount":98},[],{"trials":9230,"activeCount":98},[],{"trials":9232,"activeCount":98},[9233],{"nctId":9234,"briefTitle":9235,"status":9236,"phases":9237,"conditions":9238,"interventions":9241},"NCT05511714","Expanded Access [11C] Methionine PET Imaging","AVAILABLE",[],[9239,9240],"Central Nervous System Tumor","Head and Neck Neoplasms",[9219],{"intervention":409,"totalTrials":386,"cells":9243},{"EARLY_PHASE1":9244,"PHASE1":9246,"PHASE2":9248,"PHASE3":9250,"PHASE4":9252,"NA":9254},{"trials":9245,"activeCount":98},[],{"trials":9247,"activeCount":98},[],{"trials":9249,"activeCount":98},[],{"trials":9251,"activeCount":98},[],{"trials":9253,"activeCount":98},[],{"trials":9255,"activeCount":98},[9256],{"nctId":401,"briefTitle":402,"status":104,"phases":9257,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":9258,"interventions":9259},[90],[126],[93,409,410,133,136,137,139,78,128,113],{"intervention":410,"totalTrials":386,"cells":9261},{"EARLY_PHASE1":9262,"PHASE1":9264,"PHASE2":9266,"PHASE3":9268,"PHASE4":9270,"NA":9272},{"trials":9263,"activeCount":98},[],{"trials":9265,"activeCount":98},[],{"trials":9267,"activeCount":98},[],{"trials":9269,"activeCount":98},[],{"trials":9271,"activeCount":98},[],{"trials":9273,"activeCount":98},[9274],{"nctId":401,"briefTitle":402,"status":104,"phases":9275,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":9276,"interventions":9277},[90],[126],[93,409,410,133,136,137,139,78,128,113],{"intervention":9279,"totalTrials":386,"cells":9280},"Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine",{"EARLY_PHASE1":9281,"PHASE1":9283,"PHASE2":9285,"PHASE3":9287,"PHASE4":9289,"NA":9291},{"trials":9282,"activeCount":98},[],{"trials":9284,"activeCount":98},[],{"trials":9286,"activeCount":98},[],{"trials":9288,"activeCount":98},[],{"trials":9290,"activeCount":98},[],{"trials":9292,"activeCount":98},[9293],{"nctId":9294,"briefTitle":9295,"status":104,"phases":9296,"primaryCompletion":9297,"completion":9297,"start":9298,"enrollment":632,"conditions":9299,"interventions":9301},"NCT00187070","Large Cell Lymphoma Pilot Study III",[90],"2001-07","1997-12",[9300,9088],"Lymphoma, Large Cell",[9279],{"intervention":9303,"totalTrials":386,"cells":9304},"Defibrotide",{"EARLY_PHASE1":9305,"PHASE1":9307,"PHASE2":9309,"PHASE3":9311,"PHASE4":9313,"NA":9315},{"trials":9306,"activeCount":98},[],{"trials":9308,"activeCount":98},[],{"trials":9310,"activeCount":98},[],{"trials":9312,"activeCount":98},[],{"trials":9314,"activeCount":98},[],{"trials":9316,"activeCount":98},[9317],{"nctId":9318,"briefTitle":9319,"status":9320,"phases":9321,"start":6743,"conditions":9322,"interventions":9324},"NCT00143546","Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver","NO_LONGER_AVAILABLE",[],[9323],"Hepatic Veno-occlusive Disease",[9303],{"intervention":9326,"totalTrials":386,"cells":9327},"vinblastine, vincristine, prednisone, daunorubicin",{"EARLY_PHASE1":9328,"PHASE1":9330,"PHASE2":9332,"PHASE3":9334,"PHASE4":9336,"NA":9338},{"trials":9329,"activeCount":98},[],{"trials":9331,"activeCount":98},[],{"trials":9333,"activeCount":98},[],{"trials":9335,"activeCount":98},[],{"trials":9337,"activeCount":98},[],{"trials":9339,"activeCount":98},[9340],{"nctId":9341,"briefTitle":9342,"status":104,"phases":9343,"primaryCompletion":9344,"completion":9345,"start":9346,"enrollment":554,"conditions":9347,"interventions":9349},"NCT00187057","Study for Treatment of Cancer in Children With Ataxia-telangiectasia",[90],"2006-08","2013-06","2002-09",[9348],"Ataxia-Telangiectasia",[9326,9350,9351,9352],"doxorubicin, methotrexate, cyclophosphamide, L-asparaginase","etoposide, cytarabine, mercaptopurine","dexamethasone, procarbazine",{"intervention":9350,"totalTrials":386,"cells":9354},{"EARLY_PHASE1":9355,"PHASE1":9357,"PHASE2":9359,"PHASE3":9361,"PHASE4":9363,"NA":9365},{"trials":9356,"activeCount":98},[],{"trials":9358,"activeCount":98},[],{"trials":9360,"activeCount":98},[],{"trials":9362,"activeCount":98},[],{"trials":9364,"activeCount":98},[],{"trials":9366,"activeCount":98},[9367],{"nctId":9341,"briefTitle":9342,"status":104,"phases":9368,"primaryCompletion":9344,"completion":9345,"start":9346,"enrollment":554,"conditions":9369,"interventions":9370},[90],[9348],[9326,9350,9351,9352],{"intervention":9351,"totalTrials":386,"cells":9372},{"EARLY_PHASE1":9373,"PHASE1":9375,"PHASE2":9377,"PHASE3":9379,"PHASE4":9381,"NA":9383},{"trials":9374,"activeCount":98},[],{"trials":9376,"activeCount":98},[],{"trials":9378,"activeCount":98},[],{"trials":9380,"activeCount":98},[],{"trials":9382,"activeCount":98},[],{"trials":9384,"activeCount":98},[9385],{"nctId":9341,"briefTitle":9342,"status":104,"phases":9386,"primaryCompletion":9344,"completion":9345,"start":9346,"enrollment":554,"conditions":9387,"interventions":9388},[90],[9348],[9326,9350,9351,9352],{"intervention":9352,"totalTrials":386,"cells":9390},{"EARLY_PHASE1":9391,"PHASE1":9393,"PHASE2":9395,"PHASE3":9397,"PHASE4":9399,"NA":9401},{"trials":9392,"activeCount":98},[],{"trials":9394,"activeCount":98},[],{"trials":9396,"activeCount":98},[],{"trials":9398,"activeCount":98},[],{"trials":9400,"activeCount":98},[],{"trials":9402,"activeCount":98},[9403],{"nctId":9341,"briefTitle":9342,"status":104,"phases":9404,"primaryCompletion":9344,"completion":9345,"start":9346,"enrollment":554,"conditions":9405,"interventions":9406},[90],[9348],[9326,9350,9351,9352]]